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ABSTRACT 
 
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is 
responsible for 20-30% of all strokes. AF-related strokes are more severe, and result in longer 
hospital stays and higher mortality compared to non-AF-related strokes. In Australia, the 
prevalence of AF is 5.35% in individuals aged 55 years and older, and it is associated with a cost 
of at least AUD$1.25 billion per year, resulting largely from the incidence of stroke, heart failure 
and premature mortality.  
Oral anticoagulant (OAC) therapy is highly effective for stroke prevention in patients with AF; 
however, it is also associated with the potential risk of bleeding. Evidence from clinical trials 
demonstrates that OAC therapy reduces the risk of stroke by 64% to 70%, and is associated with 
a rate of major bleeding events of up to 3.6% per year. For optimal benefit to be derived from OAC 
therapy, patients are required to adhere to the prescribed regimen and have sufficient knowledge 
regarding their medication. Various studies have demonstrated associations between suboptimal 
adherence and inadequate knowledge regarding OAC therapy with poor treatment outcomes. 
Suboptimal adherence to OAC therapy has been associated with increased risks of both bleeding 
and embolic events, while inadequate knowledge has been associated with poor anticoagulation 
control, which in turn is associated with poorer clinical outcomes. This suggests that OAC 
knowledge and adherence are important concepts to be considered in high quality management of 
patients with AF. 
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Assessment of medication knowledge in routine clinical practice requires the use of validated 
psychometric instruments. The majority of studies conducted in patients with AF have utilised 
instruments of unknown validity to evaluate OAC knowledge. This makes it difficult to ascertain 
whether OAC knowledge has been appropriately assessed. In the last decade, the Anticoagulant 
Knowledge Assessment (AKA) by Briggs et al and the Oral Anticoagulant Knowledge test (OAK) 
by Zeolla et al were developed and validated to assess OAC knowledge. However, both the OAK 
and AKA are only able to assess knowledge related to the use of vitamin K antagonists (VKAs), 
and are not applicable to the direct-acting oral anticoagulants (DOACs). An instrument that caters 
for both patients taking VKAs and DOACs would be useful in clinical practice to identify 
knowledge deficit in patients with AF, and to guide subsequent educational intervention. 
Additionally, there is a lack of contemporary data regarding OAC knowledge level and the rate of 
non-adherence to OAC therapy in Australia, and their relationship with patient-related factors. 
Contemporary data are necessary to assess the adequacy of OAC knowledge in the population, and 
address any deficiencies or misconceptions. Furthermore, contemporary data are needed to identify 
the barriers to OAC adherence, and identify relevant predictors of non-adherence in the population. 
Studies related to OAC knowledge and adherence that have been conducted in Australia to date 
have focused primarily on participants taking VKAs (warfarin). Given the increased rate of 
prescription of DOACs, as well as switching of patients previously taking warfarin to DOACs, 
recent data on OAC therapy would be useful in evaluating the impact of DOAC prescribing on 
patients’ knowledge level and adherence to therapy. Accordingly, the development of this thesis 
was guided by the Capability, Opportunity and Motivation Model of Behaviour (COM-B), which 
hypothesises that interaction between three components, Capability, Opportunity and Motivation 
(COM), influence the performance of Behaviour (B). Factors related to each of the three 
components were explored as they influence OAC adherence. 
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Therefore, the overall objective of this research was to fill these gaps by developing an instrument 
that caters for all OACs, and assessing OAC knowledge and adherence in patients with AF.  
 The specific aims were: 
• To develop and validate a new OAC knowledge instrument that caters for both VKAs 
(warfarin) and the DOACs. 
• To use this instrument, the Anticoagulation Knowledge Tool (AKT), to investigate the 
relationships between OAC knowledge, adherence and health literacy in patients with AF. 
• To determine the level of OAC knowledge in patients with AF taking OAC therapy (either 
warfarin or a DOAC), identify any domains where significant knowledge gaps exist, and 
assess the association between patient-related factors and OAC knowledge. 
• To estimate the proportion of patients who are non-adherent to OAC and identify predictors 
of adherence, and to determine if patient-related factors vary across levels of adherence in 
patients with AF.  
Due to the absence of a suitable instrument to assess OAC knowledge, we began this research by 
conducting a comprehensive review of the literature on anticoagulation knowledge, from which a 
draft instrument was developed. Ten anticoagulation experts were contacted to provide feedback 
on the draft instrument using a Likert scale, after which the content validity index for the 
instrument was calculated. For construct validity, three groups of participants comprising of 44 
pharmacists, 50 patients and 50 members of the general public were tested using the instrument 
developed, and the results of these three cohorts were compared. Reliability analyses were 
conducted to determine if included items were measuring the same general construct, and if the 
instrument could provide consistent results. A subgroup of participants in the patient and 
pharmacist groups were re-tested approximately 2–3 months after the initial testing to assess test-
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retest reliability using Pearson’s correlation coefficient, while internal consistency reliability was 
assessed by calculating a Cronbach’s α value for the three groups. The final 28-item instrument, 
called the AKT, has a scale content validity index of 0.92, supporting content validity. The 
pharmacist group’s mean score (94%) was significantly higher than that of the patient group (62%), 
and the patient group scored significantly higher than the general public group (20%) (p <0.001), 
supporting construct validity. Internal consistency reliability was acceptable with a Cronbach’s α 
value of >0.7 across the three groups, and test-retest reliability was confirmed with a Pearson’s 
correlation coefficient of 0.72 and 0.78 for the pharmacist and patient groups, respectively.  
After the development of the AKT, the instrument was piloted in a study involving 48 patients 
designed to investigate the relationships between OAC knowledge, adherence and health literacy 
in patients with AF. Participants were recruited from general practices for a face-to-face interview 
using the AKT to assess OAC knowledge; the Morisky Medication Adherence Scale (MMAS-8) 
to assess adherence; and the Short Test of Functional Health Literacy in Adults (s-TOFHLA) to 
assess health literacy. Participants had mean scores of 61.6 ± 15.8, 7.2 ± 1.1 and 24.7 ± 9.5 for the 
AKT, MMAS-8 and s-TOFHLA, respectively. Significant correlations were observed between 
OAC knowledge and health literacy with medication adherence (0.37, p = 0.009 and 0.30, p = 
0.042, respectively), and between OAC knowledge and health literacy (0.31, p = 0.033). 
Participants with inadequate health literacy had a significantly lower mean knowledge score than 
those with adequate health literacy (55.8 ± 15.9 versus 66.1 ± 14.4, p = 0.022). In addition, 
participants who reported adequate adherence to OAC therapy had significantly higher knowledge 
scores than those who did not (67.5 ± 13.3 versus 56.1 ± 16.2, p = 0.011).  
After confirming the usability and adequacy of the AKT, the next phase of this research focused 
on assessing OAC knowledge and adherence in patients with AF in a nationally representative 
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sample of patients with AF. The study was designed as an online survey to improve reachability 
and ensure better representation. Survey components used included the AKT, the Perception of 
Anticoagulant Treatment Questionnaires (assessing treatment expectations, convenience and 
satisfaction), a modified Cancer Information Overload scale to assess perception of information 
overload, and the MMAS-8 to assess OAC adherence. Although participants taking warfarin had 
a higher knowledge score compared to those taking DOACs (n = 386, 73.4 ± 13.2 versus 65.7 ± 
13.7, p <0.001), knowledge gaps were generally observed in key areas of self-management 
including the following: missing a dose, drug interactions and recognising bleeding as an important 
side effect. Patient-related factors including age in years (p = 0.009) and perception of information 
overload (p <.001) were significant predictors of knowledge.  
To estimate the proportion of patients who were non-adherent to OAC therapy, and identify factors 
associated with adherence in the population, a secondary analysis of the data was conducted. Non-
adherence to OAC therapy was common, as only 54.9% of participants reported a high adherence 
to OAC. Participants aged ≤65 years were less likely to have high adherence compared to older 
participants (OR, 0.54; 95% CI, 0.33 – 0.88; p = 0.013), while females were more likely to be 
highly adherent compared to males (OR, 1.69; 95% CI, 1.08 – 2.64; p = 0.023). Moreover, the 
result of the secondary analysis showed that treatment satisfaction (p <0.001) and perception of 
information overload (p <0.001) varied across adherence levels.  
Mapping the results from this research to the COM-B framework suggests that each of the 
components could be explored to improve OAC adherence. Improving knowledge and health 
literacy levels may increase patients’ psychological capability to engage in the necessary thought 
process that would encourage adherence to OACs. Potentially, healthcare practitioners could use 
the results of this research to help shape patients’ perception and beliefs concerning OAC therapy 
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to improve motivation to adhere to therapy. Additionally, routine follow-up of both patients taking 
warfarin and DOACs would possibly improve healthcare practitioner-patient communication, 
thereby, providing physical opportunity that facilitates appropriate medication-taking behaviour. 
This body of work resulted in the development and validation of a novel psychometric instrument 
for the assessment of OAC knowledge that caters for patients taking either VKAs or DOACs. This 
research has also identified that significant positive associations between OAC knowledge, 
adherence and health literacy exist among patients with AF. This suggests that these three 
components are interrelated, and addressing any of the individual components could help to 
address one or more of the other two components. Therefore, future interventions to improve 
knowledge and adherence should also consider the level of health literacy in participants. 
Furthermore, this body of work has identified that significant knowledge gaps exist in patients 
taking OACs, and these deficiencies appeared to be greater in patients taking DOACs.  Knowledge 
assessment should be integrated within counselling sessions to help identify and resolve 
knowledge deficits in all patients with AF. Finally, this research has demonstrated that self-
reported non-adherence to OAC is common among patients with AF. A focus on supporting people 
who are at higher risk of non-adherence will be helpful in maximising the benefits of OAC therapy. 
Future studies are required to investigate the best strategies for improving OAC knowledge and 
adherence in the population.   
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CHAPTER ONE 
1.0 Thesis background  
1.1 Introduction 
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is a 
significant independent risk factor for ischemic stroke (1). AF is characterised by uncoordinated 
electrical activation of the atria and an irregular ventricular response leading to hemodynamic 
compromise (2). While the atria fibrillate, blood pools in the atria, which increases the likelihood 
of a clot forming in the atrial appendage, thereby increasing the risk of embolic stroke (2). AF is 
predicted by a p-wave of prolonged duration and abnormal morphology on the electrocardiogram 
(3), and is often associated with structural heart disease; however, it may be present in patients 
without any detectable heart disease (4). Patients with AF have a five-fold increase in their stroke 
risk (5); AF-related strokes are more severe and more likely to result in death than strokes in 
patients without AF (6, 7). In 2014, the prevalence of AF in Australia was estimated to be 5.35% 
in individuals aged 55 years and older, and this is expected to increase to 6.35% by the year 2034 
(8).  
Globally, AF is associated with increased hospitalisation, healthcare costs and premature mortality 
(9). In the UK, the incidence of AF-related hospitalisation increased from 800,000 to over 
2,000,000 in less than 15 years (10). In the US, over 750,000 AF-related hospitalisations occur 
each year, and the deaths of an estimated 130,000 patients are AF-related (11). Similarly, in Europe, 
2.5 million hospitalisation per year are reported to be due to AF (12). In Australia, an estimated 
45,000 hospitalisations due to AF occur each year (8).  
AF imposes a significant economic burden (13-16). In the UK, AF accounts for 1% of the National 
Health Service budget; this is estimated to be £1 billion (AU $1.7 billion) (13). Data from the US 
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showed that AF costs the economy $6 billion (AU $7.7 billion) annually, and the medical costs of 
patients with AF are $9000 (AU $11,600) higher than those who do not have AF (15). In Europe, 
the cost of AF to the economy has been estimated to be €3,000 (AU $4,500) annually per patient, 
with the total economic burden estimated at €13.5 billion (AU $20.4 billion) (14). In Australia, the 
estimated cost of AF to the economy is at least AU $1.25 billion per year, with 64% of this cost 
associated with the incidence of stroke, heart failure or premature mortality (16).  
Anticoagulant medications are used in the management of thromboembolic disorders that can 
occur due to a number of medical conditions, including AF (17). Oral anticoagulant (OAC) therapy 
is highly effective for stroke prevention in patients with AF, and anticoagulants are broadly 
classified into two groups; the vitamin K antagonists (VKAs) and the direct oral anticoagulants 
(DOACs) (18). The VKAs competitively inhibit vitamin K epoxide reductase complex, an 
essential enzyme for activating vitamin K in the body (19). Through this mechanism, VKAs 
interfere with the carboxylation of all vitamin-K dependent coagulation factors, resulting in lower 
plasma levels of multiple procoagulant (factors II, VII, IX, X) and antithrombotic factors (Proteins 
C and S) (19). The DOACs, however, bind at the active site of coagulation enzymes and inhibit a 
single protease (20). Specifically, apixaban and rivaroxaban are factor Xa inhibitors, and they act 
by decreasing the amount of thrombin generated, while the direct thrombin inhibitor (dabigatran) 
inhibits thrombin after it is already formed (21). The mechanisms of action of the DOACs have 
been modelled using the classical coagulation model, and more recently, using the cell-based 
model of coagulation (19). In the classical model, the process of thrombin generation is illustrated 
as a continuous cascade and interactions between cells and coagulation factor are limited; as such, 
the points of inhibition by DOACs are easily represented (19). The cell-based model of coagulation, 
however, is more complex and models the process of thrombin generation as occurring on cell 
surfaces in overlapping phases (19). In the cell-based model, factor Xa inhibitors exert their 
3 
 
anticoagulant effect during the initiation and propagation phases, while thrombin inhibitors exert 
their effect during the amplification phase (figure 1) (19, 21). 
 
Figure 1: An overview of the cell-based model of coagulation 
Adapted from Curry and Pierce, 2007 (22). 
 
Warfarin has been in use for more than 50 years and requires intensive coagulation monitoring; 
there is wide variation in dose-response relationships, and multiple drug-food and drug-drug 
interactions (23). The DOACs (dabigatran, apixaban, rivaroxaban) have only been recently 
introduced into clinical practice, and are expected to overcome the limitations of warfarin therapy 
(Table 1) (23). Key differences exist in the clinical management of patients taking VKAs and 
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DOACs. DOACs provide major advantages over VKAs, including fewer drugs interactions, a 
rapid onset and offset of action, predictable pharmacokinetic profiles, and no requirement for 
routine coagulation monitoring (18). Although the absence of routine coagulation monitoring 
makes DOACs more convenient to use, this could also be a potential hazard due to the lack of 
opportunities for assess the degree of anticoagulation in an individual, adherence assessment and 
knowledge reinforcement (24). Warfarin is associated with a 60-70% relative reduction in stroke 
risk and a reduction in mortality of 26% (25), while the DOACs are either comparable or superior 
to warfarin for stroke prevention in AF and are associated with an approximate 10% reduction in 
all-cause mortality (26). Despite the documented efficacy of these therapeutic strategies in clinical 
trials, optimal treatment outcomes in the real world setting involve safe and appropriate use of 
medication (18).  
Patients with optimum knowledge and adherence to OAC therapy are more likely to achieve 
optimal treatment outcomes, compared to those who do not (27). This has been highlighted by the 
result of various studies investigating the relationship between adherence levels and OAC 
knowledge with treatment outcomes. For example, Yao et al reported an increased risk of stroke 
in patients with AF, who were not taking OAC for six months or more (28). Similarly, Tang et al 
reported patients’ knowledge of OAC therapy to be an important determinant of anticoagulation 
control (29).  
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Table 1.  Pharmacokinetic characteristics of the DOACs compared with warfarin 
 Warfarin DOACs (dabigatran, apixaban, rivaroxaban) 
Pharmacokinetics Unpredictable Predictable 
Onset of action Slow onset Rapid onset of action 
Monitoring requirement Routine INR No requirement 
Food interaction Significant No significant interaction 
Tmax (hours) 72-120 Dabigatran 2-3; apixaban 1-3; rivaroxaban 2-4 
T1/2 (hours) 20-60 Dabigatran 12-17; apixaban 8-15; rivaroxaban 5-9  
INR International Normalised Ratio, Tmax time to maximum plasma concentration, T1/2 half-life 
Adapted from Akinboboye, 2015 (23). Reproduced in accordance with the Creative Commons 
Attribution Non Commercial license. 
1.2 Rationale  
Knowledge of therapy (29) and medication adherence (30) are two key factors that can affect the 
treatment outcome of patients with AF. Evidence suggests that increased knowledge of a condition 
and medication leads to improved patient adherence to medication and lifestyle changes (31). 
Medication non-adherence is of significant concern in the management of patients with AF, as it 
has been associated with an increase in the incidence of stroke, bleeding episodes, hospitalisation 
and mortality (28). This is because plasma levels of oral anticoagulants need to be maintained at a 
therapeutic level in order for patients to derive optimal benefit from OACs (18).  
Studies conducted to date have investigated anticoagulation knowledge in diverse populations. 
However, many of these studies have been limited by the use of non-validated instruments. In 
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cases where a validated instrument was used, the instrument did not cater for the recently 
introduced DOACs. Given the increased uptake of the DOACs in clinical practice, especially the 
growing tendency to switch patients taking warfarin to one of the DOACs (32), it was necessary 
to develop and validate an instrument that is able to assess oral anticoagulation knowledge and can 
cater for all currently prescribed OACs. This thesis aimed to address this need by developing an 
instrument that would be useful in assessing anticoagulation knowledge in routine clinical practice, 
as well as in research, irrespective of the anticoagulants patients are taking.  
In Australia, contemporary data are needed to help understand knowledge and adherence gaps in 
patients with AF, and to identify specific areas where patients require additional support. In 
addition, the relationship between patient-related factors with OAC knowledge and adherence is 
yet to be extensively studied. This would be useful in identifying modifiable factors that could be 
targeted to improve OAC knowledge and adherence in patients with AF.  
Overall, while the importance of anticoagulation knowledge and medication adherence are widely 
recognised in the literature, there is a need for a knowledge assessment instrument that caters for 
both VKAs and DOACs, and contemporary data regarding knowledge and adherence to 
anticoagulants in Australian patients with AF. The purpose of this thesis was to address these gaps 
and contribute to the quality use of oral anticoagulants in AF.   
1.3 Aims 
The general aim of this thesis was to assess the level of anticoagulation knowledge and adherence 
in patients with atrial fibrillation in Australia. 
The specific objectives were to: 
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i) Develop and validate a new OAC knowledge instrument that caters for both VKAs 
(warfarin) and the DOACs. 
ii) Use this instrument to investigate the relationships between OAC knowledge, adherence 
and health literacy in patients with AF. 
iii) Determine the level of OAC knowledge in patients with AF taking OAC therapy (either 
warfarin or a DOAC), identify any domains where significant knowledge gaps exist, and 
assess the association between patient-related factors and OAC knowledge. 
iv) Estimate the proportion of patients who are non-adherent to OAC and identify predictors 
of adherence, and to determine if patient-related factors vary across levels of adherence in 
patients with AF. 
1.4 Theoretical background 
The development of this thesis was guided by the Capability, Opportunity and Motivation Model 
of Behaviour (COM-B), which hypothesises that interaction between three components, Capability, 
Opportunity and Motivation (COM), influence the performance of Behaviour (B) (figure 2) (33).  
‘Capability’ refers to the patient’s capacity to engage in the required thought and physical 
processes that influences a behaviour. ‘Opportunity’ refers to factors that are outside of the patient 
that makes the performance of a given behaviour possible, while ‘Motivation’ refers to all brain 
processes that encourages and direct behaviour. Factors related to each of the three components, 
including knowledge of therapy, beliefs about treatment and outcome expectations were explored 
as they influence OAC adherence. 
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Figure 2: Capability, opportunity, motivation and behaviour (COM-B) model of 
adherence. 
Adapted from Abdou et al, 2016 (33). Permission to reproduce granted by Wiley and Sons, Inc. 
 
 
 
 
 
‘Adherence’ rather than ‘compliance’ was used throughout this thesis because it represents a philosophical shift which emphasizes 
partnership between patients and healthcare practitioners in order to ensure appropriate medication-taking behaviour.  
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CHAPTER TWO 
2.0 Literature review 
2.1 Anticoagulation knowledge in clinical practice 
Overview 
This section presents a review of the literature on OAC knowledge to identify the gaps in the 
literature relating to this area. It describes the approaches that have been employed to assess oral 
anticoagulant knowledge, the level of oral anticoagulant knowledge, and the association between 
knowledge levels and anticoagulation control as a surrogate marker of treatment outcomes. The 
results of this review suggest that OAC knowledge is suboptimal, and there is a need for the 
development of a new instrument that can assess knowledge related to both VKAs and DOACs.  
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2.1.1 Background 
Patients with thromboembolic disorders often need to participate in shared decision-making with 
their healthcare practitioners and safely use oral anticoagulant (OAC) in order to achieve a 
favourable clinical outcome. However, shared decision-making and safe use of OAC by patients 
are difficult to implement without patients having an adequate knowledge of their therapy. The 
purpose of this review is to describe the approaches that have been employed to assess OAC 
knowledge, the level of anticoagulation knowledge, and the association between knowledge levels 
and treatment outcomes. 
2.1.2 Introduction 
Anticoagulants are recommended for the prevention and management of thromboembolic 
disorders (34). They act by preventing the formation of blood clots that could potentially result in 
life-threatening complications (34). Anticoagulants are a unique class of medication because their 
doses need to be optimised to provide a balance between antithrombotic benefit and haemorrhagic 
risk (35).  
Patients with thromboembolic disorders need to participate in shared decision-making with their 
healthcare practitioners (36) and safely use their OAC medication (37) in order to achieve a 
favourable clinical outcome. However, shared decision-making (38) and safe use of OACs (39) by 
patients are difficult to facilitate without adequate knowledge of their therapy. Thus, patients need 
to be knowledgeable concerning their disease and treatment, including anticoagulant therapy.  
Warfarin has a narrow therapeutic index, is associated with numerous food and drug interactions, 
and requires routine International Normalised Ratio (INR) monitoring (40). As such, patients using 
warfarin need to be knowledgeable around these topics in order to achieve optimal benefit from 
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their therapy, while minimising complications (41). Although patients using DOACs do not 
require routine coagulation monitoring, they also require adequate knowledge to enable them to 
take their medication safely. This is because the DOACs, like the VKAs, are also associated with 
increased risk of bleeding and their relatively shorter half-lives compared to warfarin could result 
in a loss of clinical effect after a short period of medication non-adherence (35). Due to the 
importance of knowledge in ensuring patient safety while taking OAC medication, a review of 
OAC knowledge is necessary to identify knowledge levels and patient characteristics associated 
with poor knowledge levels. As such, the purpose of this review is to describe the approaches that 
have been employed to assess OAC knowledge, the level of anticoagulation knowledge, and the 
association between knowledge levels and treatment outcomes. 
2.1.3  Literature selection method 
A literature search was conducted using MEDLINE and EMBASE databases from January 1980 
to May 2017 for peer-reviewed publications. Studies related to patients’ knowledge of OAC were 
selected. Search terms used were ‘‘oral anticoagulant’’, ‘‘warfarin’’, ‘‘dabigatran’’, 
‘‘rivaroxaban’’, ‘‘apixaban’’, ‘‘edoxaban’’, in combination with ‘‘knowledge.’’ 
2.1.4 Eligibility criteria 
Studies were included in this review if they were published in a peer-reviewed journal and if they 
focused on the use of anticoagulants in clinical practice. Additionally, included studies had to 
investigate one or more of the following: (i) the development of instruments to assess 
anticoagulation knowledge; (ii) level of anticoagulation knowledge in patients taking oral 
anticoagulant OACs; and (iii) the association between knowledge levels and treatment outcomes. 
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Editorial and articles that were not published in the English language were excluded from this 
review. 
2.1.5 Results 
Figure 3 shows the summary of the literature source and selection process. After duplicates were 
removed, 1,391 unique articles were identified from MEDLINE and EMBASE. After screening 
by title or abstract, the full text of 140 articles was assessed for eligibility, of which 103 were 
excluded. The main reason for excluding these studies was that they did not focus on OAC 
knowledge. A total of 37 articles comprising of instrument validation studies (Table 2), clinical 
trials, cross-sectional and prospective studies were included in this review (Table 3).  
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Figure 3: Flow chart of selection process 
 
2.1.5.1 Vitamin K antagonist knowledge assessment instruments 
Few studies have specifically focused on the development of instruments for assessing 
anticoagulation knowledge. In an early study, Taylor et al developed an instrument to assess 
anticoagulation knowledge using information available in a hospital guideline regarding 
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anticoagulation therapy (42). A major drawback of this instrument however, is that validity and 
reliability analyses were not conducted. These analyses are important requirement in the 
development of novel instruments to ascertain that such an instrument is measuring the intended 
construct, and it is able to provide consistent results (43). In later years, researchers have used 
diverse approaches to assess the validity and reliability of OAC knowledge instruments. Briggs et 
al reported on a study conducted in 60 patients from two anticoagulation clinics (44). Content 
validity was conducted using Marzano’s taxonomy (45), while construct validity was evaluated by 
using a 31-item appropriateness checklist. The limitation of this study is that investigators did not 
mention if any reliability analysis was conducted. Zeolla et al conducted a study in 74 respondents 
taking warfarin and 27 age-matched subjects who were not taking warfarin (46). In this study, both 
validity and reliability tests were conducted (Table 2). The final instrument, called the Oral 
Anticoagulation Knowledge Test (OAK), has been subsequently validated in the Brazilian (47) 
and Malaysian populations (48).  
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Table 2. Instruments developed for the assessment of oral anticoagulant knowledge 
 Reference Sample 
size 
Participants 
characteristics 
Description Validity and reliability test  
1 Taylor et al (42) 70 Patients newly referred to 
OAC clinic (54% aged less 
than 46 years) 
20-item None reported 
2 Briggs et al (44) 60 60 English speaking 
patients currently 
receiving pharmacist-
managed OAC education 
in community pharmacies 
(mean age of 63 years) 
29-item 
(AKA) 
Content validity, construct 
validity 
3 Zeolla et al (46) 101 74 participants taking 
warfarin and 27 age-
matched participants not 
on warfarin therapy 
recruited from 
community pharmacies,  
supermarket pharmacies, 
and anticoagulation 
clinics 
20-item 
(OAK) 
Content validity, construct 
validity, internal 
consistency reliability and 
test-retest reliability 
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2.1.5.2 Assessment of anticoagulation knowledge in clinical practice 
2.1.5.2.1 Cross-sectional studies 
The majority of studies that have been conducted to evaluate OAC knowledge in clinical practice 
have employed a cross-sectional design (27, 29, 49-68). Although it is difficult to compare the 
4 Praxedes et al 
(47) 
201 Patients taking warfarin 
for at least one year  
recruited  during the 
service office-hours of an 
anticoagulation clinic, 
aged 18 years or older 
Brazilian 
version of 
OAK 
Construct validity, internal 
consistency reliability test-
retest reliability 
5 Matalqah et al 
(48) 
382 Patients taking warfarin 
for at least six months,  
over 18 years of age,  
recruited from two 
Malaysian hospitals and 
able to communicate in 
the Malaysian language 
Malaysian 
version of 
OAK 
Construct validity, internal 
consistency reliability test-
retest reliability 
OAC Oral anticoagulant, OAK Oral Anticoagulation Knowledge Test, AKA Anticoagulation Knowledge 
Assessment  
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findings of these studies, as they have used different instruments to assess knowledge, the mean 
reported scores have ranged from 36% to 75% (Table 3).  
Many cross-sectional studies have utilised non-validated instruments. A study by Wang et al 
reported a knowledge score of 60% ± 21% (mean ± SD), with less than 50% of participants 
correctly answer questions related to food and medications interactions with warfarin therapy (65). 
In a similar study by Tang et al, a mean knowledge score of 48% ± 18% was recorded, with only 
18% of participants having a score of ≥ 70% (29). Other studies that have reported similar mean 
scores to these studies include Davis et al (27), Smith et al (68) and Nadar et al (59) (Table 3) .  
Researchers have also categorised OAC knowledge into three levels, using different and arbitrary 
cut-off values. Alphonsa et al divided respondents into three levels: <50% for poor knowledge, 
50% to 70% for average knowledge, and >70% for adequate knowledge.(49). The study reported 
that 50% of the respondents had poor knowledge, 37% had an average knowledge, and only 13% 
of participants had adequate knowledge. In another study by Rocha et al involving participants 
with mechanical valve prostheses, OAC knowledge was stratified into three levels: (i) a score of 
≤4 for inadequate knowledge, (ii) >4 to ≤ 8 for moderate knowledge, and (iii) >8 to 10 for adequate 
knowledge (60). The study reported that the majority of the patients (62%) had moderate 
knowledge, 36% patients had adequate knowledge, and only 2% had inadequate knowledge.  
Two studies using an online survey to assess OAC knowledge have reported knowledge gaps in 
patients taking OACs. A survey conducted by the European Heart Rhythm Association reported 
that while over 90% of respondents knew the reason they had been prescribed an oral anticoagulant, 
only 21% of those taking DOACs knew that renal function testing at least once a year is important 
to assess their renal function (69). Using an online survey, Shuaib et al reported that more than 
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50% of participants taking OACs were unaware of any potential drug reactions or adverse effects 
related to OAC therapy (62).   
Cross-sectional studies that have employed the use of a validated instruments have also reported 
suboptimal OAC knowledge in patients taking OACs (Table 3). Khudair et al conducted a study 
in patients taking warfarin for two or more months using a modified OAK questionnaire (55). The 
study reported that participants had the lowest knowledge score concerning the consequences of 
non-adherence (42%) and the interaction of warfarin with other medications (36%). In another 
study by Shrestha et al using the AKA instrument, 94% of participants were reported to possess 
inadequate knowledge defined as a score of at less than 72% (50). Lastly, a study by Baker et al 
using the AKA instrument, reported a mean score of 78%, of which 74% of respondents had 
adequate knowledge (70).  
Demographic characteristics that have been weakly associated with patients’ OAC knowledge 
include age of participants and level of education. In the study conducted by Rocha et al, the age 
of participants was inversely associated with knowledge score (r = -0.248; p = 0.009) (60). This 
finding has been supported by other authors, including Hu et al (52) and Chenot et al (51). Another 
study conducted by St-Louis et al reported a significant positive correlations between knowledge 
score and the educational level of respondents (r = 0.10; p = 0.02) (63). Other studies that have 
reported  a similar association between educational level and OAC knowledge include studies by 
Mayet et al (56), and Yahaya et al (66) (Table 3).  
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Table 3. Oral anticoagulant knowledge in clinical practice  
 Reference Medication Instrument 
description 
Participants and 
setting 
Method N % with 
AF 
Result Key 
limitations 
Cross-sectional studies  
1 Wang et al (65) Warfarin 11-Item  Patients visiting 
anticoagulation 
clinic over a period 
of six months 
Face-to-
face 
intervie
w 
183 12 - Mean knowledge score of 60% 
- 64% of participants were 
unaware of medicines that 
interact with warfarin 
 
-Single centre 
study 
-Use of non-
validated 
instrument 
2 Shuaib et al (62) Warfarin 20-item  Patients visiting 
hospital over a 
period of three 
months 
Online 
survey 
200 NS - 56% of respondents were 
unaware of potential drug 
interactions 
- 58% of respondents unaware 
of adverse effects of warfarin 
therapy 
-Single centre 
study 
-Use of non-
validated 
instrument 
3 Nadar et al (59) Warfarin 9-item  Patients  who had 
attended 
anticoagulation 
clinics of three 
hospital at least six 
times 
Face-to-
face 
intervie
w 
180 NS - Mean knowledge score of 61% 
- 46 % of participants were 
unaware of the dose and the 
indication for warfarin therapy 
-Use of non-
validated 
instrument 
 
 
4 Tang et al (29) Warfarin  9-item  Patients visiting 
anticoagulation 
clinic over a period 
of eight weeks 
Face-to-
face 
intervie
w 
122 39 - Mean knowledge score of 48% 
- 18% had a score of ≥ 70% 
-Use of non-
validated 
instrument 
5 Shrestha et al (61) Warfarin AKA test 
(29-item) 
Patients who 
visited the 
outpatient 
pharmacy  of a 
hospital, and had 
been taking 
warfarin for at least 
2 months 
Face-to-
face 
intervie
w 
34 NS - 94% of respondents had a 
knowledge score of < 72% 
- 68% of respondents reported a 
knowledge score of < 50% 
- Small sample 
size 
-Single centre 
study 
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6 Hu et al (52) Warfarin 20-item  Patient who had 
undergone heart 
valve replacement 
Telepho
ne 
survey 
100 NS - Mean score of 71%  
- Advancing age was negatively 
associated with knowledge 
scores 
-Use of non-
validated 
instrument 
7 Khudair et al (55) Warfarin Modified 
OAK test 
(22-item) 
Patients attending 
anticoagulation 
clinic, and taking 
warfarin for at least 
two months 
Self-
administ
ered  
140 43 -58% of respondents were 
unaware of the consequences 
of non-adherence  
-64% of respondent were 
unaware of the interaction 
between warfarin other 
medications 
-Single centre 
study 
8 Moran et al (58)  Warfarin 22-item  Patients visiting an 
anticoagulation 
clinic 
Self-
administ
ered  
181 NS - 33% of participants knew more 
than one medication that can 
affect warfarin therapy 
- 57% of participants were 
unaware of any potential side 
effects with warfarin therapy 
-Use of non-
validated 
instrument 
-Single centre 
study 
 
9 Baker et al (50) Warfarin  AKA test 
(29-item) 
Patients who had 
been enrolled in an 
anticoagulation 
clinic for at least  
six months 
Self-
administ
ered  
185 61 - Mean score of 78%  
- 74% of respondents had a 
score of ≥72% 
-Single centre 
study 
10 Wilson et al (70) Warfarin 20-item  Patients visiting an 
anticoagulation 
clinic 
Face-to-
face 
intervie
w 
65 NS - Mean score of 70%  
- 50% of participants were 
knowledgeable regarding the 
side effects of warfarin therapy 
-Single centre 
study 
-Small sample 
size 
11 Alphonsa et al 
(49) 
Acenocou
marol, 
warfarin 
and 
dabigatran 
 
25-item Patients taking OAC 
who were 
attending the 
Neurology and 
Cardiology clinic 
Self-
administ
ered  
240 NS - 50% of the respondents had 
poor knowledge 
- 37% had an average 
knowledge level 
- 13% of participants had 
adequate anticoagulation 
knowledge 
 
-Use of non-
validated 
instrument 
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12 Chenot et al (51) Phenproco
umon 
13-item  Patients in general 
practice setting 
Self-
administ
ered  
345 
 
70 - 75% of participants were 
unaware that the effectiveness 
of OAC could be affected by 
non-prescription medicine 
- Advancing age was negatively 
associated with knowledge 
score 
-Use of non-
validated 
instrument 
13 Davis et al (27) Warfarin 
 
18-item  Patients attending 
two 
anticoagulation 
clinics 
Self-
administ
ered  
52 29 - The study reported a mean 
knowledge score of 60%  
- Only 37% percent of 
participants had a knowledge 
score of ≥ 70% 
-Use of non-
validated 
instrument 
-Small sample 
size 
14 Rocha et al (60) Warfarin 10-item  Patients visiting 
cardiology clinic of 
two hospitals 
Face-to-
face 
intervie
w 
110 NS - 37% of participants did not 
know their INR target range 
- Advancing age was negatively 
associated with knowledge 
score 
-Use of non-
validated 
instrument 
15 Van et al (64) Fenprocou
mon 
10-item  Patients with 
congenital 
heart disease  or 
acquired heart-
valve defects 
recruited from 
several hospitals 
 
Self-
administ
ered 
57 NS - 56% did not know that black-
coloured stool is an indication 
of internal bleeding 
- 80% of respondents did not 
know that vitamin K could 
interact with their therapy 
-Use of non-
validated 
instrument 
-Small sample 
size 
16 Smith et al (68) Warfarin 
 
 
 
 
52-item  Patients attending 
an anticoagulation 
clinic 
Self-
administ
ered 
100 100 - Participants recorded a mean 
score of 36%.  
- 93% of respondents did not 
know that vitamin K and herbal 
supplements could interact with 
their therapy 
 
 
 
-Use of non-
validated 
instrument 
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17 Jank et al (53) Phenproco
umon 
8-item  Patients attending 
an anticoagulation 
clinic 
Self-
administ
ered 
51 NS - Respondents reported a mean 
knowledge score of 55%, 
- Knowledge score was not 
associated with anticoagulation 
control 
-Use of non-
validated 
instrument 
-Small sample 
size 
 
18 St-Louis et al (63) Warfarin 9-item  Patients who were 
65 years or older 
with atrial 
fibrillation, and 
requiring OAC 
therapy for the first 
time 
Self-
administ
ered 
100 100 - Respondents reported a mean 
knowledge score of 53%,  
- No significant difference in 
knowledge scores between 
participants with poor and good 
anticoagulation control 
-Use of non-
validated 
instrument 
19  Mayet et al (57) Warfarin 8-item  Patients attending 
an anticoagulation 
clinic 
Face-to-
face 
intervie
w 
105 11 - 75% of participants had a 
score of ≥75% 
- Educational level of 
participants was associated with 
higher knowledge scores 
 
-Use of non-
validated 
instrument 
20 Yahaya et al (66) Warfarin 12-item  Patients who had 
made more than 
five visit to an 
anticoagulation 
clinic 
Face-to-
face 
intervie
w 
52 62 - Only 21% of participants had a 
knowledge score of > 80% 
- Educational level of 
participants was associated with 
higher knowledge scores 
 
-Use of non-
validated 
instrument 
-Small sample 
size 
 
21 Hasan et al (67) Warfarin NS Patients attending 
physician and 
pharmacist 
managed an 
anticoagulation 
clinics 
Face-to-
face 
intervie
w 
156 NS - Respondents reported a score 
of 67% for knowledge related to 
the mechanism of action of 
warfarin 
-Use of non-
validated 
instrument 
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- 43% for knowledge on the 
interaction between warfarin 
and alcohol 
22 Cheah et al (71) Warfarin 14-item Patient who were 
discharged on 
warfarin therapy 
Telepho
ne 
survey 
50 NS - Participants reported a mean 
score of 47% 
- Advancing age was negatively 
associated with knowledge 
score  
-Use of non-
validated 
instrument 
- Small sample 
size 
23 Roche-Nagle et al 
(72) 
Warfarin NS Patients attending 
an anticoagulation 
clinic 
Face-to-
face 
intervie
w 
150 18 - 28% of respondents were 
unaware of their indication for 
OAC therapy  
- 60% of respondents were 
unaware of the consequences 
of taking the wrong dosage of 
warfarin 
-Use of non-
validated 
instrument 
Prospective studies  
24 Joshua et al (54) Nicoumarol 
or warfarin 
20-Item  Outpatient taking 
oral anticoagulant 
from a tertiary 
hospital  
Face-to-
face 
intervie
w 
101 NS - Participants reported a mean 
knowledge score of 52.2% 
- 53% of the patients had a 
score of ≤ 50%  
-Use of non-
validated 
instrument 
25 Janoly-Dumenil et 
al (73) 
Fluindione, 
warfarin, or 
acenocoum
arol 
9-item  Patients who had 
been OAC for at 
least  three months 
Face-to-
face 
intervie
w 
50 NS - 70% of the respondents knew 
the name of their OAC  
- Only 24% of respondents knew 
their target INR levels  
-Use of non-
validated 
instrument 
26 Winans  et al (74) Warfarin OAK test 
(20-item) 
Hospitalised 
patients who newly 
initiated warfarin 
therapy divided 
into intervention 
and usual care 
groups 
Face-to-
face 
intervie
w 
40 10 - The intervention group scored 
significantly higher on the OAK 
test than the usual care group 
(74% vs 55%; p = 0.004) 
-Small sample 
size 
-Single centre 
study 
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27 Mavri et al (75) Warfarin 12-item  Patients attending 
an anticoagulation 
clinic. Knowledge 
was assessed at 
baseline and after 
an educational 
intervention 
Face-to-
face 
intervie
w 
235 20 - Mean knowledge score 
improved from 68.8% to 81.3% 
two months after an 
educational material was 
provided to participants 
-Use of non-
validated 
instrument 
28 Voller et al (76) Warfarin 16-item  Patients from three 
centres. Knowledge 
was assessed at 
baseline (T0) and 
after an three 
educational 
intervention (T1, T2 
and T3) 
Self-
administ
ered 
76 18 - Participants’ mean knowledge 
score improved from T0 to T3: 
40% (T0); 86% (T1), 94% (T2) 
and 96% (T3). 
-Use of non-
validated 
instrument 
-Small sample 
size 
29 Cook-camp bell et 
al (77) 
Warfarin 14-item  Patients taking 
warfarin and 
discharged from 
the hospital within 
the past two 
weeks.  
 
Telepho
ne 
survey 
36 67 - Participants had a mean 
knowledge score of 56%  
- Only 33% of participants knew 
the correct action to take if they 
miss a dose  
-Use of non-
validated 
instrument 
-Small sample 
size 
30 Lane et al (56) Warfarin 14-item  Patients who have 
been diagnosed 
with  AF for a 
period of three 
months or more. 
Knowledge was 
assessed at 
baseline and after 
an educational 
intervention 
Face-to-
face 
intervie
w 
93 100 - Only 57% knew that OAC 
medication is useful in 
preventing the formation of 
blood clot at baseline 
- Patients who were aware of 
their target INR range increased 
from 64% to 67% after the 
educational intervention 
-Use of non-
validated 
instrument 
Clinical trials  
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31 Stafford et al (78) Warfarin 
 
OAK test 
(20-item) 
Patients discharged 
from eight 
hospitals and 
taking warfarin for 
at least three 
months. Patients 
were  divided to 
receive usual care 
or an intervention 
involving OAC 
education  
Self-
administ
ered 
268 51 - Anticoagulation knowledge 
was significantly higher on day 8 
in the intervention group 
compared to the usual care 
group (78% vs 65%; p < 0.001), 
- At 90 days post discharge, no 
significant difference was 
observed 
- There may 
have been 
selection bias, 
as patients 
were recruited 
from selected  
hospitals 
32 Maikranz et al 
(79) 
Warfarin 13-item  Patients attending 
52 general 
practices with 
lifelong indication 
for OAC therapy. 
Patients were  
randomised to 
receive usual care 
or an intervention 
involving OAC 
education 
Self-
administ
ered 
76   81 - A significant improvement was 
observed in the intervention 
group after 12 months (0.78 
versus 0.04; p <0.001) 
- At 24 months, participants in 
the intervention group still had 
higher knowledge score, while 
the control group showed a 
slight decline (0.6 vs -0.3; p 
<0.001) 
-Use of non-
validated 
instrument 
- Small sample 
size 
OAC oral anticoagulant, AF atrial fibrillation,  INR International normalised ratio, NS not stated  
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2.1.5.2.2 Prospective studies 
Studies that have employed the use of a prospective design have also reported knowledge gaps in 
patients taking OAC. Prospective studies have been conducted to assess OAC knowledge in the 
outpatient setting, or to evaluate the impact of education on OAC knowledge. Joshua et al reported 
a mean score of 52%, with half of the respondents having a score of <50% in patients visiting a 
tertiary care teaching hospital (54). Similarly, Janoly-Dumenil et al reported that target INR levels 
and symptoms of medication overdose was known by only 24% and 22% of respondents in their 
study, respectively (73). Another study by Cook-Campbell et al reported a mean knowledge score 
of 56%, and only 33% of participants knew the correct action to take if they miss a dose (77).  
Three prospective studies have evaluated the impact of education and training on anticoagulation 
knowledge. In a study by Mavri et al, respondents’ knowledge was assessed at baseline, after 
which an educational booklet on OACs was provided (75). Two months later, anticoagulation 
knowledge was re-assessed to determine the effectiveness of the educational material. The mean 
knowledge score of participants improved from 68.8% to 81.3% (p = 0.001) (75). Similar results 
have also be observed in studies by Winans et al (74), Lane et al (56) and Voller et al (76), 
suggesting that an educational interventions could be useful in improving OAC knowledge. 
2.1.5.2.3 Clinical trials 
A non-randomised controlled trial was conducted by Stafford et al (78). The study compared 
warfarin knowledge in patients after hospital discharge who were either receiving usual care or an 
intervention that included warfarin education. Anticoagulation knowledge was assessed in the two 
groups on day 8 and 90 after hospital discharge, using the OAK test. The study reported that OAC 
knowledge was significantly higher on day 8 in the intervention group compared to the usual care 
group (78% vs 65%; p <0.001), however, at 90-days post discharge, no significant difference was 
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observed. In a cluster randomised controlled study by Maikranz et al, OAC knowledge was 
measured at baseline, and after 12 and 24 months in patients randomised into a control or 
intervention group (79). The intervention involved patient education, treatment monitoring and the 
provision of a patient-specific information leaflet. Although knowledge was similar for both the 
control and intervention group at baseline, a significant improvement was observed in the 
intervention group after 12 months (0.78 points versus 0.04 points; p <0.001), and after 24 months 
(0.6 points versus -0.3 points; p <0.001). 
2.1.6 Association between knowledge levels and treatment outcomes 
Few studies have investigated the relationship between anticoagulation knowledge and treatment 
outcomes. Available studies have essentially focused on the association between knowledge and 
anticoagulation control, with no study focusing on the incidence of stroke or bleeding events.  
Except for two studies, included studies have reported no association between knowledge levels 
and anticoagulation control. Tang et al reported a positive relationship between patients’ 
anticoagulation knowledge and the number of INR values within the target range in the four most 
recent clinic visits (r= 0.20; p = 0.024) (29). In a second study by Khudair et al, participants with 
a knowledge score of ≥75% were reported to have a better anticoagulation control, defined as a 
minimum of five INR values within the therapeutic range out of six consecutive readings, compare 
to those with scores of <75% (p <0.001) (55). A study by Baker et al employed three measures of 
anticoagulation control: (i) the number of INRs within therapeutic range, (ii) time in therapeutic 
range (TTR) determined using the Rosendaal method and (iii) the standard deviation of INR values 
(50). No significant correlation was observed between warfarin knowledge and any of the three 
measures of anticoagulation control. Similarly, studies by Rocha et al (60), Mayet et al (57), and 
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Nybo et al (80) have used different measures for anticoagulation control, and have all reported no 
association between anticoagulation control and knowledge levels. 
2.1.7 Discussion 
Validated and non-validated instruments have been employed to assess OAC knowledge in clinical 
practice, with most studies utilising non-validated instruments. Investigators have divided 
knowledge scores into two or three different categories and have mostly used arbitrary scores of 
70%, 75% or 80% to signify adequate OAC knowledge. Studies have however not provided 
justification for these knowledge categories or cut-off values. 
While knowledge levels appear to be generally suboptimal irrespective of participant 
characteristics and setting, no clear association between knowledge level and anticoagulation 
control was observed among the included studies. In addition, available studies have 
predominantly focused on warfarin therapy, with little attention given to DOACs. 
Due to the frequent use of non-validated instruments, it is difficult to ascertain the extent of 
knowledge deficit in patients taking OAC. Nevertheless, knowledge deficiency was common 
regarding adverse effects, consequences of non-adherence, and food and drug interactions. 
Considering the complexity of OAC therapy, educational intervention is therefore important as 
part of the management strategy for patients taking OAC to help improve knowledge levels.  
While advancing age and low educational level were consistently associated with poor OAC 
knowledge irrespective of study design, type of instrument and sample size, no consistent 
associations were observed with respect to other patient characteristics. Therefore, there is a need 
to focus on supporting elderly patients and those with limited formal education using simplified 
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educational resources. Some strategies that could be effective in this population include the use of 
multimedia and pictograms (81).  
The included studies are not without their limitations. Most of the studies used a small sample size, 
cross-sectional methodology, and did not use a validated instrument. Furthermore, it is also 
possible that validated instruments were not able to cover all relevant knowledge domains, or not 
sensitive enough to detect a change in knowledge levels.  
The relationship between OAC knowledge and anticoagulation control remains unclear. Although 
the majority of existing studies showed no association between the two variables, the lack of a 
consistent definition for adequate anticoagulation control makes it difficult to compare the results 
of the studies. As such, the relationship between knowledge levels and anticoagulation control is 
an area that requires further investigation. There is also a need for the development and validation 
of a simplified OAC knowledge instruments that caters for both warfarin and DOAC users. This 
would be useful in assessing patients’ OAC knowledge in clinical practice and for research 
purposes. More studies with large sample sizes and a standardised definition of adequate 
anticoagulation control are required to evaluate the relationship between OAC knowledge and 
anticoagulation control. In addition, prospective studies should be designed to focus on the 
relationship between knowledge and other clinical outcomes, including the incidence of stroke and 
bleeding. 
2.1.8 Conclusion 
OAC knowledge is suboptimal in clinical practice and knowledge gaps are present across several 
domains. This suggests that educational intervention should be incorporated into the management 
strategy of patients taking OACs. Effort should also be made by healthcare practitioners to identify 
patients who are more likely to have significant knowledge deficit based on their clinical or 
30 
 
demographic characteristics, as candidates for more rigorous and structured educational 
interventions.  
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2.2 A summary of the literature evaluating adherence and persistence with oral 
anticoagulants in atrial fibrillation 
 
Overview 
This section summarises the literature regarding adherence and persistence with oral 
anticoagulants in the management of AF. It was conducted to understand the burden of non-
adherence to OAC, and to aid the selection of a suitable approach to assess medication adherence 
in the subsequent studies reported in Chapters 4 and 6. The result of this review suggest that there 
is a need to improve adherence and persistence with anticoagulants in AF in order to optimise 
therapeutic outcomes. This review was published in the American Journal of Cardiovascular 
Drugs (https://www.ncbi.nlm.nih.gov/pubmed/27262433) on June 4, 2016.  
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2.2.1 Abstract 
Atrial fibrillation (AF) is a growing public health concern and remains an independent risk factor 
for ischemic stroke. Warfarin, a commonly used oral anticoagulant, is associated with a 60–70 % 
relative reduction in stroke risk and a reduction in mortality of 26 %. However, warfarin has several 
limitations, including a narrow therapeutic window, variable dose response, multiple interactions 
with other drugs and concurrent illnesses, and the need for frequent laboratory monitoring. In 
recent years, the direct acting oral anticoagulants (DOACs), including dabigatran, rivaroxaban, 
apixaban and edoxaban, have been developed to overcome the limitations of warfarin therapy. 
These treatment strategies are either comparable or superior to warfarin in stroke prevention in AF. 
Despite the documented effectiveness of oral anticoagulants in AF, patients may not derive optimal 
benefit if they fail to adhere or fail to continue with their medication. This may lead to treatment 
failure, increased hospitalization and mortality. This review summarises the literature regarding 
adherence and persistence (or discontinuation) rates with oral anticoagulants in the management 
of AF; the impact of non-adherence and non-persistence on treatment outcomes; and the 
effectiveness of strategies to improve adherence and persistence with oral anticoagulant therapy. 
2.2.2 Introduction 
Atrial fibrillation (AF) is the most common form of arrhythmia in clinical practice and is associated 
with significant morbidity and mortality (82, 83). AF is a potent independent risk factor for 
ischemic stroke, and this risk increases with the presence of other cardiovascular risk factors (84). 
Patients with AF are five times more likely to have a stroke compared to the general population, 
and this category of stroke accounts for about 20% of the overall incidence of stroke (85).  
Warfarin, a vitamin K antagonist (VKA), is associated with a 60-70% relative reduction in stroke 
risk and a reduction in mortality of 26%, (25). The directly acting oral anticoagulants (DOACs), 
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including dabigatran, rivaroxaban, apixaban and edoxaban, have been shown to be either 
comparable or superior to warfarin for stroke prevention in AF (86-89). Despite the documented 
effectiveness of these medications, patients will not derive optimal benefit if they fail to adhere or 
continue to take their medication.  
Medication adherence has been defined as the “active, voluntary, and collaborative involvement 
of the patient in a mutually acceptable course of behaviour to produce a therapeutic result.”(90) A 
closely related concept to adherence is medication persistence, which has been defined as “the 
duration of time from the initiation to discontinuation of therapy.” (91) Both adherence and 
persistence have been classified as medication taking behaviour (91, 92).  
Adherence can be measured using the direct and indirect method. Direct method involves the 
measurement of  either the drug or its biological marker in body fluid, while the indirect method 
involves the use of self-reports, pill counts, prescription refill rate, electronic refill rate, assessment 
of clinical response and patient diaries (93). The direct methods are considered to be more robust 
than the indirect method, however  are not practicable for routine clinical use(90) .  
This review summarises the literature regarding adherence and persistence (or discontinuation) 
rates with anticoagulant in the management of AF; the impact of non-adherence and non-
persistence on treatment outcomes; and the effectiveness of strategies to improve adherence and 
persistence with oral anticoagulant therapy.  
2.2.3 Literature selection method 
A literature search was conducted using Medline and EMBASE databases from January 1980 to 
March 2016 for English language peer-reviewed publications. Studies in clinical practice related 
to medication adherence and persistence with anticoagulants were selected. Search terms used 
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were “atrial fibrillation”, “oral anticoagulants”, “warfarin”, “dabigatran”, “rivaroxaban”, 
“apixaban”, “edoxaban”, “time in therapeutic range (TTR)” and “International Normalised Ratio 
(INR)” in combination with “adherence”, “non-adherence”, “persistence” and “discontinuation.” 
2.2.4 Eligibility criteria 
Studies were included in this review if they were published in a peer-reviewed journal between 
1980 and 2016; if they focused on the use of anticoagulants in AF; and available in English 
language. Additionally, included studies had to investigate one or more of the following: (i) 
adherence and/or persistence with the use of oral anticoagulants (VKAs and DOACs) in the 
management of AF, (ii) the impact of non-adherence and/or non-persistence on treatment 
outcomes (stroke, bleeding and mortality), and (iii) strategies to improve adherence and/or 
persistence with oral anticoagulant therapy. Studies that included adherence acetyl salicylic acid 
(ASA) as a study drug in AF were excluded for two reasons: (i) ASA is an over-the-counter 
medication, therefore quantifying adherence is problematic, and (ii) the use of ASA for the 
prevention of stroke in AF is now discouraged by major guidelines (94, 95).  
2.2.5 Results 
Figure 4 shows the results of the selection process. The titles of 2,085 articles from the electronic 
databases search were reviewed, after which 1993 articles were excluded. The full text of 92 
articles was reviewed, of which 62 studies were excluded. The major reasons for excluding these 
studies were that they either focused on adherence with clinical guidelines, or included aspirin as 
a study drug. A total of 30 articles including 8 randomised control trial and 22 cohort studies were 
included in this review (Table 4). Table 5 summarises the discontinuation rates of oral 
anticoagulants in randomised controlled trials (RCTs) that compared the DOACs with warfarin. 
Five RCTs were included: RE-LY, 2009, ROCKET-AF, 2011, J-ROCKET AF, 2012, 
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ARISTOTLE, 2011 and ENGAGE AF TIMI 48, 2013 (86-89, 96). Table 6 summarises the 
adherence rate with oral anticoagulant in clinical practice. The result of 9 retrospective (28, 97-
104), 1 prospective (105) and 3 cross sectional studies were included (27, 106, 107). Table 7 
summarises the persistence rate with oral anticoagulant in clinical practice. This consists of 10 
retrospective (103, 104, 108-115) and one prospective study. Table 8 summarises the impact of 
poor medication taking behaviour on treatment outcomes. The result of two retrospective studies 
were included (28, 102). Lastly, table 9 summarises the result of three RCTs designed to improve 
medication adherence in patients taking oral anticoagulant (116-118).  
 
Figure 4: Flow chart of selection process 
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AF atrial fibrillation, AIDS acquired immune deficiency syndrome, ASA acetyl salicylic acid, 
VTE, venous thromboembolism. 
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Table 4. Evaluation of included articles (n=30) 
Study Adherence Persistence (or 
discontinuation) 
Impact of non-
adherence on 
treatment 
outcomes 
strategies to 
improve adherence 
and/or persistence 
Randomised controlled trials 
RE-LY (86)     
ROCKET-AF (88)     
J-ROCKET AF (96)     
ARISTOTLE (87)     
ENGAGE AF TIMI (89)     
Hedegaard et al (117)     
Clarkesmith et al (119)     
Kimmel et al (118)     
Prospective cohort studies  
Kimmel et al (30)     
Beyer-Westendorf et al 
(105) 
    
Retrospective cohort studies 
Shore et al (102)     
Gorst-Rasmussen et al 
(100) 
    
Cutler et al, (99)     
Beyer-Westendorf et al 
(97) 
    
Mchorney et al  (101)     
Zhou et al (104)     
Crivera et al (98)     
Tsai et al (103)     
Gomes et al (109)     
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Fang et al (108)     
Song et al (114)     
Nelson et al (112)     
Laliberte et al (110)     
Zalesak et al (115)     
Martinez et al (111)     
Shiga et al (113)     
Yao et al (28)     
Cross sectional  
Schulman et al (107)     
Davis et al (27)     
Castellucci et al (106)     
For the present review, adherence was operationalised as taking medication as prescribed, while 
persistence as the proportion of patient who remained on oral anticoagulant therapy for a specified 
duration. 
 
2.2.6  Medication taking behaviour in clinical trials in AF 
A number of randomised controlled trials involving anticoagulants have been conducted in patients 
with AF (Table 5). Although the methodologies of these trials varied considerably, the reports 
suggest that even in well-controlled trial situations, up to 35% of participants discontinued their 
medication (86-89, 96). The major reasons to which medication discontinuation has been attributed 
are the occurrence of an outcome event, adverse effects and withdrawal of consent by the 
participants. 
The discontinuation rates for rivaroxaban, apixaban and edoxaban were similar to those of warfarin 
in the ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 trials, with recorded rates of 24% 
vs 22%; 28% vs 25%; and 34% vs 34%, respectively (86-89). The discontinuation rate with 
39 
 
dabigatran was significantly higher than warfarin (p <0.001) in the RE-LY trial, with rates of 21% 
in both the 110mg dabigatran and 150mg dabigatran groups, compared with a rate of 17% in the 
patients taking warfarin therapy. The higher discontinuation rate with dabigatran was attributed to 
the incidence of adverse events including hepatobiliary disorders, and adverse reactions including 
dyspepsia, which occurred at significantly higher rates in the dabigatran arm compared with the 
warfarin arm of the trial (86) . 
Non-adherence rates have not been specifically recorded in any of the AF trials, but it is generally 
expected that the study methodologies will attempt to ensure optimal adherence in both the 
treatment and control arm in order to achieve an unbiased comparison. The time in therapeutic 
range (TTR) has been recorded in trials that included warfarin and a value of 60% or higher has 
been generally accepted as adequate (120). A TTR value of 64% was recorded in the RELY trial; 
55% in ROCKET-AF; 62% in ARISTOTLE; and 65% in ENGAGE AF-TIMI48.  TTR is a 
measure of anticoagulation quality with warfarin therapy and may be considered as a proxy for 
adherence, although it is recognised that it can be affected by a range of other factors apart from 
medication non-adherence. (121, 122).  
The outcomes of patients who discontinued anticoagulant therapy were not captured in the 
majority of clinical trial reports. An exception to this was the ROCKET-AF study which was 
designed to assess the non-inferiority of rivaroxaban compared to warfarin in stroke prophylaxis 
in AF (88). The trial was carried out in a cohort of 14,264 patients randomly assigned to either 
adjusted warfarin or rivaroxaban therapy and followed up for a median period of 1.9 years. Patients 
who discontinued warfarin therapy or rivaroxaban therapy, of whom about half subsequently 
commenced a vitamin K antagonist, were followed up for a median period of 117 days for the 
occurrence of the study endpoint. The primary endpoint of stroke occurred in 81 patients in the 
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rivaroxaban group (4.7% per year) compared with 66 patients in the warfarin group (4.3% per year) 
(p =0.54). These recorded event rates (4.7% and 4.3) were higher compared to the total event rates 
of 1.7% and 2.2% per year for rivaroxaban and warfarin, respectively, recorded in the main study. 
The higher events rates in patients who discontinued anticoagulant therapy may be due to the 
complexity of managing high risk patients with AF who are unable to tolerate anticoagulation 
therapy, and this highlights the need for a particular focus on optimal anticoagulation coverage in 
this group of patients (123). 
 
 Table 5. Comparison of Medication Discontinuation Rates in AF Trials Involving the Direct Oral 
Anticoagulant 
 
 S.  Trial acronym Follow Drugs No.  of Mean/Median Discontinuation 
 No.  [year]  Up  patients age (years) rate (%) 
          
     Period     
    (years)     
 1.  RE-LY (86) 2.0 DAB 110mg 6015 72 
 
 
21 
      DAB 150mg 6076 21 
      Adjusted WAR 6022 17 
 2.  ROCKET-AF (88) 1.9 RIV 7131 73 
 
24 
      Adjusted WAR 7133 22 
 3.  J-ROCKET AF (96) 2.5 RIV 639 71 
 
15 
      Adjusted WAR 639 13 
 4.  ARISTOTLE (87) 1.8 API 9120 70 28 
      Adjusted WAR 9081  25 
 5.  ENGAGE AF  TIMI 2.8 EDO 30mg 7034 72 
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   48 (89)   EDO 60mg 7035 34 
      Adjusted WAR 7036 34 
AF atrial fibrillation, API apixaban, DAB dabigatran, EDO edoxaban, RIV rivaroxaban, WAR warfarin  
 
 
2.2.7  Medication-taking behaviour in clinical practice in AF  
2.2.7.1 Assessment of adherence and persistence with anticoagulants in clinical practice in AF 
Four major approaches have been used in quantifying adherence levels in clinical practice. These 
are medication possession ratio (MPR); proportion of days covered (PDC); patient self-report; and 
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medication event monitoring system (MEMS). The MPR is defined as the ratio of the number of 
days of medication supplied within the refill interval to the number of days in the refill interval, 
while PDC is defined as the ratio of the total number of days in which medication is available to 
the total number of days in the follow up period (124). Although both measures have been applied 
with a number of variations (125), a value of 80% or greater has been generally accepted as good 
adherence (90).Studies have also employed the use of patient self-report. These studies have 
employed the use of the Morisky medication adherence scale (MMAS), a validated tool originally 
designed to assess medication adherence with antihypertensive medication (126).  
The fourth approach that has been utilised in the literature is the use of MEMS. MEMS are standard 
medication containers caps fitted with a microprocessor that records the number of times a pill 
bottle has been opened, after which data are then downloaded for display as a calendar of events 
(127). Persistence on the other hand is been quantified as the proportion of patient who remained 
on oral anticoagulant therapy for a specified duration.  
2.2.7.2 Adherence to anticoagulants in clinical practice in AF 
Attempts have been made to determine adherence rates with both warfarin and the DOACs in the 
management of AF in clinical practice (Table 6). A prospective study by Kimmel et al using 
medication event monitoring system bottle caps, showed that 40% of 136 participants on warfarin 
thromboprophylaxis followed for a mean period of 32 weeks had clinically significant levels of 
poor adherence (30). In this study, poor adherence was defined as having >20% missed doses 
or >10% extra doses. This translated into an increase in the risk of both under-coagulation and 
over-coagulation in non-adherent patients. In a multivariate analysis of the study data, significant 
associations were observed between under-adherence and under-coagulation, with a 14% increase 
in the odds of under-coagulation for every 10% increase in the number of times a pill bottle was 
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not opened (30). Also, participants who had extra pill bottle opening on more than 10% of study 
days were observed to have a significant increase in INR readings. 
In another study by Davis et al involving 52 patients, the MMAS was used in assessing medication 
adherence with warfarin therapy. Adequate adherence with the MMAS is generally defined as a 
“no” response to all 4 questions, and inadequate adherence as a “yes” response to any of the four 
questions (126). Adequate adherence was reported by 50% (26) of participants, of which, only 
seven had good anticoagulation control. Among the other 26 participants who had inadequate 
adherence, none had good anticoagulation control. Statistical analysis of the study data showed a 
significant association between self-reported adherence and anticoagulation control (p = 0.01) (27). 
In a related study that also made use of the MMAS reported by Castellucci et al, 500 patients were 
surveyed, of which 74% (370) were on VKAs and 26% (130) on DOACs (rivaroxaban, dabigatran 
and apixaban). At the end of the study, adequate adherence was reported by 56% of patients taking 
the VKAs and 57% of patients taking the DOACs. A further analysis of the study data showed no 
significant difference occurred in adherence to twice daily vs once daily dosing of DOACs (106). 
Studies have also been conducted with the use of dispensing and health care claim data. A cross-
sectional study reported by Schulman et al recorded the highest adherence rate with dabigatran 
(107). In this study, pharmacy dispensing data were used to assess the adherence rate with 
dabigatran therapy in 103 patients taking dabigatran for at least 3 months. A median adherence 
rate greater than 99% was recorded in the study, and 11 (11%) patients were observed to have 
inadequate medication adherence with a MPR value of less than 80% (107). Shore et al have 
reported a similar finding with a larger population of 5376 patients taking dabigatran in a 12-month 
retrospective cohort study using the PDC approach. The study was conducted by using a national 
clinical data repository linked to data on dabigatran utilisation from a closed pharmacy system. A 
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median adherence rate of 94% was recorded and 28% of patients had a PDC of less than 80% 
(102).  
Another study conducted by Gorst-Rasmussen et al in 2,960 patients newly diagnosed with AF, 
and taking dabigatran, reported a slightly lower PDC value. The study data were obtained by 
linking three national databases: a prescription registry with records of prescriptions purchased, a 
patient register with discharge diagnoses for all hospital admissions, and civil registration database 
with demographic information. At the end of the follow up period of 1 year, a mean PDC of 84% 
was reported, with over 75% of patients having a PDC value of > 80% (100).   
A related study using the PDC approach investigated adherence to dabigatran therapy between a 
warfarin-naive cohort and a warfarin-experienced cohort. The study compared both groups by 
using administrative pharmacy claims data of 17,691 patients from a large pharmacy benefits 
scheme. At the end of the follow up period, the PDC for the warfarin-naive cohort was lower 
compared with the warfarin- experienced cohort (67.4% vs 71.2%) (103). 
Lower adherence levels have also been reported with the DOACs. A study by Zhou et al 
investigated adherence with dabigatran using health claim data. The study included 2,713 patients 
with prevalent AF who were taking a single anticoagulant (non-switchers) throughout the study 
period. A mean MPR of 73% was reported for patient followed up for 6 months, which later 
reduced to 65% in patient followed up for a 1-year period (104). This relative lower adherence 
level with dabigatran therapy has also been corroborated by Cutler et al in a study involving 159 
patients in who were not followed by an anticoagulation clinic. In this study medication adherence 
was assessed by evaluating prescriptions picked up at the local pharmacy. A mean adherence rate 
of 63% was reported using the MPR approach, and only 57% of patients had an adherence level 
of ≥80% (99).  
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Studies have also been designed to compare adherence among the DOACs. These studies have 
mainly focused on rivaroxaban, dabigatran and apixaban. A study by Mchorney et al investigated 
the pattern of adherence with the DOACs by using health claims data. This study was designed to 
compare adherence rates in 21,175 patients taking either, rivaroxaban, dabigatran or apixaban 
using the PDC approach. The result of the study showed that a higher proportion of rivaroxaban 
users had an adherence rate ≥ 80% compared to both dabigatran (73% vs 67%, p <0.001), and 
apixaban (73% vs 70%, p <0.001) users (101).  
These findings have been supported in a study conducted by Crivera et al using health care claim 
data in 9,948 DOACs users. The proportion of patients with a minimum PDC of 80% was also 
higher for rivaroxaban users compared with both dabigatran users (75.4% vs 67.6%; p <0.001), 
and apixaban users (75.4% vs 70.6%; p = 0.076). Analysis of the population that switched from 
one DOACs to the other showed that those who switched to rivaroxaban still had a significantly 
higher proportion of patients with a PDC value of ≥80% compared to both dabigatran (76.9% vs 
72.9%; p <0.001) and apixaban users (76.9% vs 71.3%; p = 0.037) (98). 
A better adherence rate was also observed with rivaroxaban in a study by Beyer-Westendorf et al 
that made use of the MPR approach to compare adherence rate between rivaroxaban and dabigatran 
in primary care patients newly starting anticoagulant therapy. The study involved 7,265 and 
patients were followed up for at least 180 days and 360 days respectively from their first 
prescription date. The result of the study showed that a greater proportion of rivaroxaban users 
compared with dabigatran users had a MPR of ≥80% compared with dabigatran users (61.4% vs 
49.5%, p <0.001), and a mean MPR of 76% and 69% respectively after 180 days (97). These 
results were also consistent for a follow up period of >360 days, with a greater proportion of 
rivaroxaban users having a MPR of ≥80% compared with dabigatran users (62.6% vs 47.6%, p 
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<0.001), and a mean MPR of 75% and 64% respectively. Lastly, a study by Yao et al using a 
retrospective analysis of administrative claims data from a large insurance database compared 
adherence with the DOACs as a group with the VKAs in 64,661 patients with AF newly initiating 
oral anticoagulant therapy. During the follow up period, a greater proportion of DOACs users 
compared with VKAs users had a PDC of ≥80% (47.5% vs 40.2%, p <0.001) (28).  
The methods that have been used in assessing adherence in these studies are not without their 
limitations. MEMS can only record the number of times a pill bottle has been opened, but cannot 
determine if a pill been taken. Dispensing and claim data may have contained inaccuracies due to 
wrong entries, and it is also impossible to know if all supplied drugs has been taken by the patient. 
Nevertheless, these studies do provide evidence there is a need to improve medication adherence 
in AF in clinical practice, and that adherence with the once daily DOAC (rivaroxaban) is 
potentially better, than for the other DOACs.
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Table 6. Adherence to Oral Anticoagulant in Clinical Practice 
 Reference Study 
design 
Medic
ation 
Method  N Age  (%) AF Follo
w-up  
Result Inference Key limitations 
1 Kimmel et al 
(30) 
Prospec
tive 
cohort 
study 
WAR MEMS 136 58.5 39* 0.62a 36% of patient 
had more than 
20% missed pill 
bottle openings, 
and 4% had 
more than 10% 
extra pill bottle 
openings 
Increase in the risk 
of both under-
coagulation and 
over-coagulation 
occurred in non-
adherent patients 
-MEMS cap 
monitoring does not 
directly measure 
adherence 
2 Schulman et 
al (107) 
Cross-
sectiona
l study 
DAB MPR  103 75.5 100 NA A median 
adherence rate 
greater than 
99% was 
recorded in 
patients taking 
dabigatran 
 Adherence to 
dabigatran appears 
to be good  
-MPR does not 
directly measure 
adherence 
-Single centre study 
3 Shore et al 
(102) 
Retrosp
ective 
cohort 
study 
DAB PDC 5376 71.3 100 0.67b A median 
adherence rate 
of 94% was 
recorded, and 
28% of patients 
had a PDC of 
<80% 
Adherence to 
dabigatran for a 
majority of patients 
appears to be 
optimal. However, 
28% of patients 
had poor 
adherence 
-Medication record 
may have contained 
inaccurate 
information 
-PDC does not 
directly measure 
adherence 
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4 Gorst-
Rasmussen 
et al (100) 
Retrosp
ective 
cohort 
study 
DAB 
 
PDC 2960 72.1 100 1a A mean 
adherence rate 
of 84% was 
recorded, with 
75% of patients 
having a PDC 
value of > 80% 
Adherence to 
dabigatran for a 
majority of patients 
appears to be 
optimal. However, 
25% of patients 
had poor 
adherence 
-PDC does not 
directly measure 
adherence 
-Findings may not be 
applicable in non-
Danish population 
5 Cutler et al 
(99) 
Retrosp
ective 
cohort 
study 
DAB MPR 159 70.7 100 1c A mean 
adherence rate 
of 63% was 
observed and 
only 57% of 
patients showed 
an adherence 
rate of ≥80% 
There is a need to 
improve adherence 
with dabigatran 
therapy 
- Medication record 
may have contained 
inaccurate 
information 
MPR does not 
directly measure 
adherence 
6 Beyer-
Westendorf 
et al (97) 
Retrosp
ective 
cohort 
study 
DAB 
&RIV 
MPR 7265 74.5 100 1b Mean 
adherence was 
higher for 
rivaroxaban 
compared with 
dabigatran (75% 
vs 64%; 
p <0.001) 
Adherence appear 
to be better with 
rivaroxaban 
compared with 
dabigatran 
- Medication record 
may have contained 
inaccurate 
information 
-MPR does not 
directly measure 
adherence 
7 Yao et al (28) Retrosp
ective 
cohort 
study 
WAR; 
DAB; 
RIV; 
API 
PDC 64 661 73  100 1.10b 47.5% of DOACs 
patients had a 
PDC of ≥80%, 
compared with 
40.2% in 
warfarin 
A higher 
proportion of 
rivaroxaban 
patients had a PDC 
of ≥80% 
- Medication record 
may have contained 
inaccurate 
information 
48 
 
patients (p 
<0.001) 
-PDC does not 
directly measure 
adherence 
 
8 Mchorney et 
al (101) 
Retrosp
ective 
cohort 
study 
DAB; 
RIV; 
API 
PDC 21,175 76.1 78.7 0.88a 72.7% of 
rivaroxaban 
users had a PDC 
value of ≥80%, 
compared to 
dabigatran 
(67.2%; 
p <0.001) and 
apixaban 
(69.5%; 
p <0.001) users 
A higher 
proportion of 
rivaroxaban 
patients had a PDC 
of ≥80% 
- Medication record 
may have contained 
inaccurate 
information 
-PDC does not 
directly measure 
adherence  
9 Zhou et al 
(104) 
Retrosp
ective 
cohort 
study  
DAB MPR 2713  63.0 100 1c Adherence rate 
reduced from 
73% to 65% 
within a year in 
patients taking 
dabigatran 
There is a need to 
improve adherence 
with dabigatran 
therapy 
- Medication record 
may have contained 
inaccurate 
information 
-PDC does not 
directly measure 
adherence 
10 Davis et al 
(27) 
Cross 
sectiona
l study 
WAR  MMAS 52 50.9 17 NA Adequate 
adherence was 
reported by 
only 50% of 
participants 
 There is a need to 
improve adherence 
with warfarin 
therapy 
-MMAS is a self-
report instrument 
and does not directly 
measure adherence 
-Small sample size 
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11 Castellucci et 
al (106) 
Cross 
sectiona
l study 
WAR; 
DAB; 
RIV; 
API 
MMAS 500 63 18 NA Adherence rate 
was 56.2% for 
patients on 
VKAs and 57.1% 
for patients on 
DOACs 
There is a need to 
improve adherence 
with oral 
anticoagulant 
-MMAS is a self-
report instrument 
and does not directly 
measure adherence 
12 Crivera et al 
(98) 
Retrosp
ective 
cohort 
study 
DAB; 
RIV; 
API 
PDC 9948 75.5 83.6 1c 75.4% of 
rivaroxaban 
users had a PDC 
value of ≥80%, 
compared to 
dabigatran 
(67.6%; 
p <0.001) and 
apixaban 
(70.6%; p >0.05) 
users 
A higher 
proportion of 
rivaroxaban 
patients had a PDC 
of ≥80% 
-PDC does not 
directly measure 
adherence 
- Medication record 
may have contained 
inaccurate 
information 
 
13 Tsai et al 
(103) 
Retrosp
ective 
cohort 
study 
DAB PDC 17691 76.4 100 1a PDC for the 
warfarin-naive 
cohort was 
67.4% 
compared with 
71.2% in the 
warfarin- 
experienced 
cohort 
A lower adherence 
rate was observed 
in the warfarin-
naive cohort 
-MMAS is a self-
report instrument 
and does not directly 
measure adherence 
API=apixaban, DAB=dabigatran, EDO=edoxaban, RIV=rivaroxaban, WAR=warfarin, NA=not applicable, MEMS=medication events monitoring system, 
PDC=proportion of days covered, MPR=medication possession ratio. a-mean; b-median; c-maximum, * Atrial fibrillation and/or flutter. 
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2.2.7.3 Persistence with anticoagulants in clinical practice in AF 
2.2.7.3.1 Persistence with warfarin 
Medication persistence focuses on how long patients are able to continue with their medication, 
and can also affect treatment outcomes (91). The discontinuation rates for warfarin in patients with 
AF have been generally observed to be greater than 25% in the first year of therapy (Table 7) (108, 
109, 114). Gomes et al reported on a large population-based cohort study of 125,195 new AF 
patients taking warfarin therapy over a 13-year study period (109). The study used multiple linked 
administrative databases to identify outpatient prescription records, hospitalisations, emergency 
department visits, physician services, patient demographics, and comorbidities for patients with a 
diagnosis of AF. The study showed that 8.9% of patients did not return for a refill after filling their 
first prescription, and 31.8% discontinued medication within the first year; this increased to 43.2% 
by the end of the second year (109).  
In another study by Fang et al, 4,188 patients newly initiating warfarin in the Anticoagulation and 
Risk Factors in Atrial Fibrillation Study (ATRIA) were identified and followed up for about 5 
years. Persistence with warfarin therapy was assessed using records from pharmacy and laboratory 
databases. The study reported a discontinuation rate of 26% at one year after the initiation of 
therapy, with an additional 3.6% of patients discontinuing warfarin therapy by the end of the third 
year (108).   
In a third study by Song et al, administrative claims data were used in evaluating persistence and 
discontinuation pattern of long-term medications in patients with AF. The study included 16,036 
patients who were prescribed warfarin within 3 months following AF hospitalisation. The 
investigators defined non-persistence as the presence of a ≥60-day gap in medication use, and 
permanent discontinuation as no evidence for the use of medication for ≥90 days until the end of 
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the study period. The result of the study showed that only 53.5% of patients were persistent with 
warfarin therapy for at least one year, and 42.6% of patients permanently discontinued therapy 
within the one year period (114).  
2.2.7.3.2 Persistence with the DOACs versus warfarin 
The majority of studies that have been conducted to date that have compared the persistence rate 
for DOACs with warfarin in patients with AF found that the DOACs were associated with 
improved medication persistence. A number of these studies have been conducted with the use of 
propensity score matching (PSM) technique in order to achieve a fair comparison amongst patients 
taking two different oral anticoagulants. Laliberte et al has reported on a study involving 18,270 
patients with AF identified from health care claims data, newly commencing warfarin or 
rivaroxaban therapy (110). The patients were matched 1:4 for rivaroxaban and warfarin 
respectively. The result of the study showed that a greater persistence rate was observed with 
rivaroxaban compared with  warfarin (82% vs 68%, p <0.0001), during a follow up period of 6 
months (110).  
Another study by Nelson et al in newly anticoagulated patients using pharmacy claim data has 
reported a similar finding (112). In this study, 32,886 patients with AF were matched 1:1 for 
rivaroxaban and warfarin respectively, and followed up for a maximum duration of 3 years. The 
results showed that patients taking rivaroxaban had a higher persistence rate compared with 
patients taking warfarin (77% vs 58%). Also, in the subgroup of patients who did not switch 
anticoagulant therapy during the follow up period, a lower discontinuation rate of 16% was 
reported for the rivaroxaban arm compared with 42% in the warfarin arms (112).  
In a third study by Zalesak et al, propensity score matching was used to identify 1,745 matched 
pairs of newly diagnosed AF patients taking dabigatran and warfarin, respectively. The persistence 
52 
 
rate was reported to be higher for dabigatran compared with warfarin at both 6 months (72% vs 
53%, p <0.001) and one year (63% vs 39%, p <0.001) respectively (115). Lower persistence rates 
have however also been reported at both 6 months and 1 year with dabigatran. Tsai et al reported 
that 40% of patients discontinued dabigatran therapy within 6 months (103), while Zhou et al has 
reported that about 50% of patients discontinued dabigatran in the first year of therapy (104). 
This increase in persistence with the DOACs has also been reported in studies that did not make 
use of the PSM technique. In a large study involving 27,514 anticoagulant-naive patients with 
incident AF, medication persistence was calculated based on the pattern of repeat prescriptions 
issued in a primary care setting. Persistence of VKA therapy fell from 76.5% to only 63.6% 
between 6 and 12 months, compared to a smaller fall from 85.9% to 79.2% for the DOACs 
(dabigatran, rivaroxaban and apixaban). After a follow up period of 12 months, the persistence 
rate was significantly higher with the DOACs compared to VKA for both the overall population, 
(79.2% vs 63.6%, p <0.0001), and for those with CHA2DS2VASc ≥2 (83.0% vs 65.3, p <0.0001) 
(111).  
A similar study was conducted by Beyer-westendorf et al to assess persistence with rivaroxaban, 
dabigatran, and VKA treatment in primary care patients newly starting anticoagulant therapy.  The 
study involved 7,265 patients with persistence assessed during a follow-up period of 180 days and 
360 days respectively after the first prescription date. Persistence rates were significantly higher 
in rivaroxaban users compare to both VKA (66% vs 58%; p <0.001), and dabigatran users (66% 
vs 60%, p <0.05) after 180 days. A similar trend was also observed after 360 days with persistence 
rates of 53%, 47%, and 25.5%, respectively for rivaroxaban, dabigatran and VKA respectively 
(97). The persistence rates observed with rivaroxaban does not seem to be affected by a history of 
warfarin exposure. A study by Beyer-Westendorf et al, in an ongoing prospective registry 
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involving more 2,600 patients, recorded similar persistence rates of 82% and 81% for patients 
switched from warfarin to rivaroxaban, and warfarin naive patients, respectively, during a median 
follow up period of 544 days. A discontinuation rate of 15% was observed for rivaroxaban in the 
first year of treatment (105), which is lower than the discontinuation rates of 26%, 30% and 32%  
recorded in large cohort studies involving VKAs (109, 128, 129).  
Despite these reports of improved persistence with the DOACs, a study conducted by Shiga et al 
has reported a contrasting finding. In this study, persistence rates were compared in 401 patients 
with AF who had newly initiated DOACs, and 200 patients with AF who had newly initiated 
warfarin in the same period. During a maximum follow-up period of 24 months, 28% patients who 
had newly started DOACs and 17% patients who had newly started warfarin discontinued their 
medication. The persistence rates of patients prescribed DOACs was consistently lower than that 
of patients prescribed warfarin at 3, 6, and 12 months (85% vs 93%; 79% vs 88%; and 70% vs 
82%, respectively). The major causes of DOACs discontinuation reported include drug adverse 
events, worsening renal dysfunction, and patients’ desire (113).  
These findings have suggested that a higher trend of persistence, although not uniform, with the 
DOACs for the majority of patients. However, non-persistence rates with all anticoagulants remain 
significant, and it is important to investigate the factors that may be associated with non-
persistence in individual patients, and implement strategies to resolve them. 
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Table 7. Persistence with oral anticoagulant medication in clinical practice 
 Reference Study 
design 
Medic
ation 
Definition of non-
persistence 
N Age %w
ith 
AF 
Follo
w-up 
(year
s) 
Result Inference Key limitations 
1 Gomes et al 
(109) 
Retro-
spective 
cohort 
study 
WAR First instance of 
discontinuing 
warfarin therapy 
125,195 ≥66 100 5c 31.8% 
discontinued 
medication 
within the first 
year; this 
increased to 
43.2% in the 
second year 
Persistence 
with warfarin 
therapy 
among older 
patients with 
AF appears to 
be low 
-Inability to 
determine if 
medication 
discontinuation 
was patient or 
physician initiated. 
Medication records 
may have 
contained 
inaccuracies or 
wrong information 
2 Fang et al 
(108) 
Retro-
spective 
cohort 
study 
WAR >/=180 
consecutive days 
off warfarin 
4,188 71.
8 
100 4.6b A 
discontinuation 
rate of 26% at 
one year. An 
additional 3.6% 
discontinued 
warfarin by the 
end of the third 
year. 
1 in 4 patients 
newly starting 
warfarin for 
atrial 
fibrillation 
discontinued 
therapy in the 
first year 
 
Medication records 
may have 
contained 
inaccuracies or 
wrong information 
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3 Song et al 
(114) 
Retro-
spective 
cohort 
study 
WAR A single 
medication gap of 
at least 60 days 
16,036 73 100 1c  53.5% of 
patients were 
persistent with 
warfarin 
therapy for at 
least one year, 
and 42.6% of 
patients 
permanently 
discontinued 
therapy within 
the one year 
period 
4 in 5 patients 
discontinued 
warfarin 
therapy with a 
year  
- Medication 
records may have 
contained 
inaccuracies or 
wrong information 
4 Nelson et al 
(112) 
Retro-
spective 
cohort 
study  
WAR: 
RAV 
A single 
medication gap of 
at least 60 days 
32886 71.
6 
 
100 2.8c A persistence 
rate of 77.1% 
was observed 
with 
rivaroxaban 
compared with 
57.8% in 
patients on 
warfarin 
therapy (p 
<0.001) 
Rivaroxaban 
demonstrated 
a trend 
towards better 
treatment 
persistence 
compared 
with warfarin 
- Medication 
records  may have 
contained 
inaccuracies or 
wrong information 
-Confounding may 
still have been 
possible even after 
propensity score 
matching 
5 Laliberte et 
al (110) 
Retro-
spective 
cohort 
analysis  
WAR; 
RAV 
A single 
medication gap of 
at least 60 days 
18,270 73.
6 
100 1.1c Persistence 
rates were 
81.5% with 
rivaroxaban 
compared with 
68.3% in 
patients taking 
Rivaroxaban 
demonstrated 
a trend 
towards better 
treatment 
persistence 
compared 
with warfarin 
- Medication 
records  may have 
contained 
inaccuracies or 
wrong information 
-Confounding may 
still have been 
possible even after 
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warfarin 
(p <0.0001). 
propensity score 
matching 
6 Beyer-
Westendor
f et al (105) 
Pro-
spective 
cohort 
study 
RIV A gap of >4 weeks 
except for major 
surgeries 
>2600 75.
0 
100 1.5b Persistence 
rates were 
82.0% and 
81.1% for 
patients 
switched from 
warfarin to 
rivaroxaban, 
and warfarin 
naïve patients, 
respectively 
 
Persistence 
with 
rivaroxaban 
therapy is 
similar in both 
groups. 
-Registry may have 
introduced the 
possibility of a 
selection bias 
7 Zalesak et 
al (115) 
Retro-
spective 
cohort 
analysis 
WAR; 
DAB 
A single 
medication gap of 
at least 60 days 
3490  73.
0 
100 1.7c Persistence 
rates were 72% 
vs 53% at six 
months 
(p <0.001), and 
63% vs 39% at 
one year 
(p <0.001) for 
dabigatran and 
warfarin, 
respectively 
Dabigatran 
demonstrated 
a trend 
towards better 
treatment 
persistence 
compared 
with warfarin 
-Inability to 
determine if 
medication 
discontinuation 
was patient or 
physician initiated. 
Medications 
records may have 
contained 
inaccuracies or 
wrong information 
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8 Martinez et 
al (111) 
Retro-
spective 
cohort 
analysis 
WAR; 
DAB; 
RIV; 
API 
Discontinuation 
of the prescribed 
drug 
27,514 74.
2 
100 1.9a Persistence of 
VKA therapy fell 
from 76.5 % to 
63.6 % between 
6 and 12 
months, 
compared with 
85.9 % to 79.2 % 
for the DOACs 
Rivaroxaban 
demonstrated 
a trend 
towards better 
treatment 
persistence 
compared 
with warfarin 
Medications 
records may have 
contained 
inaccuracies or 
wrong information 
9 Shiga et al 
(113) 
Retro-
spective 
cohort 
analysis 
WAR; 
DAB; 
RIV; 
API. 
Discontinuation 
of the prescribed 
drug 
601 69.
5 
100 2c Persistence 
rates were 
lower for 
patients 
prescribed 
dabigatran 
compared with 
patients 
prescribed 
warfarin at 3, 6, 
and 12 months 
(85% vs 93%; 
79% vs 88%; 
and 70% vs 82% 
respectively) 
Persistence 
rates with the 
DOACs were 
significantly 
lower than 
that of 
warfarin 
-Small sample size 
-Medication 
records may have 
contained 
inaccuracies or 
wrong information 
10 Zhou et al 
(104) 
Retro-
spective 
cohort 
study 
DAB A single 
medication gap of 
at least 60 days 
2713 63.
0 
100 1c Only 49% 
percent of 
patients were 
persistent with 
therapy at the 
end of a 1-year 
study period. 
1 in 2 patients 
with prevalent 
AF 
discontinued 
dabigatran in 
the first year 
of therapy. 
 
- Medication 
records may have 
contained 
inaccuracies or 
wrong information 
-Exclusion of 
patients with 
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inadequate 
coverage 
11 Tsai et al 
(103) 
Retro-
spective 
cohort 
study 
DAB A single 
medication gap of 
at least 30 days 
17,691 76.
4 
100 0.5a In the overall 
population, 40% 
of patients were 
non-persistent 
to dabigatran 
2 in 5 patients 
discontinued 
dabigatran 
therapy within 
6 months 
- Short follow-up 
period 
- Medication 
records may have 
contained 
inaccuracies or 
wrong information 
12 Beyer-
Westen-
dorf et al 
(97) 
Retro-
spective 
cohort 
study 
VKAs; 
DAB; 
RIV; 
A permanent 
discontinuation 
of 
therapy or a refill 
later than 60 days 
7265 74.
5 
100 1b Persistence 
rates were 
significantly 
higher in 
rivaroxaban 
users compared 
with both VKA 
(66.0% vs 
58.1%; 
p <0.001), and 
dabigatran 
users (66.0% vs 
60.3%, p <0.01) 
after 180 days 
Rivaroxaban 
demonstrated 
a trend 
towards better 
treatment 
persistence 
compared 
with both 
dabigatran 
and warfarin 
Medication records 
may have 
contained 
inaccuracies or 
wrong information 
API APIXABAN, DAB DABIGATRAN, EDO EDOXABAN, RIV RIVAROXABAN, WAR WARFARIN, NA NOT APPLICABLE, MEMS Medication events monitoring 
system, PDC Proportion of days covered, MPR Medication possession ratio. a-mean; b-median; c- maximum. 
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2.2.8 The impact of poor medication-taking behaviour on treatment outcomes  
There is a paucity of studies relating poor medication taking behaviour to treatment outcomes. 
However, the available studies in AF have shown that poor medication taking behaviour is 
associated with adverse treatment outcomes (Table 8). In a retrospective study of 5,376 patients 
taking dabigatran followed up for a median of 244 days, in which medication adherence was 
calculated using the PDC approach, a decrease in adherence of 10% was associated with a 13% 
increase in the combined outcome of all-cause mortality and stroke (102). These findings suggest 
the advantages of dabigatran relative to warfarin in terms of laboratory monitoring and reduced 
interactions must be balanced against the implications of non-adherence on treatment outcomes. 
In a recent study by Yao et al involving 64,661 patients newly initiating anticoagulant (warfarin, 
dabigatran, rivaroxaban, or apixaban), multivariable Cox proportional hazards models was used in 
estimating the impact of non-adherence on the risk of stroke and bleeding (28). The result of the 
study showed that no significant effect was observed between non-adherence and the risk of stroke 
in patients with CHA2DS2VASc score 0 or 1 (28). However, in patients with CHA2DS2VASc 
score 2 or 3, not taking oral anticoagulant for ≥6 months was associated with an elevated risk of 
stroke (hazard ratio (HR) 2.73, 95% CI 1.76–4.23), compared with not taking oral anticoagulants 
for <1 week. A more pronounced association was observed in patients with CHA2DS2VASc ≥4, 
with HR of 1.96 (95% CI 1.48–2.60) for not taking oral anticoagulant 1 to 3 months; 2.64 (95% 
CI 1.93–3.61) for 3 to 6 months; and 3.66 (95% CI 2.68–5.01) for ≥6 months compared with not 
taking oral anticoagulants <1 week (28). 
For overall bleeding risk, non-adherence to oral anticoagulant was generally associated with lower 
risk of bleeding. A hazard ratio of 0.46 (95% CI 0.25–0.86) was observed for not taking oral 
anticoagulant for ≥6 months in patients with CHA2DS2VASc score of 0 or 1; 0.68 (95% CI 0.52–
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0.90) for patients with CHA2DS2VASc score 2 or 3, and 0.79 (95% CI 0.67–0.93) for patients 
with CHA2DS2VASc score ≥4.  
An important finding of this study was that for patients with CHA2DS2VASc ≥2, better adherence 
was associated with lower stroke risk and a relatively small increase in bleeding risk, with no 
significant increase in intracranial bleeding. The findings of these studies suggest that better 
medication taking behaviour in the management of AF leads to improved treatment outcomes. 
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Table 8. Impact of poor medication-taking behaviour on treatment outcomes  
 Referen
ce 
Study 
design 
Medica
tion 
N % AF Age Foll
ow 
up 
Result Inference Key limitations 
1 Shore et 
al (102) 
Retros
pective 
study 
DAB 537
6 
100 71.
3 
0.6
7b 
A decrease in adherence of 
10% was associated with a 
13% increase in the 
combined outcome of all-
cause mortality and stroke 
The advantages of dabigatran 
relative to warfarin in terms 
should be balanced against 
the implications of non-
adherence on treatment 
outcomes 
Confounding variables 
not captured in database 
may have led to the 
observed association 
between adherence and 
outcomes 
2 Yao et al 
(28) 
Retros
pective 
study 
WAR 646
61 
100 73 1.1
b 
With CHA2DS2VASc score of 
≥2, not taking oral 
anticoagulant for ≥6 months 
was associated with an 
elevated risk of stroke  
 
 Poor medication taking 
behaviour is associated with 
increased stroke risk in 
patients with CHA2DS2VASc 
score of ≥2 
Confounding variables 
not captured in database 
may have led to the 
observed association 
between adherence and 
outcomes 
DAB=dabigatran, WAR=warfarin, HR=hazard ratio, b-median, CHA2DS2VASc (presence of congestive heart failure, hypertension, age 65–74 y, age ≥75 y, 
diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category). 
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2.2.9 Effectiveness of strategies for improving medication-taking behaviour in AF 
The literature has offered considerable evidence to suggest that adherence and persistence with 
anticoagulants in patients with AF need to be improved. Strategies to improve adherence and 
persistence with warfarin have resulted in mixed outcomes, and this suggests that a combination, 
and individualisation, of strategies may be required in different clinical practices and patient 
groups (Table 9). A randomised controlled trial by Hedegaard et al was conducted in patients with 
stroke or transient ischemic attack to investigate the impact of a multifaceted intervention in 
improving adherence to oral anticoagulant therapy, antiplatelets and statins in a hospital setting 
(117). A total of 203 patients participated in the study, with less than 10% of patients having a 
diagnosis of AF (117). The multifaceted intervention included motivational interviewing, 
medication review and follow-up telephone calls in patients in the intervention arm as compared 
to usual care in the control group. The investigators recorded a non-significant difference in MPR 
of 95% and 91% in the intervention and control arm, respectively.  
However, in another randomised controlled trial by Clarkesmith et al, a marginal improvement in 
medication adherence was observed (116). This trial was conducted in 97 patients with AF newly 
prescribed warfarin, randomised to either usual care or the intervention arm of the study. The 
intervention arm consisted of a one-off educational session in which patients were shown a DVD 
of basic information on oral anticoagulation therapy pertaining to the risks, benefits and potential 
interactions with drugs and food (116). Patients in the intervention arm had a significantly higher 
TTR (76.2% vs 71.3%; p = 0.035) at 6 months which became non-significant at 12 months of 
follow-up (76.0% vs 70.0%; p = 0.44). This suggests potentially greater adherence to diet and 
lifestyle recommendations, as well as the medication itself, in patients receiving the educational 
intervention.  
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An additional study by Kimmel et al used a lottery-based incentive system in attempting to 
improve warfarin adherence (118). In this study, 100 participants were randomised to either a daily 
lottery where the daily reward ranged from $3 to $100 if they adhered to their medication regimen. 
In the study, 38% of patients had a diagnosis of AF and INR readings taken over the six months 
of the study were used as a proxy to assess warfarin adherence. At the end of the study, no 
significant difference in the percentage of out of range INRs was recorded between the two arms. 
However, the incentive system was found to significantly reduce out of range INRs in a subgroup 
with a low INR at baseline.  
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Table 9. Strategies to improve adherence with oral anticoagulants  
 Reference Study 
design 
Medic
ation 
N % 
AF 
Age Intervention Result Inference Key limitations 
1 Hedegaard 
et al (117) 
RCT WAR  203 <10 62.
0 
Motivational 
interviewing, 
medication review 
and follow-up 
telephone calls 
A non-significant 
difference in MPR 
of 0.95 and 0.91 in 
the intervention 
and control arm, 
respectively. 
No significant 
improvement was 
recorded between the 
intervention group 
and usual care 
Participants in the study 
were not blinded and 
this may have been a 
source of bias 
2 Clarkesmit
h et al 
(116) 
RCT WAR 97 100 72.
9 
One-off educational 
session in which 
patients were shown 
a DVD of basic 
information about 
anticoagulants 
 A significantly 
higher TTR of 
76.2% vs 71.3% in 
the intervention 
and control arm, 
respectively. 
This may suggest 
potentially greater 
adherence to diet and 
lifestyle 
recommendations, as 
well as to warfarin 
therapy 
A number of 
participants refused to 
participate due to 
physical impairment 
 
3 Kimmel et 
al (118) 
 
RCT WAR 100 38 61.
8 
Daily lottery reward 
from $3 to $100 if 
patient adhered to 
their medication 
regimen 
The incentive 
system was found 
to significantly 
reduce out of 
range INRs in a 
subgroup with a 
low INR at baseline.  
 
This may suggest 
potentially greater 
adherence to diet and 
lifestyle 
recommendations, as 
well as to warfarin 
therapy 
It is possible that the 
expected value of the 
lottery was insufficient 
to motivate behavioural 
changes. 
WAR=warfarin, RCT=randomised controlled trial, MPR=medication possession ratio, AF=atrial fibrillation, TTR=time in therapeutic range. 
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2.2.10 Further research 
More studies are required in order to fully understand the impact of adherence and persistence with 
oral anticoagulants on treatment outcomes, and the most appropriate choice of oral anticoagulant 
for patients with poor medication taking behaviour. Prospective studies are better suited in 
achieving these objectives due to the fewer potential sources of bias and confounding compared 
with retrospective studies. A prospective study design will assist in determining the true picture of 
medication discontinuation (whether discontinuation of oral anticoagulant was by the patient or 
the physician, or whether it was in response to bleeding), and its impact on treatment outcomes. 
Prospective studies will also be useful in determining if patient medication preferences, perception 
of stroke and bleeding risk have a significant role in predicting poor medication taking behaviour.  
Secondly, more randomised controlled trials are required in the literature to aid in identifying the 
best strategies for improving adherence and persistence with oral anticoagulants in specific patient 
populations. 
Lastly, more studies are required to assess the impact of sub-therapeutic levels of the DOACs on 
treatment outcomes. This is important because the DOACs have short half-lives and are known to 
exhibit a rebound hypercoagulability effect. It therefore remains unclear if a minimum PDC or 
MPR value of 80% is acceptable as suggested in the literature, because missing a few doses of the 
DOACs may have a more severe effect on treatment outcomes compared to missing a few doses 
of warfarin with a long half-life. 
2.2.11 Discussion and conclusion 
The need for anticoagulant prophylaxis in AF will increase as the population continues to age. 
This review has considered the current adherence and persistence patterns with oral anticoagulants 
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in AF and the need for improvement in medication taking behaviour as a necessary step to improve 
patient outcomes. A detailed analysis of the data was not possible because of the inherent 
heterogeneity of available studies. However, adherence and persistence rates appears to be better 
with the DOACs compared to warfarin therapy, and as such, it could be assumed that their 
widespread use should be encouraged. However, non-adherence is currently difficult to detect in 
patients taking the DOACs because they do not require routine monitoring. This contrasts with 
warfarin management, where medication-related and/or lifestyle-related issues can be promptly 
identified during routine monitoring, after which, they can be potentially resolved. Given the 
current absence of such evidence, it is prudent to reinforce the need for medication adherence 
during every clinical interaction, irrespective of the anticoagulant patients are taking, and to 
explore other strategies of improving adherence and persistence in patients with AF. 
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CHAPTER THREE 
3.0 Development and validation of an oral Anticoagulation Knowledge 
Tool (AKT) 
 
Overview 
This study aims to address the first objective of this thesis, which was to develop and validate a 
new OAC knowledge instrument that caters for both VKAs (warfarin) and the DOACs. The 
instrument was developed based on a review of the literature, feedback from anticoagulation 
experts, and testing in three different groups of participants. This study was published in PlosOne 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924828/) on June 28, 2016. 
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3.1 Abstract 
Background: Assessing and improving patients’ anticoagulation knowledge can lead to better 
treatment outcomes. While validated knowledge instruments exist for use in people taking warfarin, 
these tools are not necessarily applicable to patients taking direct-acting oral anticoagulants. 
Objective: To develop and validate an oral anticoagulation knowledge instrument that is 
applicable to all oral anticoagulant medications. 
Methods: Ten anticoagulation experts participated in the development of the Anticoagulation 
Knowledge Tool to ensure content validity. The knowledge instrument was administered to three 
groups of participants comprising of 44 pharmacists, 50 patients and 50 members of the general 
public. A subgroup of participants in the patient and pharmacist group were retested approximately 
2–3 months after the initial testing. Statistical tests were conducted to determine the validity and 
reliability of the scale, and item analysis was used to determine the performance of individual 
questions. 
Results: The 28-item instrument developed had a scale content validity index of 0.92, supporting 
content validity. The pharmacist group’s mean score was significantly higher than that of the 
patient group, and the patient group scored significantly higher than the general public group (94% 
vs 62% vs 20%, respectively; p <0.001), supporting construct validity. Internal consistency 
reliability was acceptable with a Cronbach’s α value of >0.7 across the three groups, and the test–
retest reliability was confirmed with a Pearson’s correlation coefficient of 0.72 and 0.78 for the 
pharmacist and patient groups, respectively. 
Conclusion: The Anticoagulation Knowledge Tool is a valid and reliable instrument that can be 
used in routine clinical practice to assess patients’ anticoagulation knowledge. 
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3.2 Introduction 
Anticoagulants are widely used in the treatment and prevention of many thromboembolic disorders 
(130). Patients’ knowledge of their medication and medical condition can affect treatment 
outcomes (131), and this becomes more critical in patients prescribed oral anticoagulants due to 
the narrow therapeutic indices of this class of medication, and the potentially devastating sequelae 
of both therapeutic failure and over-anticoagulation (50). 
In the literature, attempts have been made to assess patient anticoagulation knowledge, and this 
has led to the development and use of a number of instruments in different settings. The earliest 
documented attempt to develop an instrument to evaluate patients’ anticoagulation knowledge was 
by Taylor et al, in which a scale was developed based on information available in a district hospital 
guideline for managing patients taking warfarin (42). More recent attempts by researchers have 
developed scales based on the use of patient educational material, review of the literature and 
experts’ opinion using either open ended or multiple choice questions (27, 29, 132). These scales 
have been used in a number of studies to establish the relationship between anticoagulation 
knowledge and treatment outcomes, and have yielded mixed results. Two of these studies have 
reported an association between adequate anticoagulation knowledge and positive treatment 
outcomes, (29, 132)while the other two have reported no association (27, 66). A major limitation 
of these studies, however, is that none of them have employed the use of an instrument which has 
been psychometrically validated.  
To date, only the anticoagulant knowledge assessment (AKA) by Briggs et al (133) and the oral 
anticoagulant knowledge test (OAK) by Zeolla et al (134) have been developed and validated with 
regard to both content and construct validity. However, both OAK and AKA have been designed 
to assess knowledge regarding vitamin K antagonists (VKAs) and are not applicable to the direct 
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acting oral anticoagulants (DOACs). With the recent introduction of the DOACs (dabigatran, 
apixaban, rivaroxaban and edoxaban) into clinical practice, there is need for a validated instrument 
to assess patients’ knowledge of their anticoagulation therapy that applies to both the VKAs and 
the DOACs. The objective of this study was to develop and validate a knowledge instrument that 
can be used in assessing anticoagulation knowledge related to all the available oral anticoagulant 
medications. 
3.3 Methods  
3.3.1 Anticoagulation Knowledge Tool development 
We began by conducting a comprehensive review of the literature on patient anticoagulation 
knowledge, with additional information obtained from freely available patient educational material. 
The knowledge domain covered in the review of the literature included basic drug information, 
adverse drug effect, drug-drug interactions, drug monitoring and dietary issues. Similar 
information was then grouped to form a list of 56 items consisting of both open ended and multiple 
choice questions. The usefulness of each question in assessing anticoagulation knowledge was 
then discussed by the authors, after which the items were ranked on a scale of 1 to 5 (1 = strongly 
disagreed, 5 = strongly agreed) in terms of their relevance to anticoagulation knowledge. These 
rankings were used to eliminate irrelevant questions and create a 28-item draft instrument. 
The items in the draft instrument were then discussed with 15 selected people from a non-medical 
background to ensure clarity of the sentences, simplify wording and to identify ambiguous and 
misleading terms. Items in the draft instrument were reworded based on the feedback received.  
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3.3.2 Content validity 
Content validity refers to the degree to which a scale has an appropriate sample of items to 
represent the construct of interest (135). To ensure content validity, the draft instrument was 
presented to 10 anticoagulation experts (8 pharmacists and 2 physicians) selected based on their 
work experience or research related to the use of oral anticoagulants. These experts were asked to 
rate the relevance of each item on the draft instrument on a four-point ordinal scale (1= not relevant, 
2 = somewhat relevant, 3 = quite relevant, 4 = highly relevant), and to suggest other items for the 
scale which may have been omitted. The content validity index for each item (I-CVI) and overall 
content validity of the scale (S-CVI) was then calculated using the method of Polit et al (135, 136). 
In calculating the I-CVI, the rating scale was dichotomised, with ratings of ‘1’ and ‘2’ combined 
as not relevant, and ratings of ‘3’and ‘4’ combined as being relevant, while the S-CVI was 
calculated by determining the average of all the I-CVI values. Further, I-CVI values were 
translated into values of a modified kappa index (k*) to adjust for chance agreement among the 
experts participating in the content validity exercise. The modified kappa index was determined 
using the formula – k* = (I-CVI- pc)/ (1- pc), where pc refers to the probability of chance 
agreement among the experts and was computed using the formula for a binomial random variable, 
with one specific outcome (pc = [N! /A! (N - A)!] x 0.5^N; where ‘N’ = number of experts and 
‘A’ = number of experts agreeing on relevance of an item). The average S-CVI of the scale was 
0.92 with I-CVIs ranging from 0.6-1 and k* ranging from 0.5-1 (Table 10). The final instrument 
was divided into two sections – section ‘A’ and ‘B’, with section ‘A’ comprising general 
anticoagulation knowledge questions applicable to both the DOACs and VKAs, and section ‘B’ 
comprised of VKA-specific questions.  
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Table 10. Item and Scale Content Validity Indexes 
No. General questions I-CVI Modified 
kappa 
1 What is the name of your anticoagulant medicine? 1.00 1.00 
2 Why has your doctor prescribed you this medicine? 1.00 1.00 
3 How does this medicine work in your body?   0.70 0.66 
4 How many times a day do you need to take this medicine? 1.00 1.00 
5 For how long do you need to take this medicine (for example, 3 
months, and 6 months, life-long)? 
1.00 1.00 
6 Why is it important to take this medicine exactly as your doctor has 
told you? 
1.00 1.00 
7 Is it acceptable to take this medicine at different times as long as 
you take it on the required days?  
1.00 1.00 
8 Is it acceptable to double the next dose of this medicine if you miss 
a dose? 
1.00 1.00 
9 Is it possible that skipping one dose of this medicine could worsen 
your condition? 
0.90 0.90 
10 Is it appropriate to stop taking this medicine once you feel better? 0.90 0.90 
11 Is it safe to take anti-inflammatory medicines like ibuprofen 
(Nurofen® or Advil®) while you are taking this medicine? 
1.00 1.00 
12 Is it safe to take vitamin supplements and herbal medicines with this 
medicine without consulting your doctor? 
0.90 0.90 
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13 Is there any benefit in taking more of this medicine than your doctor 
has told you to take?  
0.80 0.79 
14 Will drinking too much alcohol increase the risk of side effects with 
this medicine? 
0.90 0.90 
15 Is it necessary to inform a surgeon, dentist or other health 
professional that you are taking this medicine before undergoing 
surgery or a procedure? 
1.00 1.00 
16 Is it important that all the health care practitioners you see know 
that you are taking this medicine? 
0.90 0.90 
17 What is the most important side effect of this medicine?  0.80 0.79 
18 Three signs of side effects that you should watch out for while taking 
this medicine are: 
0.80 0.79 
19 Three things you can do to reduce your risk of side effects are: 0.60 0.50 
20 What is the best step to take if you accidentally take too much of 
this medicine?  
1.00 1.00 
 Question specific to people taking warfarin 
1 What is your target INR range?    0.90 0.90 
2 What was your last INR reading? 1.00 1.00 
3 Are routine INR tests necessary to know how well this medicine is 
working? 
1.00 1.00 
4 Is an INR value above your target range good for your general 
wellbeing? 
1.00 1.00 
5 Is it possible for INR values below your target range to be bad for 
your health? 
0.90 0.90 
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6a Is it possible for your diet to affect your warfarin therapy? 1.00 1.00 
6b If you answered ‘Yes’ above, list Three foods that can affect your 
anticoagulant therapy. 
0.90 0.90 
7 List one vitamin that can significantly affect your anticoagulant 
therapy.  
0.80 0.79 
pc (probability of a chance occurrence) was computed using the formula for a binomial random 
variable, with one specific outcome: 
pc = [N!/A!(N - A)!]*0.5^N where N = number of experts and A = Number agreeing on good 
relevance.  k* = kappa designating agreement on relevance, k* =  (I-CVI- pc)/(1- pc). 
k* of 0.4-0.59 (fair); 0.60–0.74 (good); and > 0.74 (Excellent). 
Average Scale-CVI= 0.92 
 
3.3.3 Pilot study 
In order to further ensure readability and comprehension, a pilot study was conducted in 13 
participants (5 pharmacists, 3 patients and 5 members of the general public) representing the three 
groups to be compared. The results from the thirteen pilot studies participants were not included 
in the main study. Instructions on completing and returning the questionnaire were further revised 
based on the feedback obtained in the pilot study. The final instrument used in the study is available 
in Appendix A6. 
3.3.4 Validation study 
Adults (aged > 18 years) who were able to read and complete the questionnaire independently 
were recruited into the validation study. All the participants in the validation study were recruited 
from Tasmania, Australia. Subjects were recruited into three groups comprising of a pharmacist 
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(expert) group, patient group and general public group. The pharmacist group was expected to 
serve as the positive control while the general public group was expected to serve as the negative 
control. Pharmacists were recruited from a total of 26 community and hospital pharmacies; patients 
currently prescribed oral anticoagulants were recruited from 14 community pharmacies; and 
participants from the general public group were recruited from 12 public places (e.g. parks, bus 
stops and shopping malls). Participants from the general public group were eligible to participate 
in the study if they were not health professionals, patients prescribed oral anticoagulants and did 
not have close relationships with patients taking oral anticoagulants. Information sheet for the 
study was provided to participants in the three groups which stated that anticoagulants are also 
called blood thinners, specifically to assist participants in the general public group who may be 
less familiar with the term ‘anticoagulant.’ Also, written informed consent was obtained prior to 
participation. Participants in the pharmacist and general public group were required to assume that 
they were currently taking an oral anticoagulant and answer the questions in both sections of the 
survey, while participants in the patient group were asked to respond to the survey based on the 
oral anticoagulant they had been prescribed by their physician. Patients who were prescribed any 
of the DOACS were required to answer the questions in section ‘A’ only, while patients who had 
been prescribed VKAs were asked to answer the questions in both sections. Participants in the 
pharmacist group were given the option of completing the test online or by using a paper format, 
while the other two groups completed the test by using only the paper format. Participants who 
preferred to use the paper format had the option of completing the survey on the spot, or return it 
using a reply paid envelope.  The study protocol was reviewed and approved by the Tasmanian 
Health and Medical Human Research Ethics Committee.  
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3.3.5 Validity and reliability 
Construct validity refers to the extent to which a measure adequately assesses the construct it 
purports to assess (137). Construct validity was assessed using the contrasted group approach 
which involves identifying two or more groups of individuals who are expected to have different 
scores on the characteristics being measured by an instrument (137). Using this approach, we 
hypothesised that the instrument would be sensitive to multiple levels of anticoagulation 
knowledge. Also, we expected the mean score of the pharmacist (expert) group to be higher than 
the mean patient group score, and the mean score of the patient group to be higher than that of the 
general public group.  
Two reliability tests were conducted: test-retest reliability and internal consistency reliability. In 
order to ensure the instrument’s stability, a re-test was conducted at approximately 2-3 month after 
the initial test administration, a time period considered sufficient to reduce the impact of recall. 
All the participants in the pharmacist and patient group were eligible for re-test, but only 32 
participants in the patient group and 22 in the pharmacist group participated in the second test. 
Internal consistency reliability was also conducted across the three groups to ensure the inter-
relatedness of the items in the instrument. 
3.3.6 Scoring 
Scoring was done use a dichotomous scale, with a score of ‘1’ or ‘0’ for each correct answer or 
wrong answer, respectively. A maximum score of ‘1’ was allocated to each correct answer for all 
of the questions with the exception of item ‘6’, ‘18’ and ‘19’ in section ‘A’ and item ‘6b’ in section 
‘B’. A maximum score of ‘2’ was obtainable for item ‘6’ in section ‘A’ (‘Why is it important to 
take this medicine exactly as your doctor has told you?’) 1 mark each was allotted for answers 
related to the prevention of thromboembolism and answers related to minimising the risk of 
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bleeding. For items ‘18’ and ‘19’ (‘three signs of side effects you should watch out for’ and ‘three 
things you can do to reduce your risk of side effect’, respectively) 1 mark each was allotted for 
each correct sign of side effects to look out for, 1 mark each was allotted for three correct food 
substances mentioned. A maximum total score of ‘25’ was obtainable for patients taking the 
DOACs required to answer only section ‘A’ of the questionnaire, while a maximum total score of 
‘35’ was obtainable for patients taking the VKAs (warfarin) required to answer both sections of 
the questionnaire. Final scores were presented as a percentage of correct answers for all the 
participants in the study. 
3.3.7 Statistical analysis 
Analysis of variance (ANOVA) was used in comparing the mean scores between the pharmacist, 
patient and general public groups, with p <0.05 considered statistically significant. Pearson's 
correlation was used in determining the correlation between the test and re-test scores for the 
pharmacist and patient groups, and values between 0 and 0.49 were considered as ‘very low’ to 
‘low’ correlation, while values between 0.5 and 1.0 were considered as ‘moderate’ to ‘very strong’ 
correlation. Cronbach’s alpha score was used in determining internal consistency reliability and 
across the three groups, with a score of 0.7 or greater considered acceptable (138). Lastly, the 
relative difficulty of each item and the instrument’s ability to discriminate between groups was 
also analysed by determining the differences in the percentages of items correctly answered across 
the three groups. Statistical analysis was conducted using SPSS Version 22.0. 
3.4 Results 
One hundred and forty-four participants, comprising 44 pharmacists, 50 patients and 50 members 
of the general public, participated in the validation study. Four surveys from the general public 
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group were excluded from the analysis due to participants being either health professionals or 
having experience with the use of oral anticoagulants; one survey from the patient group was 
excluded from the final analysis because the patient was not taking an oral anticoagulant at the 
time of the study. Overall, the results of 139 participants were included in the analysis (Table 
11). 
The mean score for the pharmacist (expert) group was significantly higher than that of the patient 
group, and the patient group’s mean score was significantly higher than the general public group’s 
(p <0.001; Table 12). No statistically significant difference in score was observed between patients 
taking the VKAs and the DOACS (p>0.05). For internal consistency reliability, a value of 0.92 
was obtained in the general public group, 0.71 in the patient group for the general anticoagulation 
questions and 0.87 for participants taking warfarin required to answer both sections ‘A’ and ‘B’, 
and 0.73 in the pharmacist group (Table 13). Test-retest reliability was confirmed with a Pearson’s 
correlation of 0.79 and 0.72 in the patient and pharmacist groups, respectively (Table 13). For the 
item analysis, item difficulty ranged from 0-100% across the three groups. The questions with the 
largest differences are listed in Table 14. Analysis of the patient group showed that patients taking 
the DOACs were less likely to view skipping a dose of prescribed oral anticoagulant as a problem 
compared to patients taking warfarin (p <0.05). No significant difference was observed in test 
scores based on both the type of oral anticoagulant patients were taking, and the duration of 
anticoagulation therapy.  
Although this study was not designed to assess the differences in test scores based on educational 
level, analysis of the general public group indicated that high school education or less was 
significantly associated with lower performance (p <0.01). No other differences were observed 
based on any other demographic characteristics across the three groups.  
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Table 11. Demographic characteristics  
 General public (n= 46) Patients (n= 49) Pharmacists (n= 44) 
Male n (%) 28 (64) 34 (69) 14 (34) 
Age in years (mean +/- SD) 38 ± 11 74 ± 12 34 ± 10 
Highest education completed n (%)  
High school   14 (30.4) 18 (36.7) NA 
College 8 (17.4) 5 (10.2) NA 
Technical/ Vocational 5 (10.9) 9 (18.4) NA 
Bachelor degree 5 (10.9) 11 (22.4) 35 (79.5) 
Post graduate 13 (28.3) 5 (10.2) 9 (20.5) 
No formal education 1 (2.2) 1 (2.0) 0 (0) 
Duration of oral 
anticoagulant therapy 
NA < 3 months: 3 (6.1) NA 
3-12 months: 4 (8.2) 
1-2 years: 8 (16.3) 
> 2 years: 32 (65.3) 
Not reported: 2 (4.1) 
NA = Not applicable 
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Table 12. Anticoagulation Knowledge Instrument Scores  
  General public (n=44) Patient (n=49) Pharmacist (n=44) 
Mean (%) 19.9 ± 16.4 62.0 ± 13.9 93.7 ± 6.9 
Minimum (%) 2.9 31.4 65.7 
Maximum (%) 62.9 91.4 100 
Statistics F (2, 136) = 359.8; p <0.0001 
 
Table 13. Validity and Reliability Coefficients 
 General public Patient  Pharmacist  
Internal consistency 
(Cronbach alpha) 
(n=46) 0.92 (Section A) (n=49): 0.71 (n=44) 0.73  
(Section A and B) (n=15): 0.87 
Test –retest 
(Pearson’s correlation) 
NA (n=32) 0.78 (n=22) 0.72 
NA = Not applicable 
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Table 14. Individual Item Analysis of Questions with Significant Variation Between Groups 
 Item General 
public (%) 
Patient  
(%) 
Pharmacist 
(%) 
Why has your doctor prescribed you this medicine? 7.9 89.6 100 
How does this medicine work in your body?   10.5 70.8 100 
How many times a day do you need to take this 
medicine? 
10.5 91.7 100 
For how long do you need to take this medicine (for 
example, 3 months, and 6 months, life-long)? 
10.5 91.7 100 
Is it appropriate to stop taking this medicine once you 
feel better? 
47.4 100 100 
Is there any benefit in taking more of this medicine 
than your doctor has told you to take? 
47.4 93.8 95.0 
What is the most important side effect of this 
medicine? 
2.6 60.4 100 
What is the best step to take if you accidentally take 
too much of this medicine? 
28.9 75.0 100 
  
VKA (warfarin)-specific questions 
What is your target INR range? 0 93.3 95.0 
What was your last INR reading? 0 93.3 95.0 
Are regular INR tests necessary to know how well this 
medicine is working? 
21.1 100 90.0 
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 Is an INR value above your target range good for your 
general wellbeing? 
2.6 66.7 90.0 
Is it possible for INR values below your target range to 
be bad for your health? 
10.5 80.0 87.5 
Is it possible for what you eat to affect your warfarin 
therapy? 
21.1 73.3 92.5 
 
3.5 Discussion 
We have described the development and validation of the Anticoagulation Knowledge Tool (AKT) 
- an instrument that allows for differences in anticoagulation knowledge to be measured that is 
applicable to patients taking both the VKAs and DOACs. The AKT is a 20-item knowledge 
questionnaire with eight additional questions for people taking VKAs (warfarin). Participants in 
the study were able to complete the survey independently, following written instructions, 
suggesting that the survey can be self-administered in routine clinical practice like existing tools 
such as the OAK and AKA. However, unlike the OAK and AKA, our AKT incorporates both open 
ended and multiple choice questions, as surveys with only multiple choice questions have the 
disadvantage of providing clues to the correct answers and increasing patients’ total score (139). 
Participants who filled the survey on the spot spent between 10 -15 minutes, while the length of 
time for participants who prefer to use the reply-paid envelope option could not be ascertained. 
This suggest that the questionnaire can be completed in a relatively short period of time.  
The method used in this study is consistent with recent consensus for the development and 
validation of new instruments. For content validity, a number of methods have been proposed for 
the content validation of new instruments including the T index (Tinsley & Weiss, 1975); Content 
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validity ratio ‘CVR’ (Lawshe, 1975); rWG index (James et al, 1984); CVI (Lynn, 1986) and r*WG 
index (Lindell et al, 1999) (140-144). The CVI was used in this study as it has the advantages of 
being easy to compute, easy to understand, focusing on both agreement of relevance among experts 
and consensus (proportion in agreement) rather than consistency (extent to which experts are 
consistent in their application of the rating scale), and providing both item and scale level 
information (135, 143, 145). The S-CVI value of 0.92 obtained is above the recommended standard 
of 0.8 for new scales. Furthermore, the majority of items had a modified kappa statistic that 
corresponded to either the ‘good’ or ‘excellent’ rating; only one item had ‘fair’ rating of 0.5. This 
suggests that agreement on relevance of each question was not due to chance and, overall, items 
were highly representative of the underlying construct.    
For construct validity, the result of the one-way ANOVA with post-hoc analysis showed a 
statistically significant difference across the three groups. This result is in agreement with the 
underlying principle for the group comparison method for construct validity of a new instrument 
(137), and it therefore follows that the instrument may be useful in distinguishing between different 
levels of anticoagulation knowledge. The significant variation observed with some items after the 
individual item analysis further supports the difference in knowledge across the three groups. This 
may imply that these items would be useful in routine clinical practice as a quick approach in 
identifying patients with low levels of anticoagulation knowledge.  The internal consistency and 
test-retest reliability coefficients were also acceptable. For the internal consistency reliability 
analysis, values of > 0.70 obtained across the three groups suggest that the items in the test are 
interrelated and of a reasonable length, and also measuring the same construct (138).  Further, the 
result of the test-retest reliability showed correlation coefficients of 0.78 and 0.72 in the patient 
and pharmacist group, respectively. There has been some debate on the acceptable level for test-
retest reliability due to varying statistical techniques, however, a recent systematic review 
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considered a minimum reliability threshold of 0.7 as being adequate (146). This suggests that the 
scale is expected to provide consistent scores over time in a stable population. 
Participants in the patient group in the validation study scored a mean score of 62% on the AKT. 
This result is similar to those reported in prior studies. A mean score of 64% was recorded by 
Winans et al in inpatients new to warfarin therapy (147), while Tang et al reported a mean score 
of 48% in patients attending an anticoagulation clinic for at least 2 months (29).  Similarly, Davis 
et al and Hu et al have also reported that less than 40% of patients in routine clinical practice have 
adequate anticoagulation knowledge (27, 148). These results suggest that there remains a 
significant gap in patient anticoagulation knowledge in contemporary practice, and further 
investigation in a larger cross-section of people taking oral anticoagulants is warranted.  
Another important observation in the patient group is that participants taking the DOACs were less 
likely to view skipping a dose of their medication as a problem compare to participants taking 
warfarin. This is a critical knowledge gap because the DOACs have shorter half-lives compare to 
warfarin, and non-adherence to therapy even for a short period can result in loss of clinical effect 
and expose patients to significant risk (149). This suggests that significant attention should be 
given to the concept of medication adherence when designing and implementing an educational 
intervention in patients prescribed the DOACs.  
3.6 Limitations 
Among participants in the general public group, about 70% had formal education beyond high 
school level, including 28% with a post-graduate qualification. The high literacy level of this group 
may not be truly representative of the general public. However, the average score of this group 
was still significantly lower than both the patient and pharmacist groups. Also, participants in the 
three groups were not aged matched, and it is not known if a higher median age in the general 
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public group would have given a higher result.  All the participants in the survey were given the 
opportunity of either completing the survey immediately upon receipt or returning it using a reply-
paid envelope; we cannot rule out the possibility that some participants might have accessed 
additional resources despite being encouraged not to do so in the survey instructions. This may 
have increased the overall score in the survey. The relatively high score in the patient group may 
be as a result of the recruitment of confident and enthusiastic patients who have had or are 
undergoing some form of educational training on the use of oral anticoagulant medication, and 
may not necessary reflect the broader anticoagulant-medication taking population. For the test-
retest reliability, not all the participants who completed the first test participated in the second test, 
and the impact of this on the test-retest reliability coefficient remains unknown. Lastly, the study 
was conducted in a single region, and the instrument may need to be validated in other regions 
globally.   
3.7 Conclusion 
To the best of our knowledge, the AKT is the first validated instrument that can be employed in 
assessing anticoagulation knowledge of patients taking either the VKAs or the DOACs. It appears 
to be a valid and reliable instrument in assessing different levels of anticoagulation knowledge. 
Therefore, it could be useful in routine clinical practice for determining gaps in patients’ 
anticoagulation knowledge, measuring changes in anticoagulation knowledge over a period of time 
or in response to educational interventions, and in clinical research for determining the association 
between anticoagulation knowledge and health related outcomes.  
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CHAPTER FOUR 
4.0 The relationship between knowledge, health literacy and 
adherence among patients taking oral anticoagulants for stroke 
thromboprophylaxis in atrial fibrillation 
 
Overview 
In this chapter, the Anticoagulation Knowledge Tool (AKT) was piloted in 48 patients with AF to 
investigate the relationships between oral anticoagulant knowledge, adherence and health literacy. 
This study was conducted to assess the usability of the AKT in a small sample using face-to-face 
interview. The results of the study showed that the AKT was able to detect OAC knowledge gaps 
in patients with AF, and suggest that knowledge, health literacy and medication adherence levels 
were suboptimal and positively related. This study was published in Cardiovascular Therapeutics 
(https://www.ncbi.nlm.nih.gov/pubmed/28869793) on September 26, 2017. 
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4.1 Abstract 
Background: Patients’ knowledge regarding their oral anticoagulant (OAC) treatment for stroke 
prevention in atrial fibrillation (AF), their level of medication adherence, and health literacy are 
known to affect treatment outcomes. However, contemporary data regarding the relationships 
between these variables are lacking. 
Objective: To investigate the relationships between anticoagulant knowledge, health literacy, and 
self-reported adherence in patients taking warfarin and the directly acting oral anticoagulants. 
Methods: A cross-sectional survey was conducted in 48 patients with AF identified from general 
practices. The Anticoagulation Knowledge Tool (AKT) was used to assess anticoagulation 
knowledge; the Short Test of Functional Health Literacy in Adults (s-TOFHLA) for health literacy; 
and the 8-item Morisky Medication Adherence Scale (MMAS) for medication adherence. 
Results: Participants had mean scores of 61.6 ± 15.8, 7.2 ± 1.1, and 24.7 ± 9.5 for the AKT, 
MMAS-8 and s-TOFHLA, respectively. Significant correlations were observed between 
anticoagulation knowledge and health literacy with medication adherence (0.37, P < .01 and .30, 
P < .05, respectively). Participants with inadequate health literacy had a significantly lower mean 
knowledge score than those with adequate health literacy (55.8 ± 15.9 vs 66.1 ± 14.4, P < .05). 
Participants who self-reported adherence to their OAC had significantly higher knowledge scores 
than those who did not (67.5 ± 13.3 vs 56.1 ± 16.2, P < .05). 
Conclusion: Significant correlations between health literacy, OAC knowledge, and adherence 
were observed, and these relationships should to be considered by health professionals responsible 
for monitoring patients who are prescribed anticoagulants. We also observed serious gaps in OAC 
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knowledge. Interventions designed to optimise the outcomes of anticoagulant treatment need to 
address these factors. 
4.2 Introduction 
Atrial fibrillation (AF) is associated with significant morbidity and mortality, and stroke resulting 
from AF presents a large and growing economic concern (150). Anticoagulation therapy in at risk 
patients with AF can markedly reduce stroke risk and is therefore an important component of AF 
management (150). Under-use of OACs in AF is often reported in terms of under-prescribing of 
treatment, but poor treatment outcomes in people with AF also commonly result from poor 
adherence or persistence with anticoagulant therapy even when it is prescribed, often with 
devastating consequences (28). Patients’ oral anticoagulation knowledge, level of medication 
adherence and health literacy are known to affect treatment outcomes. However, contemporary 
data regarding the relationships between these variables are lacking. 
Medication adherence in chronic disease is a worldwide problem. Up to 50% of patients are non-
adherent to medications, including OACs (27, 151, 152). Limited health literacy is associated with 
poor warfarin and AF knowledge (153, 154). In addition, poor warfarin knowledge and lack of 
education about warfarin have been associated with inadequate anticoagulant control and increased 
haemorrhagic events, and those at highest risk of stroke have been shown to have the poorest 
knowledge regarding their treatment (68, 153, 155). It is unknown whether similar results will be 
seen in patients who take directly acting oral anticoagulants (DOACs).  
The introduction of the DOACs has sought to address some of the pitfalls of warfarin therapy, 
however there are persisting challenges to overcome; adherence to the drug regimen being the 
most crucial. Due to their short half-lives, irregular or missed doses can increase the risk of stroke, 
as the patient will be inadequately anticoagulated during this time (156, 157). 
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The 2016 European Society of Cardiology (ESC) guidelines for the management of AF 
recommend an integrated approach to care with particular focus on the patient being central to 
effective management. Integral to patient-centred care is patient education, which in turn 
empowers self-management and shared decision making. As a European Heart Rhythm 
Association, priority research area and acknowledged by the ESC guidelines, more research is 
needed to determine the best way to deliver an integrated approach (150, 158). 
Given the interest in integrated AF care, and the lack of contemporary data investigating the 
relationships between health literacy, adherence behaviours and medication knowledge of patients 
taking OACs for stroke thromboprophylaxis in AF, the aim of this study was to investigate the 
relationships between these variables and to assess the strength of the relationship between 
knowledge and health literacy. 
4.3 Methods 
4.3.1 Recruitment 
Participants were recruited to the study from participating general practices or outpatient 
cardiologist clinics in Tasmania, Australia. Invitation letters with a response form were sent to the 
practices requesting their participation in the study and asking that patients with AF in their 
practices be given the opportunity to participate in the study. To be eligible to participate, 
participants had to be over 18 years of age, have a diagnosis of non-valvular AF, be currently 
taking warfarin or DOACs for stroke thromboprophylaxis and be able to provide informed consent.  
Participants were interviewed either at their regular GP surgery or in their home as these were 
considered familiar and comfortable surroundings. A $10 AUD shopping voucher was provided 
to all participants as recruitment incentive and as compensation for their time at the end of the 
interview.  
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4.3.2 Data collection 
The interview consisted of four validated questionnaires - the 8-item Morisky Medication 
Adherence Scale (MMAS-8), Anticoagulant Knowledge Tool (AKT), Short Test of Functional 
Health Literacy in Adults (s-TOFHLA) and the Atrial Fibrillation Effect on Quality of Life 
(AFEQT) questionnaire, presented to participants in this order. Participants were introduced to the 
study using a script and all questionnaires were undertaken in an interview style, with the exception 
of s-TOHFLA which participants completed by themselves within a seven-minute time limit. Each 
interview took between 20 and 45 minutes and all were completed in a single session.  
4.3.2.1 Adherence 
To assess self-reported adherence behaviour, we used the MMAS-8 questionnaire, which asks 
seven dichotomous questions and one 5-point Likert scale question (159-161). The validated 
MMAS-8 was chosen as it has been shown to be a reliable predictor of adherence in patients taking 
medications for chronic diseases, such as antihypertensives, and has been used to assess adherence 
in those taking OACs (160, 162, 163). In assessing adherence using the MMAS-8, a score of 8 
was considered adequate adherence, while a score of less than 8 was considered inadequate 
adherence (162). 
4.3.2.2 Knowledge 
To assess the level of knowledge of OAC therapy and its role, including participant 
perceptions/understanding of the risks and benefits, we used the AKT, which was developed to 
assess the anticoagulant knowledge of patients taking either warfarin or DOACs. A score of ‘1’ or 
‘0’ was given for correct and incorrect answers, respectively. Participants taking a DOAC were 
required to answer only section ‘A’ with a total maximum score of 25 and participants taking 
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warfarin were required to answer sections ‘A’ and ‘B’ with a total maximum score of 35. Final 
scores were presented as percentages of correct answers for all participants (164). 
4.3.2.3 Health Literacy 
To assess functional health literacy, we used the s-TOFHLA (165). Dichotomous scoring of ‘1’ 
for correct answers and ‘0’ for incorrect answers was used and a maximum score of 36 could be 
achieved. In scoring the s-TOFHLA scale, a score of 23 and above was considered adequate health 
literacy, while a score of 22 and less was considered inadequate health literacy (153, 166). 
4.3.2.4 Quality of Life 
To assess AF specific health related quality of life we used the AFEQT. For AFEQT questions 1-
20, responses were scored on a 1 to 7 Likert scale. An overall score of 0-100 could be achieved, 
corresponding to ‘complete disability’ to ‘no disability’, respectively. AFEQT was chosen as it 
combines the scores from four parameters: symptoms, daily activities, treatment concerns and 
satisfaction to a single measure with reliability, and has focused questions surrounding the use of 
anticoagulants (167, 168).  
4.3.3 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM, Armonk, New York, US). Means 
and standard deviations were used to summarise continuous variables, and independent sample t-
tests were used for inferential statistics. s-TOFHLA and MMAS-8 scores were analysed as both 
continuous and dichotomous variables. Correlations between AKT, s-TOFHLA and MMAS-8 
scores were determined using the Spearman rank coefficient. Logistic regression analysis was used 
to estimate regression coefficients for AKT and s-TOFHLA against MMAS-8 adherence scores in 
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both univariate and multivariate models. A p value of <0.05 was considered statistically significant 
for all analyses. 
4.3.4 Sample size 
Using a 5% margin of error and statistical power of 80%, we determined that a sample size of 40 
participants would be sufficient to detect a moderate statistical correlation of 0.4 between the AKT 
score and s-TOFHLA score with the MMAS-8 adherence score.  
4.3.5 Ethics 
The Tasmanian Health and Medical Human Research Ethics Committee (reference number 
H0015395) approved this study. Informed consent was obtained from all individual participants 
included in the study. 
4.4 Results 
4.4.1 Demographic characteristics 
Fifty participants were interviewed. The results of two participants were excluded because they 
had discontinued their OAC at the time of the interview, leaving data from 48 participants available 
for analysis. The average age of the participants was 76.4 ± 8.7 years and the majority (77.1%) 
were male (Table 15). Forty-two percent of participants had either high school education (Year 10 
equivalent) or college (Year 12 equivalent) as the highest level of education completed. The 
majority of the participants were taking a DOAC (64.6%) at the time of the study, and had been 
taking an anticoagulant for greater than 2 years (75.0%).  
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Table 15. Demographic characteristics n (%) 
Parameter Overall Sample (n= 48) 
Male  37 (77.1) 
Age in years (mean +/- SD) 76.4 ± 8.7 
Highest education completed n (%) 
High school 14 (29.2) 
College 6 (12.5) 
Technical/ Vocational 13 (27.1) 
Bachelor degree 11 (22.9) 
Post graduate 4 (8.3) 
Duration of anticoagulant therapy n (%) 
Less than 3 months 1 (2.1) 
3-12 months 5 (10.4) 
1-2 years 6 (12.5) 
Greater than 2 years 36 (75.0) 
Oral anticoagulant n (%) 
Warfarin 17 (35.4) 
DOAC 31 (64.6) 
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4.4.2 Association between level of self-reported adherence and health literacy, knowledge and 
AF-related quality of life 
Adequate adherence to the prescribed OAC was reported by 47.9% of participants and this group 
had a significantly higher total knowledge score than those who were non-adherent (67.5% vs 
56.1%, p = 0.011) (Table 16). However, no association between the level of adherence with health 
literacy and AF-related quality of life was observed. 
 
4.4.3 Level of health literacy and knowledge  
As shown in Table 17, when participants were categorised based on their health literacy scores, 
those with inadequate health literacy had a significantly lower mean total anticoagulant knowledge 
score than those with adequate health literacy (55.8 ± 15.9 versus 66.1 ± 14.4, p = 0.02). 
Table 16. Association between adherence level and study variables 
Parameter Overall 
Sample  
(n= 48) 
Inadequate Adherence 
(MMAS-8 Score < 8) 
(n=25) 
Adequate Adherence 
(MMAS-8 score = 8) 
(n=23) 
p value 
Total AKT score 61.6 ± 15.8 56.1 ± 16.2 67.5 ± 13.3 0.011* 
s-TOFHLA  24.7 ± 9.5 22.9 ± 9.9 26.7 ± 8.8 0.171 
Overall AFEQT 80.1 ± 15.8 81.3 ± 16.7 78.8 ± 14.9 0.593 
*p <0.05 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is required. 
A license agreement is available from: Donald E. Morisky, MMAS Research (MORISKY), 14725 NE 20th 
St Bellevue WA 98007, USA; dmorisky@gmail.com. 
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Furthermore, participants with inadequate health literacy were less likely than those with adequate 
health literacy to know why they had been prescribed an OAC (57.1% versus 85.2%, p = 0.04), 
less likely to know how the medication worked (42.9% versus 88.9%, p = 0.001) and less likely 
to be able to describe one sign of side effects to watch out for whilst taking an anticoagulant (28.6% 
versus 70.4%, p = 0.03). In addition, only 16.7% of all participants could mention three signs of 
side effects to watch out for while taking an OAC (Table 17).  
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Table 17. Anticoagulation knowledge score according to health literacy level 
Item 
Overall 
Sample 
(n= 48) 
n (%) 
Inadequate 
Health 
Literacy 
(n=21) 
n (%) 
Adequate 
Health 
Literacy 
(n=27)  
n (%) 
p value 
What is the name of your anticoagulant 
medicine? 
43 (89.6) 17 (81.0) 26 (96.3) 0.119 
Why has your doctor prescribed you this 
medicine? 
35 (72.9) 12 (57.1)  23 (85.2) 0.039* 
How does this medicine work in your body?   33 (68.8) 9 (42.9) 24 (88.9) 0.001* 
How many times a day do you need to take this 
medicine? 
48 (100.0) 21 (100.0) 27 (100.0) NA 
For how long do you need to take this medicine 
(for example, 3 months, and 6 months, life-
long)? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
Why is it important to take this medicine exactly 
as your doctor has told you? 
(stroke) 
28 (58.3) 10 (47.6) 18 (66.7) 0.192 
Why is it important to take this medicine exactly 
as your doctor has told you? 
(bleeding) 
1 (2.1) 1(4.8) 0 (0.0) 0.329 
Is it important to take this medicine at the same 
time each day? 
42 (87.5) 18 (85.7)  24 (88.9) 0.748 
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Is it okay to double the next dose of this 
medicine if you miss a dose? 
46 (95.8) 21 (100.0) 25 (92.6) 0.161 
Is it possible that skipping one dose of this 
medicine could worsen your condition? 
19 (39.6) 7 (33.3) 12 (44.4) 0.446 
Is it appropriate to stop taking this medicine 
once you feel better? 
44 (91.7) 18 (85.7) 26 (96.3) 0.231 
Is it safe to take anti-inflammatory medicines 
like ibuprofen (Nurofen® or Advil®) while you are 
taking this medicine? 
28 (58.3) 15 (71.4) 13 (48.2) 0.105 
Is it safe to take vitamin supplements and herbal 
medicines with this medicine without consulting 
your doctor?  
30 (62.5) 15 (71.4) 15 (55.6) 0.264 
Is there any benefit in taking more of this 
medicine than your doctor has told you to take?  
44 (91.7) 18 (85.7) 26 (96.3) 0.231 
Will drinking too much alcohol increase the risk 
of side effects with this medicine? 
18 (37.5) 9 (42.9) 9 (33.3) 0.513 
Is it necessary to inform a surgeon, dentist or 
other health professional that you are taking this 
medicine before undergoing surgery or a 
procedure? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
Is it important that all the health care 
practitioners you see know that you are taking 
this medicine? 
47 (97.9) 20 (95.2) 27 (100.0) 0.329 
What is the most important side effect of this 
medicine?  
21 (43.8) 7 (33.3) 14 (51.9) 0.208 
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THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(1/3) 
25 (52.1) 6 (28.6) 19 (70.4) 0.003* 
THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(2/3) 
15 (31.3) 5 (23.8) 10 (37.0) 0.337 
THREE signs of side effects that you should 
watch out for while taking this medicine are: 
(3/3) 
8 (16.7) 2 (9.5) 6 (22.2) 0.231 
THREE things you can do to reduce your risk of 
side effects are: (1/3) 
16 (33.3) 4 (19.1) 12 (44.4) 0.059 
THREE things you can do to reduce your risk of 
side effects are: (2/3) 
7 (14.6) 1 (4.8) 6 (22.2) 0.072 
THREE things you can do to reduce your risk of 
side effects are: (3/3) 
6 (12.5) 1 (4.8) 5 (18.5) 0.133 
What is the best step to take if you accidentally 
take too much of this medicine?  
34 (70.8) 16 (76.2) 18 (66.7) 0.482 
Warfarin specific questions 
Item 
Overall 
Sample 
(n=17) 
n % 
Inadequate 
Literacy 
(n=9) 
n (%) 
Adequate 
Literacy 
(n=8)  
n (%) 
p value 
What is your target INR range? 11 (64.7) 5 (55.6) 6 (75.0) 0.431 
What was your last INR reading? 16 (94.1) 8 (88.9) 8 (100.0) 0.347 
Are routine INR tests necessary to know how 
well this medicine is working? 
15 (88.2) 8 (88.9) 7 (87.5)  0.935 
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Is an INR value above your target range good for 
your general wellbeing? 
13 (76.5) 6 (66.7) 7 (87.5) 0.334 
Is it possible for INR values below your target 
range to be bad for your health? 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
Is it possible for what you eat to affect your 
warfarin therapy? 
14 (82.4) 6 (66.7) 8 (100.0) 0.081 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (1/3) 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (2/3) 
12 (70.6) 5 (55.6) 7 (87.5) 0.161 
If you answered ‘Yes’ above, list THREE foods 
that can affect your anticoagulant therapy: (3/3)  
11 (64.7) 4 (44.4) 7 (87.5) 0.066 
List one vitamin that can significantly affect your 
anticoagulant therapy. 
6 (35.3) 2 (22.2) 4 (50.0) 0.259 
Total AKT score (%) 61.6 ± 15.8 55.8  
± 15.9 
66.1  
± 14.4  
0.022* 
*p <0.05 
 
4.4.4 Association between adherence, knowledge and health literacy  
There were moderate positive correlations between the mean scores of self-reported adherence, 
anticoagulant knowledge and health literacy (figure 5). Multivariate analysis showed that 
anticoagulation knowledge was significantly associated with MMAS-8 score even after adjusting 
for health literacy score (OR, 1.050; 95% CI, 1.003 – 1.100; p = 0.036), Table 18). There were no 
statistically significant relationships between total AF specific health related quality of life scores 
and other study variables.  
100 
 
 
Figure 5: Correlations between study variables  
 
*Correlation is significant at the 0.05 level (2-tailed)  
** Correlation is significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
 
MMAS-8 
score
AKT score 0.309* STOFHLA score
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Table 18. Association of knowledge and health literacy scores with MMAS-8 score (logistic regression) 
Independent 
variables 
Unadjusted model Adjusted model 
 OR (95%CI) p value OR (95%CI) p value 
Knowledge Score 1.054 (1.009 – 1.101) 0.017* 1.050 (1.003 – 1.100) 0.036* 
Health Literacy 
Score 
1.045 (0.981 – 1.114) 0.171 1.018 (0.948 – 1.092) 0.631 
Model statistics: Nagelkerke R2 = 18.1% 
CI, confidence interval; MMAS-8, 8-item Morisky medication adherence scale. 
* p <0.05 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is required. 
A license agreement is available from: Donald E. Morisky, MMAS Research (MORISKY), 14725 NE 20th 
St Bellevue WA 98007, USA; dmorisky@gmail.com. 
 
4.5 Discussion 
This study provides valuable data supporting relationships between adherence, OAC knowledge 
and health literacy. Participants who self-reported adherence to their OAC had significantly higher 
knowledge scores than those who did not. In addition, participants with adequate health literacy 
achieved significantly higher knowledge scores. Positive correlations between health literacy, 
knowledge and adherence scores were also observed, suggesting that these concepts are interlinked 
and should be considered when managing patients taking OACs for stroke thromboprophylaxis in 
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AF. The Capability, Opportunity and Motivation (COM-B) model of Behaviour to increase 
medication adherence provides a dynamic framework in order to identify appropriate interventions 
that address the modifiable factors influencing non-adherence (33, 169). Mapping the results from 
this study to the COM-B framework suggests each of the domains (COM) are involved and need 
to be addressed in order to increase OAC adherence (B) (33, 169). 
Poor adherence to OACs is frequently reported in the literature and has been associated with poor 
clinical outcomes (27, 28, 40, 102, 152). In our study, 48% of participants reported adequate 
adherence to their prescribed OAC. This is similar to the study by Davis et al. in patients taking 
warfarin, in which only 50% of participants reported adequate adherence (27). A recent review of 
adherence and persistence to OACs in AF found that in the studies available, poor adherence is 
associated with poor treatment outcomes such as stroke and bleeding (40). Yao et al recently 
undertook a large retrospective cohort study in patients taking OACs for stroke prevention in AF 
and found that those with a high estimated stroke risk were at an increased risk of stroke when 
they were not taking anticoagulation for 6 months or more (hazard ratio 2.73, p <0.001), clearly 
indicating that better medication taking behaviour leads to better outcomes (28). 
Taking into consideration the importance of adherence in ensuring a steady plasma concentration 
with DOACs and their lack of routine laboratory monitoring(157), our study suggests that patients 
taking DOACs may require routine follow up by health care practitioners (HCPs) to ensure that 
they adhere to their medication. This fit within the COM-B sub-category of Physical Opportunity, 
which suggests that HCP-patient communication and relationships can be improved through 
routine clinical follow up, in turn leading to increased adherence (33, 169).  
We observed a total mean knowledge score of 62%. This is similar to the result of other studies in 
the literature, where a mean knowledge score of less than 70% has been reported in different 
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populations (46, 74, 164, 170). From the results of our study, participants who were considered 
adherent had a significantly higher mean total knowledge score than those who were non- adherent, 
and knowledge remained significantly associated with adherence even after adjusting for the level 
of health literacy. Forty percent of all participants did not know that taking an OACs as the doctor 
had prescribed reduced the risk of stroke and 60% of all participants did not know that skipping a 
dose of their OAC could worsen their condition. In support of these findings, a recent study by 
Desteghe et al found that 34% were unaware that AF could cause a stroke and 57% of the patients 
taking DOACs did not know what to do when they miss a dose (170). Lane et al found that only 
approximately 50% could name their condition and perceived it as a serious condition that could 
predispose them to a stroke (56). Few studies have examined whether poor DOAC knowledge 
leads to poor clinical outcomes, however this has been demonstrated in those taking warfarin (68, 
153, 155). Our study reveals specific deficiencies in the knowledge of both warfarin and DOAC-
taking participants. In addition, it provides a platform to inform the development of educational 
interventions and justifies the need for further research in this area. 
Limited health literacy may be an indicator of deficits in warfarin knowledge (153, 154). Fang et 
al reported that 67% of patients taking warfarin for stroke prevention in AF had limited health 
literacy (s-TOFHLA score of 0-22) and this group had significantly inadequate disease and 
medication-related knowledge in comparison to those with adequate health literacy (153). These 
results align well with our study, which found that those with inadequate health literacy had a 
significantly lower mean total anticoagulant knowledge score in comparison to those with 
adequate health literacy. Participants with inadequate health literacy were less likely than those 
with adequate health literacy to know why they had been prescribed an OAC, less likely to know 
how the medication works and less likely to be able to describe one sign of side effects to watch 
out for while taking an anticoagulant. Patients need to know what they have been prescribed and 
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why, as well any possible side effects. Paucity in patients’ knowledge can have a profound effect 
on the management of AF (171).  
Lack of knowledge and health literacy, comprehension of the disease and treatment, perception of 
illness and beliefs about treatment including concern of side effects and bleeding fits within the 
COM-B sub-categories of Psychological Capability and Reflective Motivation (33, 169). It has 
been suggested that these categories can be addressed by HCPs giving information to patients to 
shape their knowledge, with the intention to enhance a patient’s capability to understand and 
engage in their therapy (33, 169). With the goal of improving adherence through patient centred 
care, consideration of health literacy and its association with knowledge and adherence in patients 
taking OACs for stroke prevention in AF should therefore not be overlooked. Adherence may be 
improved through implementation of individually tailored educational interventions focusing on 
improving the disease and medication-related knowledge of the patient.  
4.6 Limitations 
There are a number of limitations to this study, including the cross-sectional methodology and 
small sample size. Furthermore, we did not collect information on the quality of education given 
to participants on their OACs upon initiation, nor did we determine if participants who were taking 
a DOAC at the time of the interview had previously been taking warfarin. The limitations of the 
tools used should also be considered. We anecdotally observed that many participants were unable 
to differentiate between the effect of AF and other co-morbidities such as heart failure or older age 
on quality of life. This made it difficult for participants to definitively say that AF was the condition 
causing their symptoms, such as shortness of breath or limiting their ability to exercise. Medication 
adherence was quantified by self-report; this approach can possibly overestimate the level of 
adherence observed (172). 
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4.7 Implications for further research 
Recent clinical guidelines have placed emphasis on integrating the patient and their preferences 
into AF management to improve outcomes (150). The results of this study help to inform the 
implementation of patient centred integrated AF management and reinforce the need for additional 
research. Considering the demonstrated correlation between health literacy, knowledge and 
adherence, larger studies are required to determine if improving these patient centred aspects of 
OAC management in AF leads to improved treatment outcomes. Moreover, this study reveals gaps 
in the knowledge of participants taking OACs. A large prospective study assessing anticoagulant 
knowledge in this population will be useful in identifying specific areas of lacking knowledge to 
improve OAC education.   
4.8 Conclusion 
In conclusion, the results of this study demonstrate a significant relationship between health 
literacy, OAC knowledge and self-reported adherence behaviours. They also highlight inadequate 
medication adherence behaviour and health literacy levels, and gaps in patient oral anticoagulation 
knowledge. To adopt a true patient centred approach to AF management, it is important for HCPs 
to consider these variables in patients taking OACs for stroke prevention in AF. Interventions 
designed to optimise the outcomes of anticoagulant treatment need to address these factors. 
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CHAPTER FIVE 
5.0 Anticoagulation knowledge in patients with atrial fibrillation: an 
Australian survey 
 
Overview 
This study aimed to address the third objective of this thesis. It focused on the use of the 
Anticoagulation Knowledge Tool to determine the level of oral anticoagulant knowledge in 
patients with AF, identifying domains where knowledge gaps exist, and assessing the association 
between patient-related factors and oral anticoagulant knowledge. The results from the pilot study 
reported in Chapter 4 suggested that OAC knowledge was suboptimal, and the AKT was able to 
provide reliable results using a traditional face-to-face interview approach. As such, the study 
reported in this chapter explored the use of an alternative approach, namely an online survey, to 
assess OAC knowledge in a larger, nationally representative sample of patients with AF. This 
paper was submitted to the International Journal of Clinical Practice in September 2017, and is 
currently under review. 
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5.1 Abstract 
Background: Atrial fibrillation (AF) is the most commonly diagnosed arrhythmia in clinical 
practice, and is associated with a significant medical and economic burden. Anticoagulants reduce 
the risk of stroke and systemic embolism by approximately two-thirds compared to no therapy. 
Knowledge regarding anticoagulant therapy can influence treatment outcomes in patients with AF. 
Objective: To measure the level of anticoagulation knowledge in patients with AF taking oral 
anticoagulants (OACs), investigate the association between patient-related factors and 
anticoagulation knowledge, and compare these results in patients taking warfarin and direct acting 
oral anticoagulant (DOACs). 
Methods: Participants were recruited for an online survey via Facebook. Survey components 
included the Anticoagulation Knowledge Tool, the Perception of Anticoagulant Treatment 
Questionnaires (assessing treatment expectations, convenience and satisfaction), a modified 
Cancer Information Overload scale and the Morisky Medication Adherence Scale. Treatment 
groups were compared and predictors of OAC knowledge were identified. 
Results: Participants taking warfarin had a higher knowledge score compared to those taking 
DOACs (n = 386, 73.4% ± 13.2% vs 65.7% ± 13.7%, p <0.001). Advancing age, type of OAC, 
health information overload and ease of OAC use (treatment expectation) were significant 
predictors of knowledge. Treatment expectation, including the belief that OAC treatment would 
cause bleeding side effects, varied significantly between participants taking warfarin and DOACs 
(p = 0.011). 
Conclusion: The study identified knowledge gaps in patients taking OACs, and these deficiencies 
appeared to be greater in participants taking DOACs. Knowledge assessment should be integrated 
within patient counselling sessions to help identify and resolve knowledge deficits. 
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5.2 Introduction 
Atrial fibrillation (AF) is the most commonly diagnosed arrhythmia in clinical practice, and is 
associated with a significant medical and economic burden (34). Patients with AF have a five-fold 
increase in their stroke risk (5); AF-related strokes are more severe and more likely to result in 
death compared to strokes in patients without AF (6, 7). Anticoagulants reduce the risk of stroke 
and systemic embolism by approximately two-thirds compared to no therapy irrespective of 
baseline risk (173) ; however, there are a number of factors that limit their optimal use (108, 174). 
It is well recognised that shared decision making with informed patients is important in the 
management of AF (36). Thus, patients need to be appropriately informed about their disease and 
treatment, including anticoagulant therapy.  
Knowledge regarding anticoagulant therapy can influence treatment outcomes in patients with AF 
(29, 175). Patients with optimum knowledge regarding their medication and condition can 
participate in self-management and are more likely to adhere to prescribed medications, compared 
to those with inadequate knowledge (31, 176, 177). Various studies suggest that oral anticoagulant 
(OAC) therapy requires complex patient understanding for adequate self-management (27, 70, 
174). Various patient-related factors including health information overload (178), treatment 
expectation (179), treatment convenience and satisfaction have been reported to be associated with 
knowledge regarding medication and therapy (180, 181). Health information overload has been 
investigated in patients with cancer (178); treatment expectation has been investigated in patients 
taking antibiotics (179); treatment convenience and satisfaction have been investigated in patients 
with hypertension and endocrine diseases (180, 181). These factors, however, have not been 
adequately studied in patients with AF.  
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In Australia, there has been an increasing rate of prescription of direct-acting oral anticoagulants 
(DOACs), as well as switching of patients previously taking warfarin to DOACs, since their 
approval and subsequent government subsidisation (32, 182, 183). The increased uptake of 
DOACs in clinical practice has also been corroborated by data from the United States, Canada, 
and the United Kingdom (184-187). Despite the increased uptake, most studies exploring OAC 
knowledge have been limited to participants taking vitamin K antagonists (VKAs), and have not 
involved patients taking DOACs (29, 50, 58, 59, 61, 147, 174, 188).  
While DOACs have several advantages over warfarin, OAC therapy remains a high-risk treatment 
strategy (189). It is therefore important to be able to assess the adequacy of anticoagulation 
knowledge in patients prescribed either VKAs or DOACs and address any deficiencies or 
misconceptions. Therefore, this study aimed to (i) determine the level of anticoagulation 
knowledge in patients with AF taking oral anticoagulants (either warfarin or a DOAC), compare 
this level of knowledge between patients taking warfarin versus DOACs, and identify any domains 
where significant knowledge gaps exist; and (ii) investigate the association between treatment 
expectation, convenience and satisfaction, health information overload, and medication adherence 
with anticoagulation knowledge, and whether these factors differ for participants taking warfarin 
and DOACs.  
5.3 Methods 
5.3.1 Recruitment 
Participants were recruited for an online survey (via LimeSurveyTM) using Facebook. A Facebook 
page was created which contained the advertisement that was shown to users in their newsfeeds or 
on the right-hand advertising column of their Facebook page. A paid advertisement on Facebook 
targeted Australian residents over the age of 18 years. Potential survey participants were able to 
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click on the Facebook advertisement, from where they were directed to the LimeSurveyTM page 
containing an information page and the survey. A chance to enter into a drawing for an Apple iPad 
mini was used as an incentive to encourage participation. To maintain anonymity, prize draw 
details were not linked to survey responses. Participants were excluded from the analysis if they 
did not complete the survey, did not report having a diagnosis of AF, or did not report taking an 
OAC. 
5.3.2 Survey 
5.3.2.1 Recruitment 
The survey requested participant demographic information including age, gender, postal code, 
annual income, highest educational level and employment status. Participants were then asked the 
name of the OAC they were taking, how long they had been taking it, and if they currently had a 
diagnosis of AF.  
5.3.2.2 Anticoagulation Knowledge Tool 
Anticoagulation knowledge was evaluated using the Anticoagulation Knowledge Tool (AKT), 
developed and validated in 2016 to assess the anticoagulation knowledge of patients taking either 
VKAs (warfarin) or DOACs (164). The AKT consists of two sections comprising general 
questions (section A - 20 items) and VKA-specific questions (section B - 8 items). All participants 
are required to answer the questions in section A, while only participants taking warfarin are 
required to answer the questions in section B. Participants taking DOACs can score a maximum 
of 25 points as they are only able to complete section A (164). Participants taking warfarin can 
score a maximum of 35 points as they need to complete both sections A and B (164). As per the 
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original design of the AKT, the present study reports final anticoagulation knowledge scores as 
percentages of answers correct, for all eligible participants.  
5.3.2.3 Perception of Anticoagulant Treatment Questionnaire 1 
Treatment expectation was evaluated using the validated Perception of Anticoagulant Treatment 
Questionnaire 1 (PACT-Q1) (190, 191) . The PACT-Q1 consists of seven items on a five-point 
Likert scale (1 = not at all, 5 = extremely), from which participants can select their response (190, 
191). The PACT-Q1 scale has no global score. As such, each item was analysed individually.  
5.3.2.4 Perception of Anticoagulant Treatment Questionnaire 2 
Treatment convenience and satisfaction were evaluated using the validated Perception of 
Anticoagulant Treatment Questionnaire 2 (PACT-Q2). The PACT-Q2 consists of 20 items on a 
five point Likert scale. Of the 20 items, 13 items assessed treatment convenience, while seven 
items assessed treatment satisfaction. Global scores for both sections were calculated according to 
the original reports (190, 191). 
5.3.2.5 Health information overload 
Health information overload was assessed using a scale adapted from the Cancer Information 
Overload (CIO) scale (192). This scale, which has only been validated to predict colonoscopy 
screening, consists of eight items on a four-point Likert scale (1 = strongly disagree, 4 = strongly 
agree). The scale was adapted to assess the extent to which patients are overwhelmed by AF-
related health information. The CIO scale was scored by summing the responses to all items, as in 
the original report (192). 
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5.3.2.6 Medication adherence 
Medication adherence was assessed using the validated 8-item Morisky Medication Adherence 
Scale (MMAS-8) (160). Scores were calculated as stated in the original reports (159-161). 
5.3.3 Sample size 
The survey was active from February 2017 to May 2017. We estimated that a sample size of at 
least 384 was required to ensure that our results are generalizable to the Australian population, 
where the estimated prevalence of AF is 1-2% (8). This sample size calculation allowed for a 5% 
margin of error and a 95% confidence interval based on an estimated population of 460,000 people 
with AF (8). The recruitment period was open until a minimum of 384 eligible responses were 
obtained. Participants who did not have a diagnosis of AF or were not taking an OAC were 
considered ineligible. 
5.3.4 Statistical analyses 
Statistical analyses were conducted using SPSS version 23 (IBM, Armonk, New York, US). 
Sample means and standard deviations were used to summarise continuous variables, while 
proportions were used to summarise categorical variables. Independent sample t-tests and 
ANOVA were used for group comparison involving continuous variables, while the Mann-
Whitney U test was used to compare the medians of ordinal variables. Chi-square tests were 
conducted to compare categorical variables. Linear regression analyses were used to identify the 
predictors of knowledge score in the univariate model, and variables with a p value of less than 
0.1 were included in the multivariate model. (193-195). This p value was chosen because a less 
restrictive alpha value in the univariate analyses can identify a broad range of predictor variables 
that might be associated with the response variable (196). A p value of <0.05 was considered 
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statistically significant for all analyses. Standardised regression coefficients were determined to 
compare the association between predictor variables.   
5.3.5 Ethics and consent 
The Tasmanian Social Science Human Research Ethics Committee approved this study (reference 
number H0015972). Consent was implied by submission of the survey. 
5.4 Results 
A total of 924 responses to the online survey were received, of which 386 (41.8%) were complete 
and eligible for inclusion (figure 6). The mean cost of advertising through Facebook was $2.71 per 
response. The mean age of participants was 67.4 years (SD ± 7.9 years), and 68.4% were female 
(Table 19). Almost three-quarters were taking a DOAC, while a greater proportion of participants 
taking warfarin had been on the medication for more than 2 years than those taking a DOAC (84.0% 
vs 53.5%; p <0.0001). 
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Figure 6: Flow chart of recruitment process 
 
 
 
 
 
 
 
924 total responses  
 208 (22.5%) did not 
get past the 
demographic 
information page 
181 (19.6%) did not 
report having a 
diagnosis of AF 
716 (77.5%) 
participants 
completed at least one 
questionnaire 
 386 (41.8%) 
responses available 
for analysis 
535 (57.9%) 
participants reported 
having a diagnosis of 
AF 
149 (16.1%) did not 
complete the survey, 
or did not report 
taking an oral 
anticoagulant 
medication 
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Table 19. Demographic information 
Characteristic 
Response (N=386)  
n (%) 
Sex 
Male  122 (31.6) 
Female  264 (68.4) 
Highest education completed 
Year 10 or below 138 (35.8) 
Year 11 or 12 55 (14.2) 
Certificate 52 (13.5) 
Diploma 70 (18.1) 
Bachelor’s degree 41 (10.6) 
Post graduate 25 (6.5) 
Missing  5 (1.3) 
Current employment status 
Not currently working 285 (73.8) 
On leave (long-service)   7 (1.8) 
Casual work 19 (4.9) 
Part-time work 34 (8.8) 
Full-time work   41 (10.6) 
Annual income range 
0 – $18,200   104 (26.9) 
$18,201 – $37,000    113 (29.3) 
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Participants taking warfarin had a higher overall knowledge score compared to those taking a 
DOAC (73.4% vs 65.7%; p <0.0001). On analysis of section A (the general questions), warfarin 
users still had a significantly higher knowledge score than DOAC users (71.6% versus 65.7%; 
p <0.0001). No significant difference was observed for any of the items in the knowledge test 
between participants taking different DOACs. Of all participants, 5.9% of participants could 
identify three things they could do to reduce the risk of adverse effects, 23.8% could list three signs 
of side effects to look out for, 26.4% agreed that skipping a dose of their medication could have a 
negative consequence on their health, and 65.5% knew that the most important adverse effect of 
OAC therapy is bleeding. 
$37,001 – $80,000     70 (18.1) 
$80,001 and greater 39 (10.1) 
Prefer not to say 60 (15.5) 
Duration of anticoagulant therapy 
Less than 3 months 25 (6.5) 
3-12 months 44 (11.4) 
1-2 years 80 (20.7) 
Greater than 2 years 237 (61.4) 
Oral anticoagulant 
Warfarin 100 (25.9) 
Rivaroxaban 123 (31.9) 
Apixaban 121 (31.3) 
Dabigatran 42 (10.9) 
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Items on the knowledge test answered correctly by a significantly different proportion of 
participants taking warfarin to those taking the DOACs are shown in Table 20. 
 
Treatment expectations are shown in Table 21. Compared to those taking DOACs, participants 
taking warfarin had a significantly higher median score on the PACT-Q1 scale regarding (i) 
Table 20. Items from the knowledge test with significant variation between participants taking warfarin 
and DOACs 
Item (AKT) 
Warfarin 
(N=100) 
n (%) correct 
DOACs (N=286)  
n (%) correct 
p value 
For how long do you need to take this medicine 
(for example, 3 months, and 6 months, life-long)? 99 (99.0) 273 (94.5) 0.026 
Why is it important to take this medicine exactly 
as your doctor has told you? (bleeding)a 22 (22.0) 14 (4.9) <0.001 
Is it important to take this medicine at the same 
time each day? 93 (93.0)  224 (78.3) <0.001 
Is it safe to take vitamin supplements and herbal 
medicines with this medicine without consulting 
your doctor?  
77 (77.0) 182 (63.6) 0.009 
Will drinking too much alcohol increase the risk of 
side effects with this medicine? 66 (66.0) 121 (42.3) <0.001 
What is the most important side effect of this 
medicine?  75 (75.0) 178 (62.2) 0.015 
THREE things you can do to reduce your risk of side 
effects are: (two)b 34 (34.0) 55 (19.3) 0.005 
Total knowledge score (% ± SD) 73.4 ± 13.2 65.7 ± 13.7 <0.001 
 
a Number of participants who could mention ‘to minimise the risk of bleeding.’  
b Number of participants who could mention two things they could do to reduce the risk of side effects. 
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confidence in the prevention of blood clot by OACs, (ii) expectation of bleeding side effects, and 
(iii) concerns about making a mistake when taking OACs (Table 21: items A1, A3, and A5). 
Conversely, those taking DOACs had a higher median score regarding (i) OAC that is easy to use, 
(ii) self-management of therapy, and (iii) concern regarding cost of therapy (Table 21: items A4, 
A6, and A7).  
Table 21. Comparison of treatment expectations between participants taking warfarin and the DOACs 
Items (PACTQ-1) Warfarin 
median (IQR) 
DOACs 
median (IQR) 
p value 
 
A1. How confident are you that your 
anticoagulant treatment will prevent 
blood clots? 
4 (4-5) 4 (3-4) 0.040 
A2. Do you expect that your anticoagulant 
treatment will relieve some of the 
symptoms you experience? 
2 (1-3) 2 (1-3) 0.691 
A3. Do you expect that your anticoagulant 
treatment will cause side effects such as 
minor bruises or bleeding? 
4 (3-4) 3 (2-4) 0.011 
A4. How important is it for you to have an 
anticoagulant treatment that is easy to 
take? 
4 (4-5) 5 (4-5) 0.008 
A5. How concerned are you about making 
mistakes when taking your anticoagulant 
treatment? 
2 (1-3) 1 (1-2) 0.002 
A6. How important is it for you to take 
care of your anticoagulant treatment by 
yourself? 
4 (4-5) 5 (4-5) 0.042 
A7. How concerned are you about how 
much you may have to pay for your 
anticoagulant treatment? 
1.5 (1-3) 2 (1-4) 0.044 
1= not at all, 5= extremely 
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The mean scores for treatment convenience and satisfaction were 88.4% ± 10.34 and 68.6% ± 
14.51, respectively. (ii) The mean scores for health information overload was 16.8 ± 3.95 (out of 
a possible score of 32) and 7.2 ± 1.14 (out of a possible score of 8) for medication adherence. No 
significant differences were observed between participants taking warfarin and DOACs for each 
of these variables.  
In multivariate analysis, age, type of OAC, health information overload score, and ease of use 
(PACT-Q1) were significant independent predictors of knowledge. The standardised regression 
coefficients showed that type of OAC and information overload had the largest effect on OAC 
knowledge (-0.245 and -0.189, respectively) (Table 22). The analysis showed that the predictors 
explained 15.0% of the variance in knowledge score (R2=0.15, F (10, 374) = 7.76, p <0.0001) 
(Table 22). 
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Table 22. Predictors of anticoagulation knowledge score (multivariate analysis) 
Independent variables B (95% CI) β (95% CI) p value 
Age (years) -0.226 (-0.396 – -0.056) -0.128 (-0.221 – -0.035) 0.009* 
 
Gender (male) 
 
-2.757 (-5.595 – -0.081) -0.092 (-0.183 – 0.002) 0.057 
 
Education  
(> year 12) 
1.344 (-1.387 – 4.074) 0.048 (-0.050 – 0.142) 0.344 
Duration of oral anticoagulant 
therapy   
(> 2 years) 
1.651 (-1.135 – 4.438) 0.058 (-0.036 – 0.155) 0.245 
Type of oral anticoagulant 
(DOACs) 
-7.793 (-10.942 – -4.645) -0.245 (-0.340 – -0.153) <0.001* 
 
Cancer Information overload scale  -0.666 (-1.014 – -0.318) -0.189 (-0.283 – -0.094) <0.001* 
 
A1. How confident are you that 
your anticoagulant treatment will 
prevent blood clots? 
1.113 (-0.543 – 2.770) 0.066 (-0.031 – 0.161) 0.187 
A3. Do you expect that your 
anticoagulant treatment will 
cause side effects such as minor 
bruises or bleeding? 
0.950 (-0.167 – 2.066) 0.080 (-0.015 – 0.169) 0.095 
A4. How important is it for you to 
have an anticoagulant treatment 
that is easy to take? 
2.278 (0.791 – 3.766) 0.153 (0.060 – 0.253) 0.003* 
A6. How important is it for you to 
take care of your anticoagulant 
treatment by yourself? 
-0.048 (-1.463 – 1.367) -0.003 (-0.103 – 0.093) 0.947 
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5.5 Discussion and conclusion  
5.5.1 Discussion 
We have described the result of a national survey on anticoagulation knowledge involving 386 
participants with AF taking OACs. While studies have been conducted to investigate 
anticoagulation knowledge in several countries (27, 29, 50, 54, 57, 58, 61, 66, 69, 147, 148), most 
of these studies have either not provided information regarding the validity of the instrument used 
in assessing anticoagulation knowledge (27, 29, 57, 58, 66, 69), or have focused solely on the 
VKAs (50, 61, 147). The present study presents a unique approach as it uses a scale that has been 
validated in the Australian population and included participants taking warfarin and the DOACs. 
Overall, knowledge gaps were observed in key areas of self-management including missing a dose, 
drug interactions, recognising bleeding as an important side effect, actions to reduce the risk of 
side effects and the effect of excessive alcohol consumption. These findings are similar with those 
of other studies across several populations in which suboptimal OAC knowledge has been 
consistently reported (27, 29, 50, 54, 57, 58, 61, 66, 69, 147, 148). However, to our knowledge, 
this is the first study to compare OAC knowledge between patients taking warfarin and DOACs. 
This is important because of the intrinsic differences in self-management of DOACs compare to 
warfarin therapy, especially the non-requirement for routine coagulation monitoring and shorter 
half-lives of the DOACs.  
B = Unstandardised regression coefficient, β = Standardised regression coefficient, CI = confidence 
interval 
*Significant independent predictors. 
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Participants taking warfarin had a significantly higher knowledge score in both the general 
questions and the overall test than those taking DOACs. There are several potential explanations 
for this finding. Patients taking warfarin may have received more intensive counselling, especially 
if dose modification was required after an international normalised ratio (INR) test. Conversely, 
due to the relative simplicity of DOAC therapy, DOAC users could have had less frequent 
interactions with health care practitioners (HCPs). The number and quality of patient-HCP 
interactions has been reported as a determinant of medication knowledge (197-199); the number 
of patient-HCP interactions is perceivably higher in warfarin users compared to DOAC users given 
the requirement for frequent INR monitoring. However, we did not capture the number of 
counselling interactions or the quality of education participants had received. Furthermore, the 
standardised regression coefficients showed that taking a DOAC was negatively associated with 
knowledge, and had the largest effect on knowledge scores. This further confirms the lower 
knowledge level observed in participants taking DOACs. 
The influence of age on OAC knowledge level has been investigated in diverse settings, and 
advancing age has been identified as negatively correlated with OAC knowledge in several studies. 
Joshua et al (54) and Nadar et al (59) have reported lower knowledge levels in patients older than 
60 and 61 years, respectively. Various other studies (56, 60-64) have found that advancing age is 
negatively associated with OAC knowledge. Thus, our finding aligns with the wider literature.  
The association between information overload and knowledge may be mediated by individual 
differences in health literacy levels and information-seeking behaviours. In a United States study 
involving patients taking warfarin through an anticoagulation clinic, limited health literacy was 
strongly associated with poor OAC knowledge, even after adjusting for age, sex, ethnicity, 
education and duration of OAC therapy (174). While there are not any studies examining health 
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information overload in patients with AF, there is research to suggest that health information 
overload is a probable cause of decline in information-seeking behaviour of breast cancer survivors 
(200). The authors suggested that the decline could be because survivors were overwhelmed and 
frustrated by the amount of information they encountered (200). Consequently, patients with 
limited health literacy and poor information-seeking behaviour would be more likely to have 
suboptimal knowledge. The importance of having an OAC that is easy to take was positively 
associated with OAC knowledge level. This could be because patients with greater knowledge 
genuinely understand the complexity of OAC therapy and therefore value a hassle-free treatment 
option. 
The comparison of treatment expectation between participants taking warfarin and DOACs 
showed that those taking warfarin were more confident that their OAC would prevent blood clots 
compare to those taking the DOACs. This could be related to the typically longer treatment 
duration among patients taking warfarin. Participants taking warfarin, however, had a greater 
expectation that their OAC would cause bleeding side effects and were more concerned about 
making mistakes when taking their OAC therapy. This could be due to the receipt of more 
comprehensive medication counselling regarding the complexities and risks of warfarin therapy, 
reinforced by the requirement for routine INR monitoring and the prescription of varying doses of 
warfarin in accordance with their INR results (2). 
Participants taking DOACs attached a greater importance to having an OAC that is easy to use and 
self-manage. If these patients were actively involved in the prescribing decision about their OAC, 
as dictated by best practice guidelines (34), this could be the reason why they were prescribed a 
DOAC by their physician. However, participants taking DOACs were more concerned about the 
cost of their medication, perhaps related to the younger demographic of respondents based on the 
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recruitment strategy employed. These findings highlight that patients’ preferences should be 
considered among other factors when initiating and continuing OAC treatment in AF. 
Further research is required to identify reasons for the lower knowledge scores in participants 
taking the DOACs, and the impact of counselling and education intervention on the knowledge 
level of patients prescribed OAC in general. We also need to better understand treatment 
expectations and the burden of health information experienced by patients taking OAC and the 
impact of these factors on other patient-related outcomes, including anticoagulation knowledge. 
The study is not without some potential limitations. As is common with online surveys, 
participants may have accessed other sources while providing responses (201), which may have 
influenced the results obtained. In addition, recruiting through Facebook may have led to the 
sampling of a selected population that may not fully represent the target population, and the 
inclusion of only confident and enthusiastic respondents. There is increasing evidence, however, 
that Facebook is a useful tool for recruiting older patients aged 65 years and above. Greenwood et 
al, reported that of all online adults, 62% of those aged 65 years and older used Facebook (202). 
A recent study by Cowie et al also reported that Facebook is a useful tool for enrolling older 
participants into clinical trial (203). The CIO scale, although validated to predict colonoscopy 
screening, is yet to be validated in patients with AF. Lastly, since the study was designed as a self-
reported online survey, it was not possible to verify the accuracy of respondents’ diagnosis, clinical, 
and demographic characteristics. Our study was strengthened by the use of a knowledge scale pre-
validated in the same population (164), and a large sample size to ensure the results are 
generalisable to Australian residents with AF. 
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5.5.2 Conclusion   
This study identified significant knowledge gaps in patients with AF taking OACs, and these 
deficiencies appear to be greater in participants taking the DOACs. Type of OAC, health 
information overload, advancing age, and patients’ perceptions regarding the ease of use of OAC 
were significantly associated with OAC knowledge. Lastly, treatment expectations varied between 
participants taking warfarin and DOACs. These findings may increase understanding of patient-
related factors that can influence treatment outcome in OAC therapy. 
5.5.3 Practice implications 
Patients with adequate anticoagulation knowledge can better participate in shared-decision making 
and self-management of their condition. We have demonstrated that OAC knowledge is 
suboptimal in the Australia setting, with even lower knowledge levels among patients taking 
DOACs. Knowledge assessment should be integrated within counselling sessions, and be provided 
to patients at initiation of OAC therapy and periodically thereafter, to identify and address 
knowledge gaps. In the absence of routine anticoagulation monitoring for DOACs, a similar 
follow-up program should be implemented for DOAC users to assess OAC knowledge and other 
patient-related outcomes. Treatment expectations of patients should also be assessed prior to 
commencement of therapy, as this would help guide the choice of OAC. These approaches would 
potentially improve self-management and subsequently positively influence treatment outcomes.  
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CHAPTER SIX 
6.0 Adherence to oral anticoagulants in atrial fibrillation: an Australian 
survey 
 
Overview 
This study aimed to address the fourth objective of this thesis. It focused on estimating the 
proportion of patients who are non-adherent to oral anticoagulants, identifying predictors of 
adherence, and determining if patient-related factors vary across levels of adherence in patients 
with atrial fibrillation. The results from the pilot study reported in Chapter 4 suggested that OAC 
adherence was suboptimal in patients with AF. As such, the present study further investigated the 
extent of OAC non-adherence and identified relevant predictors in a nationally representative 
sample. Moreover, the present study explored factors related to each of the three components of 
the Capability, Opportunity and Motivation Model of Behaviour (COM-B) as they have been 
previously reported to influence OAC adherence. This study was a secondary analysis of data from 
the previous knowledge survey. This paper was submitted to the Cardiovascular Drugs and 
Therapy in December 2017, and is currently under review. 
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6.1 Abstract 
Objective: Oral anticoagulant (OAC) therapy is highly effective for stroke prevention in patients 
with atrial fibrillation (AF). However, optimal adherence is essential to ensure its efficacy and 
safety. The aim of this study was to investigate the proportion of patients who are non-adherent to 
OAC, identify the predictors of adherence, and determine if patient-related factors vary across 
adherence levels in Australia. 
Methods: Respondents were recruited for an online survey using Facebook. Survey instruments 
included the Morisky Medication Adherence Scale, the Anticoagulation Knowledge Tool, the 
Perception of Anticoagulant Treatment Questionnaires, and a modified Cancer Information 
Overload scale. Predictors of medication adherence were identified using ordinal regression 
analysis. 
Results: Of the 386 responses eligible for analysis, only 54.9% reported a high level of adherence. 
Participants aged 65 years or younger were less likely to have high adherence compared to older 
participants (OR, 0.54; 95% CI, 0.33 – 0.88; p = 0.013), while females were more likely to be 
highly adherent compared to males (OR, 1.69; 95% CI, 1.08 – 2.64; p = 0.023). The ordinal 
regression analysis showed that age, gender, treatment satisfaction, information overload, concerns 
about making mistake when taking OACs and cost of medication were significant predictors of 
adherence. 
Conclusion: Self-reported non-adherence to OAC is common among patients with AF. A focus 
on supporting people who are at higher risk of non-adherence is needed to maximise the benefit of 
OAC therapy in this population. 
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6.2 Introduction 
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is 
responsible for 20-30% of all strokes (34). Oral anticoagulant (OAC) therapy is highly effective 
for stroke prevention in patients with AF (204). Evidence from clinical trials demonstrates that 
both warfarin (205) and the direct oral anticoagulants (DOACs) (26) reduce the risk of stroke by 
64% to 70% (206). However, optimal adherence is essential to ensure both efficacy and safety 
with OAC therapy (40). 
Studies have reported that more than 40% of patients with AF are non-adherent to OAC therapy 
(27, 106). Patients who adhere to OAC therapy are less likely to suffer stroke or major bleeding 
compared to those who do not (28, 30). As a result, experts have recently recommended a 
structured follow-up programme for all anticoagulated AF patients to improve adherence and 
persistence to OAC therapy (207). 
Various studies have investigated adherence issues surrounding warfarin usage (27, 30). Warfarin 
use is challenging in clinical practice due to the requirement for routine blood monitoring, and 
numerous food and drug interactions (18); these factors often impose lifestyle changes on the 
patient (18, 208). They can lead to non-adherence, instability of anticoagulation control, as well as 
discontinuation of therapy (208). Consequently, poor adherence to warfarin therapy has been 
associated with increases in the rate of both bleeding and embolic events (30).  
While international normalised ratio monitoring can be useful in identifying non-adherent warfarin 
patients, identifying non-adherent DOAC patients is more challenging in the absence of a similar 
test (209). Additionally, compared to warfarin, it has been suggested that even a short period of 
medication non-adherence to DOACs could result in a catastrophic loss of clinical effect (18).  
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Patient-related factors such as knowledge (59), health information overload (210), treatment 
convenience and satisfaction (211) have been investigated in patients with cardiovascular diseases. 
However, little is known about variation in patient-reported factors with regards to adherence in 
patients with AF. Consequently, we aimed to (i) estimate the proportion of patients who are non-
adherent to OAC and identify predictors of adherence, and (ii) determine if patient-related factors 
vary across levels of adherence in patients with AF.  
6.3 Methods 
This study was a secondary analysis of an Australian OAC knowledge survey in patients with AF, 
in which respondents were recruited online (via LimeSurveyTM) using Facebook. The survey 
requested socio-demographic characteristics including age, gender, level of education, annual 
income and type of employment. The survey also requested the type of OAC respondents were 
taking and the duration of therapy.  
6.3.1 Survey instruments and scoring 
Survey instruments used included the Morisky Medication Adherence Scale (MMAS-8) (159-161) 
to assess levels of adherence (low, medium and high); the Anticoagulation Knowledge Tool (AKT) 
to assess OAC knowledge (164); the Perception of Anticoagulant Treatment Questionnaires 
(PACT-Q1 and PACT-Q2) to assess treatment expectations, convenience and satisfaction (190, 
191); and the modified Cancer Information Overload (CIO) scale to assess health information 
overload (192).  The CIO scale was modified by replacing the word ‘cancer’ with ‘atrial fibrillation’ 
to suit patients with AF. 
The MMAS-8 consist of eight items and was scored according to the information in the original 
reports (159-161). The AKT consists of two parts with 20 general items and eight items related to 
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vitamin K antagonists (VKAs), respectively. In addition to the general questions, participants 
taking warfarin are also required to answer the VKA-specific items. Final knowledge scores were 
presented as percentages in accordance with the original report (164). The PACT-Q1 scale 
assessing treatment expectation comprises seven items on a five-point Likert scale (1 = not at all, 
5 = extremely) and has no global score; as such, each item was scored individually (190, 191). The 
PACT-Q2 assessing treatment convenience and satisfaction consists of 20 items on a five-point 
Likert scale. Global convenience and satisfaction scores were calculated according to the 
procedure in the original reports (190, 191). The CIO scale was scored by summing the responses 
to all eight items, as in the original report (192).  
6.3.2 Recruitment and sample size 
The survey targeted Australian residents with AF who were taking an oral anticoagulant. A paid 
advertisement on Facebook targeted adults over the age of 18 years. We estimated that a sample 
size of 384 Australians with AF was sufficient to make the results generalisable to the broader 
Australian population of people with AF considering an estimated prevalence of 1-2% (8). The 
sample size estimation was based on a calculation used for prevalence studies (212), considered a 
5% margin of error and a 95% confidence interval. Screening questions were included in the survey 
to exclude respondents who did not have a diagnosis of AF or were not currently taking an OAC.  
6.3.3 Statistical analyses 
Analyses were conducted using SPSS version 23 (IBM, Armonk, New York, US). Continuous 
variables were reported as means and standard deviations, while categorical variables were 
reported as proportions. ANOVA was used to compare study variables across the levels of 
adherence, while predictors of medication adherence were identified using ordinal regression 
analyses. Ordinal regression analysis was chosen to model the three levels of adherence 
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simultaneously, while considering the ordered relationship between them (213). The maximum 
number of variables to be included in the multivariate analysis was determined using the 50+ 8k 
rule (214), where k represents the number of predictors (214). Variables with a p value of less than 
0.1 in the univariate analyses were considered eligible for the multivariate analysis (196), and a p 
value of less than 0.05 was considered statistically significant for all analyses. 
6.3.4 Ethics and consent 
The Tasmanian Social Science Human Research Ethics Committee (reference number H0015972) 
granted ethical approval for the research. Consent was implied by submission of the survey. 
6.4 Results 
There were a total of 924 respondents to the survey, and 386 (41.8%) participants reported taking 
an OAC for AF, and completed the survey. The mean age of respondents was 67.4 years 
(SD ± 7.9 years), of whom 69% were aged 65 years or older; 74.1% were taking a DOAC. A 
total of 212 respondents (54.9%) reported high adherence (Table 23). There were statistically 
significant associations between current employment and gender and adherence. Of note, 
females had a significantly higher score on two items on the MMAS-8 measuring unintentional 
non-adherence: ‘Do you ever forget to take your medicine?’ (0.81 versus 0.71; p = 0.04), and 
‘How often do you have difficulty remembering to take your medicine?’ (0.93 versus 0.89; 
p = 0.02). No significant difference in adherence was observed between patients taking warfarin 
and DOACs. Respondents were evenly distributed based on Socio-Economic Indexes for Areas 
(SEIFA), an index that ranks areas in Australia based on relative socioeconomic characteristics 
(215). 
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Table 23. Demographic information 
 Low 
Adherence 
(MMAS <6) 
(n=54) 
Medium 
Adherence  
(MMAS 6 to <8) 
(n=120)  
High Adherence 
(MMAS 8) (n=212) 
p value 
Gender 
Female  28 (51.9) 81 (67.5) 154 (72.6)  
0.014 
Male 26 (48.1) 39 (32.5) 58 (27.4) 
Education a 
Year 12 and below 27 (50.0) 53 (44.2) 113 (53.3)  
 
0.108 Greater than year 12 27 (50.0) 63 (52.5) 98 (48.7) 
Missing 0 (0.0) 4 (3.3) 1 (1.3) 
Employment 
Not currently working 36 (66.7) 79 (65.8) 170 (80.2)  
0.007 
Currently working 18 (33.3) 41 (34.2) 42 (19.8) 
SEIFA 
Decile 1-5 26 (48.1) 62 (52.1) 105 (49.8)  
0.870 
Decile 6-10 28 (51.9) 57 (47.9) 106 (50.2) 
Duration of therapy 
<2 years  23 (42.6) 52 (43.3) 74 (34.9)  
0.257 
>2 years 31 (57.4) 68 (56.7) 138 (65.1) 
Type of oral anticoagulant 
Warfarin 15 (27.8) 25 (20.8) 60 (28.3)  
 
0.620 Apixaban 15 (27.8) 39 (32.5) 67 (31.6) 
Rivaroxaban 17 (31.5) 45 (37.5) 61 (28.8) 
Dabigatran 7 (13.0) 11 (9.2) 24 (11.3) 
SEIFA, Socio-Economic Indexes for Areas  
a ‘Missing’ was excluded from the analysis.  
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Use of the ©MMAS is protected by US and International copyright laws. Permission for use is 
required. A license agreement is available from Donald E. Morisky, MMAS Research (MORISKY), 
14725 NE 20th St Bellevue WA 98007, USA; dmorisky@gmail.com. 
 
Although no significant difference in knowledge scores was observed across the three adherence 
levels, treatment convenience and satisfaction scores were significantly greater in the high 
adherence group than both the low and medium adherence groups (Table 24). Participants who 
reported high adherence also had a significantly lower information overload score than both the 
low and medium adherence groups. 
 
The ordinal regression analysis showed that age, gender, treatment satisfaction, information 
overload, concerns about making mistake when taking OACs and cost of medication were 
significant predictors of adherence (Table 25). The model indicated that females were almost twice 
as likely to be adherent as males (OR, 1.7; 95% CI, 1.1 – 2.6; p = 0.02), while patients aged 65 or 
younger were less likely to be adherent to OAC than older patients (OR, 0.5; 95% CI, 0.3 – 0.9; 
Table 24. Association between adherence levels and patient-related factors 
Parameter Low Adherence 
(MMAS< 6) 
(n=54) 
Medium Adherence 
(MMAS 6 to <8) 
(n=120)  
High Adherence 
(MMAS 8) (n=212) 
p value 
Knowledge 
score  
66.3 ± 13.8 66.2 ± 13.7 69.0 ± 14.0 0.169 
Convenience 
score 
83.7 ± 11.4 85.9 ± 12.7 91.0 ± 7.5 <0.001 
Satisfaction 
score 
58.9 ± 15.7 65.8 ± 13.9 72.6 ± 13.0 <0.001 
Information 
overload scale 
18.1 ± 4.2 17.7 ± 3.6 16.0 ± 3.9 <0.001 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is 
required. A license agreement is available from Donald E. Morisky, MMAS Research (MORISKY), 
14725 NE 20th St Bellevue WA 98007, USA; dmorisky@gmail.com. 
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p = 0.01). The predictors included in the multivariate model explained 29.8% of the variation in 
adherence (Nagelkerke R2=0.298; χ2 = 113.76, p <0.001). 
135 
 
Table 25. Multivariate ordinal logistic model of factors associated with high adherence to oral 
anticoagulants 
Characteristics Odds ratio (95%CI) p value 
Age (≤ 65 years) 0.54 (0.33 – 0.88) 0.013 
Gender (female) 1.69 (1.08 - 2.63) 0.023 
Employment (not working) 1.41 (0.85 –  2.36) 0.187 
Knowledge score 1.01 (1.00 – 1.03) 0.180 
Satisfaction score 1.04 (1.02 – 1.06) <0.001 
Convenience score 1.00 (0.98 – 1.02) 0.954 
Information overload score 0.94 (0.89 – 1.00) 0.048 
A1. How confident are you that your 
anticoagulant treatment will prevent 
blood clots? 
1.11 (0.15 – 1.47) 0.497 
A2. Do you expect that your 
anticoagulant treatment will relieve 
some of the symptoms you experience? 
1.06 (0.89 – 1.27) 0.521 
A5. How concerned are you about 
making mistakes when taking your 
anticoagulant treatment? 
0.69 (0.57 – 0.83) <0.001 
A6. How important is it for you to take 
care of your anticoagulant treatment by 
yourself? 
1.11 (0.90 – 1.38) 0.334 
A7. How concerned are you about how 
much you may have to pay for your 
anticoagulant treatment? 
0.84 (0.72 – 0.97) 0.020 
Nagelkerke R2 = 29.8 % 
Use of the ©MMAS is protected by US and International copyright laws. Permission for use is 
required. A license agreement is available from Donald E. Morisky, MMAS Research (MORISKY), 14725 
NE 20th St Bellevue WA 98007, USA; dmorisky@gmail.com. 
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6.5 Discussion  
Approximately 50% of respondents reported low or medium adherence to OACs in this study, 
which highlights the need to support OAC adherence among Australian patients with AF. 
Specifically, patients who are aged ≤65 years, dissatisfied with their therapy, with higher 
perception of information overload, and concerned about making mistakes with taking OAC or the 
cost of their medications should be targeted for support and education. 
The present study has some limitations. The use of self-reported adherence has been associated 
with overestimated adherence levels (93); however the MMAS-8 has been validated in several 
populations (216). Recruiting online may have also led to the inclusion of patients not adequately 
representative of the broader population of patients with AF. Although studies have found 
demographic and baseline characteristics to be comparable in respondents recruited online and 
face-to-face, online respondents tend to be significantly younger (217). As a result, this study may 
have focused more on younger patients with AF. In addition, the survey design required only 
patients taking OAC to participate. This may have resulted in the exclusion of patients with AF 
who had discontinued OAC therapy altogether. Despite the potential limitations, our study is 
strengthened by the inclusion of participants taking warfarin and DOACs, therefore capturing 
responses from participants taking a spectrum of OAC medications used in clinical practice. 
Additionally, given the large sample size, and the recruitment of participants nationally, our 
findings may be applicable to a wider population of Australian adults with AF. While many online 
studies have reported respondents to be largely from a higher socioeconomic background (218), 
in the present study an even distribution of participants was observed based on socioeconomic 
characteristics. This further suggests the sample was representative of the broader population.   
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The relationship between age and adherence has been investigated in patients with cardiovascular 
diseases (131, 219, 220). Although different study designs and age group classifications have been 
employed, the available evidence suggests that younger patients are more likely to be non-adherent 
to prescribed medication (131). This is consistent with our finding that patients aged 65 years and 
younger were more likely to be non-adherent to OAC. The reason for better adherence in older 
patients could be related to the presence of multiple comorbidities, thereby making older patients 
more concerned about their health, leading to better medication-taking behaviour (131). Since non-
adherence to OAC is a significant concern in AF management, more emphasis should be placed 
on younger patients, as they may require additional support with managing their medication. 
The relationship between gender and adherence to medication is inconsistent. Some studies have 
reported females to have better adherence to prescribed medication (221, 222), while other studies 
have reported the contrary (223, 224). In addition, some studies have not reported any association 
between gender and adherence levels (225, 226). The lower adherence in males in the present 
study could be attributed to their responses on two questions related to unintentional non-
adherence; this suggests unintentional non-adherence is the likely cause of lower adherence in 
males. In clinical practice, collaborative efforts should be made by healthcare workers to 
understand if patients’ non-adherence behaviour is intentional or unintentional. This would assist 
in the development of appropriate strategies for improving medication-taking behaviour. For 
example, reminders and pill organisers, among other strategies, may be beneficial in resolving 
unintentional non-adherence (227).  
Although satisfaction with treatment was a significant predictor of adherence in the multivariate 
analysis, treatment convenience was not. This suggests that how reassured patients felt after taking 
an OAC is a more important determinant of adherence than difficulty experienced with OAC 
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therapy. This is further supported by the similar adherence levels observed between respondents 
taking warfarin, and the more convenient DOAC therapy (228). While satisfaction has been 
consistently associated with adherence in both cardiovascular and non-cardiovascular diseases 
(229), one study in patients taking warfarin has reported no association, although the number of 
warfarin users who were adherent was very low (230). The positive association observed in the 
present study is consistent with the broader literature. Therefore, efforts should be made to evaluate 
patients’ satisfaction with OAC therapy in routine practice and interventions to improve 
satisfaction should be incorporated where necessary. Patient satisfaction could be improved by 
encouraging better patient-healthcare professional communication, such that patients’ beliefs, 
expectations and preferences are considered in the choice of OAC therapy (231). Future studies 
should aim to determine whether improvement in patients’ satisfaction positively influence 
medication adherence.  
The significant negative association observed between the perception of information overload and 
adherence could be due to over-emphasis of the negative effects, especially adverse effects, of 
OAC therapy. An understanding of patients’ beliefs concerning their therapy can be useful in 
resolving medication non-adherence (232), because health beliefs that are based on skewed or 
inaccurate information can have a negative consequence on health behaviour (233). Given the 
importance of information in shaping health beliefs (233), and the subsequent impact of health 
beliefs on medication adherence (234), health care workers need to be educated on how to 
communicate health information to patients taking OACs. Research should be conducted to 
ascertain patients’ beliefs regarding OAC, as this would assist in tailoring educational 
interventions accordingly.   
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Patients who were more concerned about making mistakes when taking a prescribed OAC and the 
cost of their medication were more likely to be non-adherent. While there is a paucity of studies 
focusing on patients’ concerns about OAC therapy, studies in patients taking analgesics (235) and 
corticosteroids (236) have reported medication-related concerns to be inversely associated with 
adherence. Thus, identifying and addressing patients’ concerns could help in improving adherence.  
Cost of medication has been identified as a major barrier to adherence in different populations and 
this is also consistent with the findings of our study (131). However, the Australian government 
subsidises the cost of OAC medications through the Pharmaceutical Benefits Scheme (237). As 
such, the reason why cost is a predictor of non-adherence in this population remains unclear, and 
may be related to the demographic of the respondents in the survey. Qualitative studies are 
necessary to investigate patients’ concerns with OAC therapy, and potential reasons why 
medication cost is a barrier to adherence in this population.  
6.6 Conclusion 
Self-reported non-adherence was common in this study. Predictors of non-adherence included 
male gender, younger patients, lower satisfaction with therapy, higher burden of health information 
and more concerns about making mistakes when taking OACs and cost. These findings suggest 
that identifying and resolving modifiable patient-related factors has the potential to improve 
adherence to OAC. Interventions to improve patients’ satisfaction with therapy, better 
communicate health information, and address OAC-related concerns should be incorporated into 
the care process for patients with AF receiving OAC therapy.  
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CHAPTER SEVEN 
7.0 General discussion and conclusion 
 
This body of work has focused on anticoagulation knowledge and medication adherence in patients 
with AF. These are two important factors that could potentially affect treatment outcomes in 
patients taking OACs (27), and understanding them requires a comprehensive approach. Patients’ 
knowledge levels can influence outcomes as those with optimal OAC knowledge have been 
reported to have better anticoagulation control (29, 132), a decreased incidence of adverse events, 
(132, 238) and a reduction in the frequency of hospitalisation (239). Similarly, poor adherence to 
OAC therapy has been associated with increases in the rates of both bleeding and embolic events, 
and is a barrier to effective stroke prevention in patients with AF (30).     
In this thesis, a series of interlinked studies, using diverse data collection methods including postal 
survey, online survey and face-to-face interview were employed to assess OAC knowledge and 
adherence. Unlike previous studies, which examined knowledge and adherence in relation to 
warfarin, this work included DOACs, which were only introduced into clinical practice in 
Australia in 2013 for the prevention of stroke in AF (149). Several studies in Australia (32, 183, 
240) and other settings (184-187) have documented the rapid adoption of DOACs into clinical 
practice, including the switching of patients previously taking warfarin to DOAC therapy (241, 
242). This could be because DOACs are more convenient to use due to the non-requirement for 
routine anticoagulation monitoring, and absence of the numerous food and drug interactions 
associated with warfarin therapy (149). However, in the absence of anticoagulation monitoring for 
patient taking DOACs, there are fewer opportunities for HCPs to provide information and 
reinforce the need for OAC adherence (243). 
141 
 
The research presented in this thesis also explored several factors that may influence patients’ 
capacity to engage with their own care, as recommended by the integrated care model in AF, which 
advocates for patients to be actively involved in their own management, while being supported by 
a multidisciplinary team and the community (247). The COM-B model guided the development of 
this thesis, and factors related to each of the components were explored at different stages. Factors 
related to ‘Capability’ were considered in the pilot study, while factors affecting all three 
components were explored in the national survey. Altogether, this body of work represents a 
significant contribution to research in the use of OACs in patients with AF, and the findings have 
several implications for clinical practice. 
Prior to any exploration of medication knowledge in contemporary clinical practice, there was the 
need to develop and validate a new knowledge assessment instrument capable of assessing 
knowledge in patients taking DOACs, and at the same time cater for patients taking warfarin. This 
was achieved in the first stage of this research (Chapter 3). Subjects were recruited into three 
groups, comprising of a pharmacist (expert) group, patient group and general public group, using 
a postal survey and face-to-face approach. Like previous validation studies, the instrument 
demonstrated good internal consistency with a Cronbach’s α value of >0.70 in the three test groups, 
and a correlation coefficient of 0.78 confirming test-retest reliability (44, 46). Comparable to the 
study of Zeolla et al (46), the instrument could discriminate between different levels of OAC 
knowledge as demonstrated by the significant difference observed in knowledge scores across the 
three groups utilised in the study, supporting construct validity. Based on these results, we are 
confident that the newly validated instrument, called the AKT, will be useful in clinical practice 
for knowledge assessment to identify patients with inadequate knowledge, and designing 
necessary educational interventions.  
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Having developed and validated a suitable tool to assess OAC knowledge, the subsequent phases 
of this thesis focussed on specific aspects of the COM-B model. This model proposes that 
Capability, Motivation and Opportunity are components that collectively influence behaviour 
(244). The findings of this research suggest that all three components could be explored to improve 
OAC adherence.  
Psychological capability, which refers to patients’ capability to engage in the necessary thought 
processes that influence behaviour, can be affected by inadequate knowledge of disease and 
treatment, and limited capacity for judgement. The results of the pilot study (Chapter 4) and 
national survey (Chapter 5 and 6) suggest that suboptimal OAC knowledge and limited health 
literacy is prevalent among patients with AF. However, the impact of knowledge on adherence 
levels is less clear. While findings from the pilot study showed a positive relationship between 
OAC knowledge and adherence, no significant association was observed in the national survey. 
This could be due to the presence of a reasonable proportion of patients aged ≤65 years in the 
national survey. While several studies have utilised older participants and reported a  positive 
relationship between knowledge and adherence, no association occurred in a study by Al-Omair 
et al, where respondents had a mean age of 52 years (245). This may suggest that knowledge levels 
do not play a major role in improving adherence in younger patients. Younger patients tend to have 
fewer co-morbidities compared to older patients (131), and this could be a driver of poor adherence, 
regardless of knowledge levels in this population. 
Regardless of patients’ age, an educational programme should be incorporated into patients care 
plan. Patient education is important for promoting the safe and appropriate use of OACs, especially 
with respect to bleeding events (238). Bleeding is the most important complication of OAC therapy 
and may lead to permanent disability, increased hospital visits and death (246). A study by the 
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Centre for Disease Control and Prevention showed that bleeding-related adverse events from 
OACs accounted for more emergency department visits than adverse events from any other class 
of medication (247). Similarly, data from the United States Food and Drug Administration showed 
that 80% of all reported OAC-related injuries or death were due to haemorrhages (248). An 
educational intervention is therefore necessary in helping patients identify the signs and symptoms 
of adverse effects of OAC therapy, and knowing appropriate measures that could be taken to 
minimise future bleeding occurrences. Patient education is also required to ensure that patients 
have adequate knowledge to participate in shared-decision making with HCPs, and to play a central 
role in their own management. Productive interactions between patients and HCPs has the potential 
to facilitate the care process and improve treatment outcomes, and are more likely with informed 
patients who have gained relevant knowledge and skills to manage their condition (249).  
The design of educational intervention may affect learning outcomes (250). Various studies have 
suggested that a structured education is more effective in improving OAC knowledge compared 
to unstructured approach (56, 74, 251), and should be preferably conducted on a routine basis (76). 
A study by Voller et al. in which OAC knowledge was assessed after three educational 
interventions over a period of six weeks, reported a sustained improvement in patients’ knowledge 
score (76). HCPs can help to improve OAC knowledge by scheduling periodic educational 
sessions for patients receiving treatment in their practice. Clarkesmith et al. reported that 
knowledge of patients who had received OAC education returned to pre-intervention levels after 
a period of 3-6 months (175), further suggesting that continuous education is required in patients 
taking OACs.  In situations where periodic educational sessions are not feasible, the provision of 
take-home educational video on OAC therapy could also be useful in reinforcing OAC knowledge 
in patients with AF (252).  
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Some other studies have suggested that despite educational intervention, patient knowledge is still 
poor, as information provided is easily misunderstood (27, 52, 253). This could be due to limited 
health literacy in the study population. Limited health literacy is closely associated with 
medication knowledge, and has been reported as a predictor of treatment outcomes in patients with 
AF (174). A number of studies have suggested that many patients taking OAC have limited health 
literacy (174, 254), and the majority of OAC information materials are written at a high readability 
level (253, 255). Therefore, HCPs should consider the characteristics of the intended patient 
population prior to the design of educational intervention, in order to tailor intervention 
accordingly. For interventions involving written educational material, HCPs should ensure that 
materials are developed at a suitable readability level, preferably at a sixth-grade level or lower, 
as recommended by the Institute of Medicine, in order to promote easy understanding (256). If 
desirable results are not obtained with the use of written materials, HCPs could also consider the 
use of audio-visual educational resources, as recent evidence has supported their usefulness in 
patients with limited health literacy (257). Finally, it is important to identify knowledge areas that 
would require additional reinforcement after the commencement of an educational intervention. 
HCPs can use the teach-back method, which assesses patient understanding and recall of new 
concepts (258). Eliciting patients’ feedback would ensure that messages with clinical implications 
are well communicated and understood (258). This would potentially contribute to influencing 
positive medication adherence behaviour. 
Motivation in the COM-B model comprises all brain processes that stimulate and direct behaviour 
(244). Reflective motivation, which involves evaluations and creating an actual plan to achieve an 
outcome, can be influenced by patients’ treatment expectations and beliefs about medication (244). 
The results of the national survey suggest that patients’ treatment expectations should considered 
prior to the start of therapy, as this could affect patients’ predisposition, especially adherence to 
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OAC therapy. Poor motivation in patients may be as result of incorrect knowledge, low levels of 
self-efficacy, effort beliefs, value belief and outcome expectancies (259, 260). HCPs are well 
placed to identify the underlying cause of poor motivations in patients and design strategies to 
resolve it. Motivation for behaviour change could be improved by shaping knowledge and 
improving self-efficacy (244, 261). HCPs should employ a sympathetic and non-confrontational 
approach in building self-efficacy and shaping patients’ knowledge during counselling sessions 
(262). Such interactions should guide, rather than push patients towards behaviour change (262). 
This could subsequently lead to correct medication knowledge, improved self-efficacy, and better 
adherence to medication. This has been supported by the work of Davis et al, which showed that 
a customised video intervention assisted in improving self-efficacy, reducing problems with 
medication use, and led to better adherence in diabetes patients (263).    
Opportunity refers to factors outside of the individual that prompts performance of a behaviour 
(244). Routine clinical follow up by HCPs provides physical opportunity through which patient-
HCPs communication and relationships could be improved. From the national survey, 
approximately 50% of respondents reported inadequate adherence to OACs, and this underscores 
the need to support OAC adherence in this population. Taking into consideration the importance 
of adherence in ensuring adequate thromboprophylaxis in AF, especially with the DOACs, this 
result suggests that patients taking OACs require routine follow-up by HCPs to ensure that they 
adhere to OACs. During patient follow-up, it is important for to HCPs to constantly build trust and 
improve relationship with their patients. The results of several studies have suggested that trusting 
relationships between HCPs and patient can influence treatment outcomes (264). Effective 
interpersonal communication between HCPs and patients could lead to greater patient satisfaction 
with therapy plan, and thereby foster adherence to medication and lifestyle recommendations (265). 
For instance, a study by Linetzky et al  in diabetic patients suggest that patients’ perception of the 
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quality of interactions with HCPs affected their adherence to insulin therapy (266).  Therefore, 
improved patient-HCP interaction would potentially encourage adherence to OACs in patients 
with AF. 
In recent years, there has been a push for the adoption of the integrated care approach in the 
management of patients with AF, in order to enhance treatment outcomes (267). Patients will be 
unable to fully participate in an integrated care model if they do not understand the risks and 
benefits of their treatment (268). The findings of this research showed that many patients with AF 
have inadequate knowledge and limited health literacy levels. This underscores the need for HCPs 
to continually build capacity in this population. Additionally, the integrated care approach 
advocates for the redesigning of daily clinical practice to ensure that care plan is tailored to patients’ 
needs and value (269). The findings of this research suggest that patients’ perceptions, expectations 
and experiences with OACs vary considerably, supporting the need for an individualised and 
patient-centred approach in the management of AF. Overall, this research has emphasised the need 
for capacity building in patients with AF, and the adoption of coordinated systems of care into 
routine clinical practice, in order to improve treatment outcomes.  
Recommendations and Future Directions 
Knowledge assessment should be incorporated into the management strategy of patients with AF, 
as this would assist with identification of knowledge gaps and the design of interventions to resolve 
knowledge deficit. Since many patients taking OAC have limited health literacy, readability 
assessment should be incorporated into the development of psychometric instruments, and in the 
design of written educational materials. This would enable better comprehension and utilisation of 
health information in this population. An evidence-based system of care model in the management 
of patients with AF should be rapidly adopted into clinical practice. 
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The National Patient Safety Goal introduced by the Joint Commission of the United States has 
outlined several elements to be present in an educational intervention programme (270). This 
includes anticoagulation basics, risk-benefits, access to health care, medication adherence, 
laboratory monitoring, and dietary and lifestyle modification. Future research should focus on 
determining the extent to which these components are being included in current educational 
strategies, and identify barriers to effective patient education. While provision of information is a 
requirement in educational interventions designed to improve patients’ knowledge, findings from 
this research have suggested that patients’ perception of information overload is associated with 
poor levels of OAC knowledge. Future research is necessary in identifying approaches for 
improving OAC knowledge, while minimising information overload. 
The influence of knowledge on behaviour change is an aspect that requires further investigation. 
Future research should be designed to determine components of knowledge-focused interventions 
that would help drive behaviour change, especially OAC adherence in younger patients with AF.  
Considering that patient-related factors played an important role in determining knowledge and 
adherence levels, future studies should focus on determining the best approach for improving 
modifiable patient-related factors, and the subsequent impact on OAC knowledge and adherence.  
Lastly, future studies should be designed to understand the impact of patients’ perceptions and 
concerns with OAC therapy on treatment outcomes, especially the incidence of stroke and bleeding 
events. These studies would help in identifying and resolving patients’ perceptions, which may 
have clinically significant implications.  
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Appendix A: Validation study forms  
 
Appendix A1 
Validation of Oral Anticoagulant Knowledge Questionnaire 
 Participant Information Sheet – Patient Group 
 
You are invited to participate in a research study, conducted by the University of Tasmania, 
School of Medicine. Before you decide whether or not you wish to participate in this study, 
it is important for you to understand why the research is being done and what it will involve. 
Please take the time to read the following information carefully and discuss it with others 
if you wish. 
 
1. What is purpose of this study? 
Anticoagulants, also called blood thinners, are used in preventing the formation of blood 
clots. It is important for patients on anticoagulants to have a good knowledge of using them 
appropriately so as to be able to achieve the best possible outcome. The purpose of this 
study is to develop a questionnaire that will be useful in the future to measure patients’ 
knowledge of these medications. 
 
2. Why have I been invited to participate in this study? 
You are eligible to participate in this study because you are taking an anticoagulant 
medication, and have completed a high school education (or further education). 
 
3. What if I don’t want to take part in this study, or if I want to withdraw later? 
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Participation in this study is voluntary. It is completely up to you whether or not you 
participate. If you decide not to participate, it will not affect you in any way. 
 
4. What does this study involve? 
This study will involve answering a set of 10-14 multiple choice and 10-12 open ended 
questions related to anticoagulants (blood thinners). You will be asked to answer the same 
set of questions again after a period of two months. It is estimated that it will take 
approximately 10 minutes to complete this questionnaire each time. 
 
5. What are the benefits of this study? 
Your participation in this study will assist in the development of a questionnaire that will 
be useful in determining the level of knowledge of people taking anticoagulant medications.   
 
6. How will my confidentiality be protected? 
Only basic demographic information and contact details will be collected so that we will 
be able to send you the second questionnaire. All identifying details will be removed after 
the receipt of the second questionnaire.   
 
7. Will I benefit from this study? 
This study aims to validate a questionnaire that will be useful in future studies and may not 
benefit you directly. 
 
8. Will I be compensated for participating in this study? 
You will be offered a $10 shopping voucher as compensation for your participation. 
 
9. What should I do if I want to discuss this study further before I decide? 
When you have read this information, if you have any queries regarding this study or your 
participation in this study, please do not hesitate to contact one of the study investigators 
listed below: 
 
  
Associate Professor Luke Bereznicki 
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Associate Head (Pharmacy) & Deputy Head, School of Medicine 
Telephone: 03 6226 2195; Email: Luke.Bereznicki@utas.edu.au 
Dr Leanne Chalmers  
Lecturer, Pharmacy, School of Medicine 
Telephone: 03 6226 1095; Email: Leanne.Chalmers@utas.edu.au 
Mr Kehinde Obamiro (PhD candidate) 
Telephone:            Email: Kehinde.Obamiro@utas.edu.au 
10. Who should I contact if I have concerns about the conduct of this study?
This project has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. If you have any concerns of an ethical nature, or complaints about the 
manner in which the study is conducted, you may contact the Executive Officer of the 
Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive 
complaints from research participants.   Please quote the ethics reference number -------- 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
 
 
 
University of Tasmania 
Pharmacy, School of Medicine 
Private Bag 26 
HOBART  TASMANIA 
7001  AUSTRALIA ABN 30 764 374 782 / CRICOS 00586B 
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Appendix A2 
Consent Form – Patient Group 
Title of Project: “Validation of Oral Anticoagulant Knowledge Questionnaire” 
1. I acknowledge that the nature, purpose and contemplated effects of the project so far
as it affects me, have been fully explained to my satisfaction by the research worker
and my consent is given voluntarily.
2. I have read and understood the ‘Participant Information Sheet’ of this study.
3. The details of the project methods have also been explained to me. I understand that I
will be required to answer a set of questions regarding oral anticoagulants. I will also
be required to answer the same set of questions again after a period of two months.
4. Although I understand that the purpose of this research project is to improve the quality
of medical care, it has also been explained that my involvement may not be of any
benefit to me.
5. I have been given the opportunity to have a member of my family or friend present
while the project was explained to me.
. 
6. I understand that my involvement in the project will not affect my relationship with the
pharmacist(s) involved in the management of my health. I also understand that I am
free to withdraw from the project at any stage and withdraw any of my data that may
have been collected. My withdrawal will not affect my legal rights or the care I receive
from my pharmacist(s).
166 
7. I understand that I will be given a signed copy of this Participant Information Sheet and
consent form. I am not giving up my legal rights by signing this consent form.
8. I understand that the study will be conducted in accordance with the latest versions of
the National Statement on Ethical Conduct in Human Research 2007 and applicable
privacy laws.
Name of participant: __________________________________       
Signature of participant: ___________________ Date: _______ 
9. I have explained this project and the implications of participation in it to the participant
and I believe that the consent is informed and that he/she understands the implications
of participation.
Name of investigator: ___________________________________       
Signature of investigator: ___________________ Date: ________         
 
 
University of Tasmania 
Pharmacy, School of Medicine 
Private Bag 26 
HOBART  TASMANIA 
7001  AUSTRALIA ABN 30 764 374 782 / CRICOS 00586B 
167 
Appendix A3 
Dear Sir/Madam, 
Invitation for PSA Members to Participate in the Validation of an Oral Anticoagulant Knowledge Tool 
I write to invite the members of the Pharmaceutical Society of Australia (PSA) to participate in a research 
study conducted by the Division of Pharmacy, School of Medicine, University of Tasmania to validate an 
oral anticoagulant knowledge tool.  
There is need for a convenient and validated tool to assess the medication knowledge of patients taking 
anticoagulants. Tools have previously been developed to assess knowledge relating to warfarin, however 
a tool is required that it relevant to all anticoagulants, including the novel oral anticoagulants (NOACs). 
This is important in order to objectively assess patients’ medication knowledge, identify possible 
knowledge gaps and develop strategies to improve the current use of anticoagulants. 
In order to validate this tool, members of the PSA will be required to answer basic questions related to the 
use of both warfarin and the NOACs. After two months, the participants will be requested to complete the 
same questionnaire a second time. After two months, participants will be requested to complete the same 
questionnaire a second time as part of the validation process. 
This study will require a minimum of 65 pharmacists and it is estimated that it will take approximately 10 
minutes to complete the questionnaire. 
Please kindly send the information below to the members of the PSA. 
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“You are invited to participate in the validation of an oral anticoagulant knowledge tool being 
conducted by researchers from the Division of Pharmacy, School of Medicine, University of Tasmania. 
Your involvement will assist in the development of an objective approach to assessing patients’ 
anticoagulant knowledge whether they are taking warfarin or one of the NOACs. This has the future 
potential to identify possible knowledge gaps and facilitate the development of strategies to improve the 
current use of anticoagulants. Further information and access to the questionnaire is available at 
https://www.pharm.utas.edu.au/surveys/index.php/441768/lang-en. All participants completing the 
study will receive a shopping voucher in appreciation of their involvement.  Your assistance will be very 
much appreciated. ” 
 
Your support is highly appreciated. 
 
 
 
Yours faithfully, 
Obamiro Kehinde 
PhD Candidate 
 
 
 
 
 
 
 
 
 
 
 
University of Tasmania 
Pharmacy, School of Medicine 
Private Bag 26 
HOBART  TASMANIA 
7001  AUSTRALIA 
 
 
 
 
ABN 30 764 374 782 / CRICOS 00586B 
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Appendix A4 
Survey Script 
Hello, I'm Kehinde Obamiro, a student from the University of Tasmania. We are doing a survey 
and are asking questions related to people’s knowledge of anticoagulant medicines or ‘blood 
thinners’.   
The information provided will be used to validate a questionnaire that will be useful in the future 
in measuring patients’ knowledge and identifying knowledge gaps with the use of these medicines. 
This is very important to help people get the most out of their medicines. 
We are looking for people who have a minimum of high school education, are not healthcare 
workers, are not taken any anticoagulant medicine and do not have a family member taking and 
anticoagulant medicine. Does that sound like you? 
If you are interested in participating in our study, you may wish to take some time to go through 
the study materials, sign the consent form and complete the questionnaire. 
You also have the option of taking study materials home to discuss with family members or a 
friend, and return it through a reply paid envelope.  
You can always reach me on my mobile (          ) for further information and clarification. 
Thank you. 
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Appendix A5 
Dear Pharmacist, 
Thank you for consenting to recruit patients for this study. 
You will find enclosed with this letter 20 envelopes each containing an information statement, a 
consent form, the questionnaire and a reply paid envelope to be given to patients receiving a repeat 
supply of an oral anticoagulant medication. 
Participants in this study should be refiling their prescription for an oral anticoagulant medication 
(new patients are excluded). 
The questionnaire is designed to be self-administered and as such participant is to complete it 
without any assistance from the pharmacy staff. 
At the end of this study, you will be eligible to enter into a draw to win an iPad mini. 
Thank you for your cooperation. 
Yours Sincerely 
Obamiro Kehinde 
PhD Candidate 
University of Tasmania 
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Appendix A6 
Anticoagulant Knowledge Tool Validation Survey (Patient Group) 
Introduction 
We thank you in advance for agreeing to fill in this questionnaire and we appreciate you taking 
the time to support this research. By completing this questionnaire, you will help in validating a 
tool that will be useful in caring for people taking anticoagulant medicines. Your responses, 
including demographic information will remain anonymous, and your confidentiality will be 
protected. 
Instructions on completing the questionnaire if you are currently taking an oral 
anticoagulant medicine: 
 Please complete the following questions to reflect your opinions as accurately as possible
and to the best of your knowledge.
 If you do not know the response to a question, please write ‘I don’t know’ in the space
provided.
 If you are not sure of the response to a multiple choice question, please tick ‘not sure’
among the options provided.
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Section 1: Demographic Information 
1. What is your gender?
a. Male
b. Female
2. How old are you? ……………….. years 
3. What is the highest level of education you have completed?
a. High school or equivalent
b. College
c. Technical or vocational education
d. Bachelor’s degree
e. Postgraduate degree
f. No formal education
4. How long have you been taking an oral anticoagulant medicine?
a. Less than 3 months
b. 3 -12 months
c. 1 -2 years
d. Greater than 2 years
e. I’m not taking an anticoagulant medication
173 
 
Section 2: Anticoagulation Knowledge  
 
2.1 General questions 
 
1. What is the name of your anticoagulant medicine? 
  
………………………………………………………………………………………………
.. 
2.  Why has your doctor prescribed you this medicine? 
  
………………………………………………………………………………………………
.. 
3.  How does this medicine work in your body?   
   
………………………………………………………………………………………………
.. 
4.  How many times a day do you need to take this medicine? 
  
……………………………………………………………………………………………… 
5.  For how long do you need to take this medicine (for example, 3 months, and 6 months, 
life-long)? 
  
………………………………………………………………………………………………
.. 
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6. Why is it important to take this medicine exactly as your doctor has told you? 
  
…………………………………………………………………………………………… 
7. Is it acceptable to take this medicine at different times as long as you take it on the 
required days?  
a) Yes          b) No   c) Not sure 
 
8.  Is it acceptable to double the next dose of this medicine if you miss a dose? 
a) Yes            b) No   c) Not sure 
 
9.   Is it possible that skipping one dose of this medicine could worsen your condition? 
a) Yes            b) No   c) Not sure 
 
10.  Is it appropriate to stop taking this medicine once you feel better? 
a) Yes            b) No   c) Not sure 
 
11. Is it safe to take anti-inflammatory medicines like ibuprofen (Nurofen® or Advil®) while 
you are taking this medicine? 
a) Yes            b) No   c) Not sure 
 
12.  Is it safe to take vitamin supplements and herbal medicines with this medicine without 
consulting your doctor?  
 a) Yes            b) No   c) Not sure 
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13.  Is there any benefit in taking more of this medicine than your doctor has told you to take?  
a) Yes            b) No   c) Not sure 
 
14. Will drinking too much alcohol increase the risk of side effects with this medicine? 
a) Yes            b) No   c) Not sure 
 
15. Is it necessary to inform a surgeon, dentist or other health professional that you are taking 
this medicine before undergoing surgery or a procedure? 
a) Yes             b) No   c) Not sure 
 
16. Is it important that all the health care practitioners you see know that you are taking this 
medicine? 
a) Yes             b) No   c) Not sure 
 
17. What is the most important side effect of this medicine?  
……………………………………………………………………………………… 
 
18. THREE signs of side effects that you should watch out for while taking this medicine are: 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
 
19. THREE things you can do to reduce your risk of side effects are: 
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……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
 
20.  What is the best step to take if you accidentally take too much of this medicine?  
 
……………………………………………………………………………………….. 
 
2.2 For people taking warfarin 
 
1. What is your target INR range? .................................. 
 
2. What was your last INR reading? …………............... 
 
3. Are routine INR tests necessary to know how well this medicine is working? 
a) Yes             b) No   c) Not sure 
 
4. Is an INR value above your target range good for your general wellbeing? 
a) Yes             b) No   c) Not sure 
 
5. Is it possible for INR values below your target range to be bad for your health? 
 a) Yes             b) No   c) Not sure 
 
6a. Is it possible for your diet to affect your warfarin therapy? 
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a) Yes             b) No   c) Not sure 
 
6b. If you answered ‘Yes’ above, list THREE foods that can affect your anticoagulant therapy. 
 
…………………………………………………………………………………… 
…………………………………………………………………………………… 
…………………………………………………………………………………… 
 
7. List one vitamin that can significantly affect your anticoagulant therapy.  
 
…………………………………………………………………………………… 
Thank you for your participation in this survey. 
Please provide your contact details in the space below to enable us send you a second copy of this 
questionnaire to complete after two months. This will also enable you to receive your shopping 
voucher on completion of the second survey.  
Name: …………………………………………………………………………………… 
 
Postal address: …………………………………………………………………………… 
 
Date ……………………………………………………………………………………….                                                                                                                           
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Appendix B: Stroke prophylaxis in atrial fibrillation forms (Pilot study) 
Appendix B1 
 
Recipient Name 
Address 
 
Dear Recipient 
 
Re: Invitation to participate in University of Tasmania research into stroke prophylaxis in atrial 
fibrillation 
 
Stroke prophylaxis in atrial fibrillation (AF) has evolved rapidly in recent years. The Unit for Medication 
Outcomes Research and Education in the School of Medicine has a long history of working with clinicians 
and patients to attempt to optimise the quality use of anticoagulants, especially in the setting of AF.  
  
Patients’ perceptions of and experiences with the use of oral anticoagulants can affect their treatment goals 
and quality of life. These factors are yet to be studied in Tasmanians with AF in the community setting, and 
can potentially improve treatment outcomes of patients with AF. 
  
Why are we writing to you?  
 
We are writing to ask for your help in inviting patients with AF in your practice taking warfarin or the new 
oral anticoagulants (apixaban, dabigatran or rivaroxaban) to participate in a study that is intended to assess 
their medication related knowledge, health literacy, medication adherence and quality of life. The study will 
involve an interview using a set of four questionnaires.  
 
What will be required of you?  
 
We’ll aim to keep it simple! What we’ll need you to do is: 
- Assist with identifying your patients with AF 
- Send out a postage paid envelope containing study information and a consent form to the identified 
patients 
- Provide a space in your practice where patients who consent to participate in the study can be 
interviewed.  
 
What do you have to gain? 
This study provides a great opportunity to identify ‘best practice’ in the local setting in stroke prophylaxis in 
AF, to assist in the identification of the need for additional patient or prescriber support resources, and to 
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contribute to the development of these resources. All of which means the best possible outcomes for 
you and your patients! 
 
Please discuss this opportunity within your practice and complete the attached form to indicate whether 
you are interested in participating in these project opportunities. The form can be returned via mail to the 
return address below, faxed to 6227 2870 or emailed to Luke.Bereznicki@utas.edu.au. Should you require 
more information, please feel free to contact me using the contact details below. 
 
Thanking you in anticipation for your support of our research. 
 
 
Yours sincerely 
Associate Professor Luke Bereznicki 
Deputy Head, School of Medicine, Associate Head (Pharmacy) 
Tel: +61 3 6226 2195 
Email: Luke.Bereznicki@utas.edu.au  
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Appendix B2 
 
Date: 
 
Practice Name: 
 
Practice Address: 
 
Contact person: 
 
Re: Invitation to participate in University of Tasmania research into stroke prophylaxis in atrial 
fibrillation 
 
 YES, we are interested in participating in this research. Please send us further 
information. 
 
Preferred contact method: 
 
 Email (email address: __________________________________________)  
 
 Post (address as above)  
 
 
 
 NO, we are unable to participate in this research at this time. 
 
 
 
Signed: 
 
 
Please return this form via fax to 6227 2870, email to luke.bereznicki@utas.edu.au or post to Assoc Prof 
Luke Bereznicki, Pharmacy, School of Medicine, Private Bag 26, HOBART TAS 7001.   
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Appendix B3 
 
 
“Patient experiences, perceptions and knowledge of stroke thromboprophylaxis in atrial 
fibrillation” 
 
 
Participant Information Sheet 
 
You are invited to participate in a research study, conducted by the University of Tasmania, School of 
Medicine. Before you decide whether or not you wish to participate in this study, it is important for you to 
understand why the research is being conducted and what it will involve. Please take the time to read the 
following information carefully and discuss it with others if you wish. This study is being undertaken by a 
Chanelle Rolls, a Pharmacy Honours student, and Kehinde Obamiro, a PhD candidate, under the 
supervision of Associate Professor Luke Bereznicki and Dr Leanne Chalmers. 
 
1. What is purpose of this study? 
Anticoagulants, also called blood thinners, are used to help prevent the formation of blood clots in people 
with the heart rhythm abnormality, atrial fibrillation. We would like to know how much people know about 
their medicine and heart condition, how they take their prescribed medicine, their overall quality of their life 
and how much they understand health related information.   
 
The purpose of this study is to understand the issues people face surrounding the use of blood thinner 
medicines to help improve the use of these medicines to achieve better outcomes. 
 
2. Why have I been invited to participate in this study? 
You are eligible to participate in this study because you are taking an anticoagulant medication for stroke 
prevention in atrial fibrillation, and are over the age of 18 years. 
 
3. What if I don’t want to take part in this study, or if I want to withdraw later? 
Participation in this study is voluntary. It is completely up to you whether or not you participate. If you decide 
not to participate, it will not affect you in any way. 
 
4. What does this study involve? 
This study will involve answering a set of four questionnaires during an interview with one of the researchers 
at your regular GP surgery. Questions will be related to anticoagulants (blood thinners) and atrial fibrillation 
as well as your ability to understand and interpret health information and some questions will measure your 
overall quality of life. It is estimated that it will take approximately 45 minutes to complete the survey (4 
questionnaires). 
 
5. What are the benefits of this study? 
Your participation in this study will assist us to understand the issues people face surrounding the use of 
anticoagulant medicines. The information gained from this survey will potentially help to identify the need 
for additional educational support for people with atrial fibrillation taking blood thinners and may assist in 
the development of the educational resources to be used in the future. This is very important in helping 
people get the most out of their medicines. 
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6. Are there any risks associated with participation in this study? 
People may become distressed or anxious if they do not know the answers to some of the questions, or if 
the questionnaires highlight particular health concerns that they may have. If you find yourself becoming 
distressed during the interview, you are able to ask the researcher to stop the interview or to move onto a 
different questionnaire. If necessary, we can arrange for you to see a counsellor at no expense. 
 
7. How will my confidentiality be protected? 
Only basic demographic information and contact details will be collected so that we will be able to contact 
you if we need are missing any important information. All identifying details will be removed after the 
information has been deemed complete.   
 
8. Will I benefit from this study? 
This study aims to improve the use of anticoagulants and the related outcomes for people taking these 
medicines. It may not benefit you directly. 
 
9. What should I do if I am not sure of the answers to the questions posed in the interview and wish 
to find out?  
To find out any answers to the questions posed in the interview, you should contact your doctor or 
pharmacist for appropriate counselling specific to your needs. 
 
10. Will I be compensated for participating in this study? 
You will be offered a $10 shopping voucher as compensation for your participation. 
 
11. What should I do if I want to discuss this study further before I decide? 
When you have read this information, if you have any queries regarding this study or your participation in 
this study, please do not hesitate to contact one of the study investigators listed below: 
  
Associate Professor Luke Bereznicki 
Associate Head (Pharmacy) & Deputy Head, School of Medicine 
Telephone: 03 6226 2195; Email: Luke.Bereznicki@utas.edu.au 
 
Dr Leanne Chalmers  
Lecturer, Pharmacy, School of Medicine 
Telephone: 03 6226 1095; Email: Leanne.Chalmers@utas.edu.au 
 
Mr Kehinde Obamiro (PhD candidate) 
Telephone: 0415 225 361; Email: Kehinde.Obamiro@utas.edu.au 
 
Ms Chanelle Rolls (BPharm(Hons) candidate) 
Telephone: 0422 373 862; Email: Carolls@utas.edu.au 
 
12. Who should I contact if I have concerns about the conduct of this study? 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics Committee. 
If you have any concerns of an ethical nature, or complaints about the manner in which the study is 
conducted, you may contact the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network on (03) 6226 7479 or human.ethics@utas.edu.au. The Executive Officer is the person nominated 
to receive complaints from research participants.   Please quote the ethics reference number -------- 
 
Thank you for taking the time to consider this study. 
If you wish to take part in it, please sign the attached consent form. 
This information sheet is for you to keep. 
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Appendix B4 
Consent Form – Patient Group 
 
Title of Project: Patient Experiences, Perceptions and Knowledge of Stroke 
Thromboprophylaxis in Atrial Fibrillation 
 
 
1. I acknowledge that the nature, purpose and contemplated effects of the project so far 
as it affects me, have been fully explained to my satisfaction by the research worker 
and my consent is given voluntarily. 
   
2. I have read and understood the ‘Participant Information Sheet’ of this study. 
 
3. The details of the project methods have also been explained to me. I understand that I 
will be required to answer a set of four questionnaires during an interview with one of 
the researchers. Questions will be related to; anticoagulants (blood thinners), atrial 
fibrillation, my ability to understand and interpret health information and my overall 
quality of life.  
 
4. I understand that if I wish to find out the answers to any of the questions posed during 
the interview, I should contact my doctor or pharmacist for appropriate counselling 
specific to my needs. 
 
5. If I become distressed by any of the questions, I will be offered the opportunity to stop 
the interview, or end the session and reconvene at another time. I will be offered 
counselling free of charge by the University if distressed by the questions. 
 
6. Although I understand that the purpose of this research project is to improve the quality 
of medical care, it has also been explained that my involvement may not be of any 
benefit to me. 
 
7. I have been given the opportunity to have a member of my family or friend present 
while the project was explained to me. 
 
8. I understand that my involvement in the project will not affect my relationship with my 
medical advisers in their management of my health.  I also understand that I am free to 
withdraw from the project at any stage and any of my data that have been collected.  
My withdrawal will not affect my legal rights, my medical care or my relationship with 
my health care practitioners.  
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9. I understand that I will be given a signed copy of this Participant Information Sheet and
consent form. I am not giving up my legal rights by signing this consent form.
10. I understand that the study will be conducted in accordance with the latest versions of
the National Statement on Ethical Conduct in Human Research 2007 and applicable
privacy laws.
Name of participant: _________________ Preferred contact number: _________
Signature of participant: ______________ Date: ______________
11. I have explained this project and the implications of participation in it to the participant
and I believe that the consent is informed and that he/she understands the implications
of participation.
Name of investigator: ___________________________________       
Signature of investigator: ___________________ Date: ________     
*** If you are happy to participate in the study, please fill out this consent form and 
return to the researchers using the reply paid envelope. *** 
 
 
University of Tasmania 
Pharmacy, School of Medicine 
Private Bag 26 
HOBART  TASMANIA 
7001  AUSTRALIA 
ABN 30 764 374 782 / CRICOS 00586B 
185 
Appendix B5: 8-item Morisky Medication Adherence Scale 
This adherence scale been 
removed for copyright or 
proprietary reasons.
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Appendix B6 
Anticoagulant Knowledge Tool  
Introduction 
We thank you in advance for agreeing to fill in this questionnaire and we appreciate you taking 
the time to support this research. By completing this questionnaire, you will help in validating a 
tool that will be useful in caring for people taking anticoagulant medicines. Your responses, 
including demographic information will remain anonymous, and your confidentiality will be 
protected. 
Instructions on completing the questionnaire if you are currently taking an oral 
anticoagulant medicine: 
 Please complete the following questions to reflect your opinions as accurately as possible
and to the best of your knowledge.
 If you do not know the response to a question, please write ‘I don’t know’ in the space
provided.
 If you are not sure of the response to a multiple choice question, please tick ‘not sure’
among the options provided.
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Section 1: Demographic Information 
5. What is your gender?
c. Male
d. Female
6. How old are you? ……………….. years 
7. What is the highest level of education you have completed?
g. High school or equivalent
h. College
i. Technical or vocational education
j. Bachelor’s degree
k. Postgraduate degree
l. No formal education
8. How long have you been taking an oral anticoagulant medicine?
f. Less than 3 months
g. 3 -12 months
h. 1 -2 years
i. Greater than 2 years
j. I’m not taking an anticoagulant medication
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Section 2: Anticoagulation Knowledge  
 
2.1 General questions 
 
1. What is the name of your anticoagulant medicine? 
  
………………………………………………………………………………………………
.. 
2.  Why has your doctor prescribed you this medicine? 
  
………………………………………………………………………………………………
.. 
3.  How does this medicine work in your body?   
   
………………………………………………………………………………………………
.. 
4.  How many times a day do you need to take this medicine? 
  
………………………………………………………………………………………………
.. 
5.  For how long do you need to take this medicine (for example, 3 months, and 6 months, 
life-long)? 
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………………………………………………………………………………………………
.. 
6. Why is it important to take this medicine exactly as your doctor has told you?
………………………………………………………………………………………………
.. 
7. Is it important to take this medicine at the same time each day?
a) Yes b) No c) Not sure
8. Is it okay to double the next dose of this medicine if you miss a dose?
a) Yes b) No c) Not sure
9. Is it possible that skipping one dose of this medicine could worsen your condition?
a) Yes b) No c) Not sure
10. Is it appropriate to stop taking this medicine once you feel better?
a) Yes b) No c) Not sure
11. Is it safe to take anti-inflammatory medicines like ibuprofen (Nurofen® or Advil®) while
you are taking this medicine?
a) Yes b) No c) Not sure
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12.  Is it safe to take vitamin supplements and herbal medicines with this medicine without 
consulting your doctor?  
 a) Yes            b) No   c) Not sure 
 
13.  Is there any benefit in taking more of this medicine than your doctor has told you to take?  
a) Yes            b) No   c) Not sure 
 
14. Will drinking too much alcohol increase the risk of side effects with this medicine? 
a) Yes            b) No   c) Not sure 
 
15. Would you inform a surgeon, dentist or other health professional that you are taking this 
medicine before undergoing surgery or a procedure? 
a) Yes             b) No   c) Not sure 
 
16. Is it important that all the health care practitioners you see know that you are taking this 
medicine? 
a) Yes             b) No   c) Not sure 
 
17. What is the most important side effect of this medicine?  
……………………………………………………………………………………… 
 
18. THREE signs of side effects that you should watch out for while taking this medicine are: 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
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……………………………………………………………………………………….. 
19. THREE things you can do to reduce your risk of side effects are:
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
20. What is the best step to take if you accidentally take too much of this medicine?
……………………………………………………………………………………….. 
2.2 Section 2 
1. What is your target INR range? .................................. 
2. What was your last INR reading? …………............... 
3. Are regular INR tests necessary to know how well this medicine is working?
a) Yes b) No c) Not sure
4. Is an INR value above your target range good for your general wellbeing?
a) Yes b) No c) Not sure
5. Is it possible for INR values below your target range to be bad for your health?
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a) Yes b) No c) Not sure
6a. Is it possible for what you eat to affect your warfarin therapy? 
a) Yes b) No c) Not sure
6b. If you answered ‘Yes’ above, list THREE foods that can affect your anticoagulant therapy. 
…………………………………………………………………………………… 
…………………………………………………………………………………… 
…………………………………………………………………………………… 
7. List one vitamin that can significantly affect your anticoagulant therapy.
…………………………………………………………………………………… 
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Appendix B7: Functional health literacy 
This test has been removed 
forcopyright or proprietary
reasons.
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Appendix B8: Quality of life 
This questionnaire has been 
removed forcopyright or 
proprietary reasons.
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Appendix C: Oral anticoagulant knowledge survey forms (National study) 
Appendix C1 – Facebook advertisement 
This appeared in the advertising column on the right-hand side of people’s Facebook 
newsfeeds. 
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Appendix C2 – Facebook page  
This page provided some basic information and allowed us to also share the survey by 
users sharing the page or a status update of the page. This is a draft mock-up of what 
the page look liked. 
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Appendix C3 – Facebook status to share 
This is the status that appeared in people’s main newsfeed, rather than off to the side like 
most advertisements. The top blue link linked to the Facebook page while the bottom link 
went to the survey itself. This is how a status update done though the Facebook page 
looked. Users had the option to ‘like’ or ‘comment’ on the status or they could ‘share’ it 
with others. This helped to increase the number of people the page reached.  
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Appendix C4 
 
 
 
 
1. What is your age? 
 
 
 
2. What is your gender? 
 Female 
 Male 
 
 
3. What is your postcode? 
 
 
 
4. What is your highest level of completed education? 
 Year 10 or below 
 Year 12 
 Certificate 
 Diploma 
 Bachelor Degree 
 Master’s Degree 
 Doctor of Philosophy 
 
 
Appendix 4- Survey 
Anticoagulant Knowledge in Patients with Atrial Fibrillation in 
Australia 
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5. What best describes your current employment status? 
 Full-time work 
 Part-time work 
 Casual work 
 Not currently working 
 On leave (long-service) 
 
 
6. Which of the following best describes your annual income range? 
 0 – $18,200 
 $18,201 – $37,000 
 $37,001 – $80,000 
 $80,001 – $180,000 
 $180,001 and over 
 
 
7. Why have you been prescribed an oral anticoagulant (blood thinner) medicine? 
 Atrial fibrillation 
 Deep vein thrombosis 
 Pulmonary embolism 
 Heart failure 
 Artificial heart valve 
 Others………………. 
 
 
8. How long have you been taking an oral anticoagulant (blood thinner) medicine?  
    Less than 3 months 
 3-12 months 
 1-2 years 
 Greater than 2 years 
 
 
 
Please answer the following questions to help us understand how you take your oral 
anticoagulant (blood thinner) medicine.  
 
 
1) Do you ever forget to take your medicine? 
a) Yes            b) No  
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2) People sometimes miss taking their medications for reasons other than forgetting. 
Thinking over the past two weeks, were there any days when you did not take your 
medicine? 
a) Yes            b) No  
 
 
3) Have you ever cut back or stopped taking your medicine without telling your doctor 
because you felt worse when you took it? 
a) Yes            b) No  
 
 
4) When you travel or leave home, do you sometimes forget to bring along your 
medicine? 
a) Yes            b) No  
 
 
5) Did you take all your medicine yesterday? 
a) Yes            b) No  
 
 
6) When you feel like your symptoms are under control, do you sometimes stop taking 
your medicine? 
a) Yes            b) No  
 
 
7) Taking medicine every day is a real inconvenience for some people. Do you ever 
feel hassled about sticking to your treatment plan? 
a) Yes            b) No  
 
8) How often do you have difficulty remembering to take your medicine? 
 
 Never/rarely 
 Once in a while 
 Sometimes 
 Usually 
       All the time 
 
The following questions are about your knowledge regarding your oral anticoagulant 
(blood thinner) medicine. 
 
1. What is the name of your anticoagulant medicine? 
 ………………………………………………………………………………………….. 
2.  Why has your doctor prescribed you this medicine? 
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 ………………………………………………………………………………………….. 
3.  How does this medicine work in your body?   
 …………………………………………………………………………………….. 
4.  How many times a day do you need to take this medicine? 
 ………………………………………………………………………………………… 
5.  For how long do you need to take this medicine (for example, 3 months, and 
6 months, life-
long)? ……………………………………………………………………………………
…….. 
6. Why is it important to take this medicine exactly as your doctor has told you? 
………………………………………………………………………………………… 
7. Is it important to take this medicine at the same time each day?  
a) Yes          b) No   c) Not sure 
8.  Is it okay to double the next dose of this medicine if you miss a dose? 
a) Yes            b) No   c) Not sure 
9.   Is it possible that skipping one dose of this medicine could worsen your 
condition? 
a) Yes            b) No   c) Not sure 
10.  Is it appropriate to stop taking this medicine once you feel better? 
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a) Yes            b) No   c) Not sure 
11. Is it safe to take anti-inflammatory medicines like ibuprofen (Nurofen® or 
Advil®) while you are taking this medicine? 
a) Yes            b) No   c) Not sure 
12.  Is it safe to take vitamin supplements and herbal medicines with this 
medicine without consulting your doctor?  
 a) Yes            b) No   c) Not sure 
13.  Is there any benefit in taking more of this medicine than your doctor has told 
you to take?  
a) Yes            b) No   c) Not sure 
14. Will drinking too much alcohol increase the risk of side effects with this 
medicine? 
a) Yes            b) No   c) Not sure 
15. Would you inform a surgeon, dentist or other health professional that you 
are taking this medicine before undergoing surgery or a procedure? 
a) Yes             b) No   c) Not sure 
16. Is it important that all the health care practitioners you see know that you are 
taking this medicine? 
a) Yes             b) No   c) Not sure 
17. What is the most important side effect of this medicine?  
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……………………………………………………………………………………… 
18. THREE signs of side effects that you should watch out for while taking this 
medicine are: 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
19. THREE things you can do to reduce your risk of side effects are: 
……………………………………………………………………………………….. 
……………………………………………………………………………………….. 
20.  What is the best step to take if you accidentally take too much of this 
medicine?  
…………………………………………………………………………………….. 
 (For people taking warfarin) 
1. What is your target INR range? .................................. 
 
2. What was your last INR reading? …………............... 
 
3. Are regular INR tests necessary to know how well this medicine is working? 
a) Yes             b) No   c) Not sure  d) Not applicable 
4. Is an INR value above your target range good for your general wellbeing? 
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a) Yes             b) No   c) Not sure  d) Not applicable 
5. Is it possible for INR values below your target range to be bad for your health? 
 a) Yes   b) No   c) Not sure   d) Not applicable 
6a. Is it possible for what you eat to affect your warfarin therapy? 
a) Yes             b) No   c) Not sure   d) Not applicable 
6b. If you answered ‘Yes’ above, list THREE foods that can affect your 
anticoagulant 
therapy.…………………………………………………………………………………… 
7. List one vitamin that can significantly affect your anticoagulant therapy  
…………………………………………………………………………………… 
Please answer the following questions to help us understand how convenient it is to take 
your medicine. 
Please check one box per line. 
 
1 How difficult is it to take your anticoagulant treatment (i.e., pills or injections, 
number of pills or injections, frequency of intake ...)? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
2  How bothered are you by taking your anticoagulant treatment? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
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3  Some anticoagulant treatments may need dose adjustments; how difficult is 
this for you? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
4  Certain medications CANNOT be taken with anticoagulant treatments; how 
difficult is this for you? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
5 It is recommended that certain foods be avoided while taking an 
anticoagulant treatment; how difficult is this for you? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
6 How difficult is it for you to take your anticoagulant treatment when you are 
away from home? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
7  How difficult is it for you to plan your time around your anticoagulant 
treatment (i.e., appointments with nurses, doctors or labs …)? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
8 How bothered are you by the medical follow-up required with your 
anticoagulant treatment? 
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1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
9  How difficult is it for you to take your anticoagulant treatment as directed on 
a regular basis? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
10  Do you feel more dependent on others (i.e partner, family, nurse…) because 
of your anticoagulant treatment? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
 
11 How worried are you about having to interrupt or stop your anticoagulant 
treatment? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
Please answer the following questions to help us understand how your disease and its 
treatment affect you. 
Please check one box per line. 
 
1  Because of potential side effects (i.e., minor bruises, bleeding…), do you limit 
your usual activities (i.e., work, leisure, social, or physical activities…)? 
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1 2 3 4 5 
Not at all A little Moderately A lot Extremely 
 
 
2  How much physical discomfort do you have due to bruises or pain? 
 
1 2 3 4 5 
None A little Moderate A lot Extreme 
Please answer the following questions to help us understand how satisfied you are with 
your treatment. 
Please check one box per line. 
 
1  How reassured do you feel by your anticoagulant treatment? 
 
1 2 3 4 5 
Not at all A little Somewhat Very Completely 
 
 
2 Do you feel that your anticoagulant treatment has decreased your symptoms 
(i.e., leg pain or swelling, palpitations, shortness of breath, or chest pain…)? 
 
1 2 3 4 5 
Not at all A little Moderately A lot Completely 
 
 
3  How did your experience with side effects such as minor bruises or bleeding 
(i.e., while shaving, cooking, after small cuts…) compare to what you 
expected?  
 
1 2 3 4 5 
It is much 
worse than 
what I 
expected 
It is worse 
than what I 
expected 
It is exactly 
what I 
expected 
It is better 
than what I 
expected 
It is much 
better than 
what I 
expected 
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4  Regarding the follow-up of your disease and anticoagulant treatment, how 
satisfied are you with your level of independence? 
 
1 2 3 4 5 
Extremely 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Extremely satisfied 
 
 
5 How satisfied are you with the methods (i.e., appointments with nurses, 
doctors, labs…) used to ensure the follow-up of your disease and 
anticoagulant treatment? 
 
1 2 3 4 5 
Extremely 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Extremely satisfied 
 
 
6  How satisfied are you with the form of your anticoagulant treatment (oral pill 
/ injection)? 
 
1 2 3 4 5 
Extremely 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Extremely satisfied 
 
 
7 Overall, how satisfied are you with your anticoagulant treatment? 
 
1 2 3 4 5 
Extremely 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Extremely satisfied 
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The following questions asks you how you feel about information on atrial fibrillation 
management.  
 
Please indicate how much you agree/disagree with the following statements by selecting 
the relevant option (1 = strongly disagree, 4 = strongly agree). Please check one box 
per line. 
1 There are so many different recommendations about managing atrial fibrillation, it’s 
hard to  know which ones to follow 
   
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
      
2 There is not enough time to do all of the things recommended to manage 
atrial fibrillation.  
 
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
 
3 It has gotten to the point where I don’t even care to hear new information 
about atrial  fibrillation.  
 
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
4 No one could actually do all of the atrial fibrillation management 
recommendations  that are given. 
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Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
5 Information about atrial fibrillation all starts to sound the same after a while. 
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
6. I forget most of the information about atrial fibrillation right after I hear it. 
Strongly 
Disagree 
  Strongly 
Agree 
1  2  3  
 
4  
7 Most things I hear or read about atrial fibrillation seem pretty far-fetched. 
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
8 I feel overloaded by the amount of information about atrial fibrillation I am 
supposed to know. 
Strongly 
Disagree   
Strongly 
Agree 
1  2  3  
 
4  
 
 
Thank you for your time. 
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Appendix C5 – Eligibility Check 
 
 
 
Eligibility 
 
To participate in this short survey: 
 You must be above the age of 18 
 You must reside in Australia 
 You are currently taking an oral anticoagulant (blood thinner) for the prevention of stroke due to 
the heart condition- atrial fibrillation. 
 
If the above apply to you and you would like to participate, please press ‘next’.  
 
This will take you to an information page and then to the survey itself. The survey should take you less 
than twelve minutes and at the end you can enter to win an iPad mini. This only requires an email 
address and is separate to the survey.  
 
 
 
Anticoagulant Knowledge in Patients with Atrial Fibrillation in Australia 
226 
 
 
 
 
Appendix C6 – Draw for an iPad mini 
 
 
Draw for iPad mini 
Please enter your email address into the box below to go into the draw to win an iPad mini. 
Remember this cannot be linked to your survey responses and your email will only be used to 
contact if you are the winner of the iPad mini. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Anticoagulant Knowledge in Patients with Atrial 
Fibrillation in Australia 
 
227 
 
 
 
The following article has been 
removed from the appendix 
for copyright or proprietary 
reasons. 
It has been published as: Obamiro, K. O.,  Chalmers, L., Bereznicki, L. R. 2016. A 
summary of the literature evaluating adherence and persistence with oral 
anticoagulants in atrial fibrillation, American journal of cardiovascular drugs, 
16(5), 349-63
243 
 
244 
 
245 
 
246 
 
247 
 
248 
 
249 
 
250 
 
251 
 
252 
 
 
 
 
The following article has been 
removed from the appendix 
for copyright or proprietary 
reasons. 
It has been published as: Rolls, C. A., Obamiro, K. O., Chalmers, L., Bereznicki, L. 
R. E., 2017. The relationship between knowledge, health literacy, and 
adherence among patients taking oral anticoagulants for stroke 
thromboprophylaxis in atrial fibrillation. Cardiovascular therapeutics, 35(6), 
1-8, e12304
The following article has been 
removed from the appendix 
for copyright or proprietary 
reasons. 
It has been published as: Obamiro, K.O., Chalmers, L., Lee, K., Bereznicki, B. J., 
Bereznicki, L. R.E., Anticoagulation knowledge in patients with atrial fibrillation: 
An Australian survey. International journal of clinical practice, 72(3), e13072
